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Abstract
Analysis of analytes present in the blood stream can potentially deliver crucial information
on patient health and indicate the presence of numerous pathologies. Existing clinical
techniques for this analysis can, however, be costly and time-consuming. The potential of
Raman spectroscopic analysis of human plasma and/or serum for diagnostic purposes has
been widely investigated and, increasingly, its feasibility for clinical translation has been
explored. However, as the concentration of many analytes in plasma/serum is relatively low,
to date such analysis has commonly been performed on air-dried drops deposited on
substrates, leading to inhomogeneity and inconsistencies. This study explores the potential
of Raman spectroscopy, coupled with fractionation and concentration techniques, as well as
multivariate regression analysis, to quantitatively monitor diagnostically relevant changes in
high and low molecular weight proteins as well as therapeutic drugs, in liquid plasma/serum.
Having optimised the protocols for pure aqueous solutions and spiked serum samples,
measurement protocols to detect the imbalances in plasma/serum analytes (fibrinogen,
albumin, γ globulins, total protein content, glucose and urea), as an indicator of various
diseases, and therapeutic monitoring of drugs (busulfan and methotrexate), using Raman
spectroscopy were optimised in liquid serum, such that strategic clinical applications for early
stage disease diagnostics and therapeutic drug monitoring can be evaluated. Furthermore, an
adapted Extended Multiplicative Signal Correction algorithm was applied to raw spectra to
remove background signal and spectral interferents. Using a validated partial least squares
regression method, prediction models were built for the analytes, with accuracies which are
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comparable with those reported for the conventional methods, without any additional sample
preparation steps. This methodology was extended to determine the Limit of Detection
(LOD) and Limit of Quantification (LOQ) for therapeutic drug monitoring in human serum,
using the examples of Busulfan, a cell cycle non-specific alkylating antineoplastic agent, and,
Methotrexate, a chemotherapeutic agent. This study demonstrates the options and
alternatives that are available to make Raman spectroscopy suitable for the human bodily
fluid analysis in the liquid form, leading to a better accuracy and repeatability and thus a
better sensitivity.
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Chapter 1
Introduction
Vibrational spectroscopic techniques, both Raman and Infrared absorption, are certainly one
of the most important analytical techniques available to scientists, as they provide the unique
opportunity to investigate the molecular composition of both organic and inorganic
compounds. They are routine, standard techniques used for fingerprinting and identifying
chemicals, as they can give specific biochemical information without the use of extrinsic
labels and without being extremely invasive or destructive to the system studied. Since both
techniques are truly label-free, their potential for diagnostic applications has been well
investigated and demonstrated, notably in various pathologies (1–7) and therapeutic drug
monitoring (8–10).
Bodily fluids (e.g plasma, serum, saliva or urine) are emerging as a potentially important
source of samples for disease diagnosis and therapeutic monitoring, as their collection is
largely non-invasive, cost effective and easy (11–17). Blood plasma/serum is not only the
primary clinical specimen that contains a large number of proteins, but has also been studied
even before genes were known to exist (18). Increasingly, many diagnostic tests are
performed on bodily fluids, as sample collection is minimally invasive, compared to biopsy
based techniques. However, in hospitals or medical centers, there is a time lapse between
collection of bodily fluids, such as urine or blood, from patients and analysis of these samples
for diagnose diseases, as these analysis are performed in specialised laboratories. Bodily
fluids are usually collected from a large number of patients in a hospital, further delaying the
1

performance of the analysis and availability of results, which may in turn delay the therapy,
and prolong patient anxiety. The accuracy of the test kits that enable point-of-care-testing is
often poor and they are frequently avoided because of high cost (19,20). There is a need for
objective and cost effective methods capable of accurate early disease diagnosis from bodily
fluids in a point-of-care clinical setting. For this purpose, vibrational spectroscopic
techniques are appropriate, as they are nondestructive, label-free, rapid, cost-effective, easy
to operate, and require minimal sample preparation. Moreover, the use of plasma, serum or
urine for diagnostics has the added advantage of being relatively non-invasive compared to
conventional diagnostic methodologies such as biopsies.
This study aims to optimise protocols for Raman spectroscopic analysis of human blood
plasma/serum in the liquid form, and to explore applications for the analysis and
quantification of pathologically significant imbalances of constituent components, as well as
to monitor therapeutic drug administration.
1.1 Raman and Infrared Spectroscopy in the analysis of bodily fluids
Vibrational spectroscopy usually refers specifically to the optical techniques of Raman and
infrared (IR) absorption spectroscopy. Measurement using these techniques provides a great
deal of information that is potentially useful in the medical environment and can be exploited
for disease diagnosis and therapy (21). The quest for biomarker identification and analysis
through bio-spectroscopy in general is an emerging field with huge potential and has recently
been explored through vibrational spectroscopic approaches (6,17,21–23). The sensitivity to
detect subtle changes in the biochemical composition and ability to detect the presence of
specific biomarkers makes vibrational spectroscopy an ideal diagnostic tool. Considering the
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advancement in spectroscopic technologies, and data analysis capabilities, coupled with
filtration and fractionation techniques; bodily fluids can be analysed rapidly and noninvasively to detect disease related fluctuations in protein concentration (24–27).
Raman spectroscopy is a complementary tool to IR spectroscopy and is compatible with
aqueous samples. This technique allows the analysis to be carried out in the native state of
bodily fluids, and, therefore, the additional drying step can be eliminated. A comprehensive
proof of concept has been designed and conducted to detect hepatocellular carcinoma (HCC)
from patient serum using micro-Raman spectroscopy (22). The aim of the study was to
differentiate serum samples of patients with HCC and patients without HCC. Two groups of
patients were classified with an overall accuracy of 84.5% to 90.2% for dried serum drops
and 86% to 91.5% for freeze-dried serum. A Surface-enhanced Raman scattering (SERS)
based immunoassay has been developed to monitor levels of the mucin protein MUC4 in
patient serum, which could help in the early detection and diagnosis of pancreatic cancer
(28). Another study demonstrated the ability of Raman spectroscopy to detect trace amounts
of glucose in urine that was ten-fold diluted, with an accuracy of 92% for abnormal (8mg/mL)
and normal (0.15mg/mL) urine samples (29). In recent years, SERS has also been reported
to be a good candidate for therapeutic drug monitoring (TDM) of various drugs in biological
fluids (8,9,30),(31),(10), since quantitative analysis of drugs can be performed rapidly and
higher sensitivity. Critical issues of using SERS for TDM include development of
standardised substrates, intense surface enhanced resonance SERS responses from other
biological molecules such as carotenoids and also the spectral interference from the
fluorescence that could interfere with the drug detection (9,32).
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IR absorption spectroscopic analysis of bodily fluids has been explored for disease screening
and monitoring numerous conditions including cancer, arthritis, heart diseases, liver diseases
and diabetes (21,25,33). A comprehensive study conducted using mid-infrared (mid-IR)
spectroscopy of dried serum films demonstrated good accuracy for total cholesterol,
triglycerides, total protein, urea and glucose, whereas this method was found to be less
suitable for creatinine and uric acid (34). Another study demonstrated that both low density
lipoprotein and high density lipoprotein cholesterol can be independently quantified using IR
spectroscopy of dried serum films (35). Attenuated Total Reflectance-Fourier Transform
Infrared (ATR-FTIR) was successfully used to detect and differentiate blood, saliva, semen
and vaginal secretions (36). Freshly collected bodily fluids were deposited on to the analysis
stage and measurements were carried out upon immediate deposition, using further scans at
regular time intervals until the sample was completely dry. The identification was based on
the unique spectral pattern and peak frequencies corresponding to sugars, proteins and
phosphates in each bodily fluid. Blood components, such as serum and plasma, can be
exploited for liquid biopsies as they contain biomarkers that can be used for disease
diagnosis. ATR-FTIR has been proven to be a promising screening tool for diagnosing
ovarian cancer from human blood serum (37). Plasma/serum based ATR-FTIR successfully
discriminated ovarian cancer from controls with a success rate of ~97% from plasma and
~95% when compared to the histological diagnosis by a pathologist. Centrifugal filtration
techniques coupled with ATR-FTIR of human serum have been employed to deplete the
abundant high molecular weight proteins and subsequently enhanced the ability to monitor
changes in the low molecular weight constituents. Glucose was used to spike the serum and
it was demonstrated that fractionating the serum prior to spectroscopic analysis improves the
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quantitative model based on the partial least squares regression (PLSR) algorithm (38). As
IR spectroscopy is an absorption based technique, water cannot be used as a solvent due to
its intense absorption in the IR region (39). IR analysis of the serum samples has therefore
been predominantly performed on air dried samples which leads to chemical and physical
inhomogeneity due to the adsorption of serum proteins on to the substrate surface based on
their differing affinities, known as the Vroman effect (40–42). The Vroman effect is the main
limiting factor of using air-dried samples for spectral analysis. Thus, the use of dried plasma
samples will give rise to variations in the spectral features due to chemical and physical
inhomogeneity, leading to unreliable results and, is not the ideal protocol for diagnostic
applications.
An improved protocol of Raman spectroscopy set up, coupled with fractionation of serum
using centrifugal filters to concentrate and separate low molecular weight proteins was
demonstrated (43). Whereas FTIR spectra were recorded in aqueous solutions of gelatin at
concentrations as low as 100mg/L, using Raman spectroscopy, high quality spectra of gelatin
solutions as low as 10mg/L was achieved. Spectral features of human serum were found to
be weak and partially obscured by water features. Dried deposits are shown to be physically
and chemically inhomogeneous resulting in unreliable results. Concentration of the serum
using commercially available centrifugal filter devices resulted in enhanced spectral intensity
and quality. Improved analysis of serum using Raman spectroscopy was reported when the
sample was analysed in the inverted geometry using the water immersion objective with a
785nm laser as source.
This project aims to evaluate the potential of Raman spectroscopy for the analysis of blood
plasma/serum in the liquid state in order to detect subtle variations in the sample composition
5

and specific biomarkers linked to numerous pathologies and therapeutic drug monitoring.
The initial stages involve optimisation of the analysis protocol, exploring the available range
of laser source wavelengths, sample measurement substrates and measurement geometries.
A simulated blood plasma is employed to establish the appropriateness and sensitivities of
the combination of Raman spectroscopic, data pre-processing and multivariate analysis
techniques. Centrifugal filtration and ion exchange chromatography are explored as a method
for fractionation and concentration of the constituent proteins to improve the measurement
sensitivity.

1.2 Research question and hypothesis

Question:Can Raman spectroscopy detect imbalances in plasma/serum analytes and small molecule
biomarkers or drugs to enable early disease diagnosis or monitor patient therapies?
Hypothesis:A point-of-care, rapid, cost-effective disease/therapeutic monitoring system can be
developed using Raman spectroscopy.

1.3 Thesis summary

Chapter 2 is a reproduction of the submitted book chapter titled as ‘Vibrational
Spectroscopic Analysis and Quantification of Proteins in Human Blood Plasma and Serum’,
Vibrational Spectroscopy in Protein Research, Elsevier. It details the application of
vibrational spectroscopic analysis for quantification of proteins in human plasma/serum. This
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chapter also gives an insight into the constituents of serum /plasma and the pathologies
related to serum/plasma analytes. Moreover, this chapter describes the fundamental principle
underlying the Raman and IR spectroscopic analysis and the basic instrumentation.
Chapter 3 focuses on the methodology that has been used throughout the study in detail. The
measurement protocol of Raman spectroscopy for liquid serum analysis, serum fractionation
techniques and the use of multivariate analysis techniques to extract information from the
Raman data sets are discussed. This chapter will also describe in detail the optimal Raman
measurement protocol for aqueous samples in terms of geometry of the instrument, substrate,
sample volume and laser line.
Chapter 4 reproduces the published journal article entitled ‘Raman spectroscopic analysis
of high molecular weight proteins in solution: considerations for sample analysis and data
pre-processing’. Analyst. 2018;143(24):5987–98. It explores the potential of Raman
spectroscopy, coupled with multivariate regression and protein separation techniques, to
monitor diagnostically relevant changes in high molecular weight proteins in liquid plasma.
Measurement protocols to detect the imbalances in plasma proteins as an indicator of various
diseases using Raman spectroscopy are also optimised. Two types of data preprocessing
methods (Rubberband and Extended Multiplicative Signal Correction (EMSC)) are
introduced and compared in this chapter.
Chapter 5 consists of the published journal article entitled ‘Analysis of bodily fluids using
vibrational spectroscopy : a direct comparison of Raman’. Analyst. 2019;144:3334 – 3346.
It demonstrates the use of Raman spectroscopy, similarly coupled with centrifugal filtration
and multivariate analysis techniques, to monitor diagnostically relevant changes of glucose
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in liquid serum samples, and compares the results with similar analysis protocols using
infrared spectroscopy of dried samples. This study has been conducted on 25 patient serum
samples.
Chapter 6 reproduces the published journal article entitled ‘Raman spectroscopic screening
of High and Low molecular weight fractions of human serum’ Analyst. 2019, DOI:
10.1039/C9AN00599D. It illustrates the suitability of Raman spectroscopy as a bioanalytical
tool, when coupled with centrifugal filtration and multivariate analysis, to detect imbalances
in both high molecular weight (total protein content, γ globulins and albumin) and low
molecular weight (urea and glucose) fractions of the same samples of human patient serum,
in the native liquid form. The strategy to digitally remove spectral interferents such as βcarotene is demonstrated here.
Chapter 7 is adapted from a submitted journal article titled as ‘Raman spectroscopy as a
potential tool for label free therapeutic drug monitoring in human serum: the case of Busulfan
and Methotrexate’ Analyst, 2019, which describes the methodology, based on Raman
spectroscopy coupled with multivariate analysis, to determine the Limit of Detection (LOD)
and Limit of Quantification (LOQ) for TDM in human serum, using the examples of
Busulfan, a cell cycle non-specific alkylating antineoplastic agent, and, Methotrexate, a
chemotherapeutic agent and immune system suppressant.
Chapter 8 summarises the main findings from this thesis and provides an overview of the
recent advancements in the field of liquid Raman spectroscopic analysis of bodily fluids. The
impact of scaling the data to the water content using EMSC algorithm and inverse correlation
between LOD and spectral intensity is also highlighted in this chapter. The chapter has been
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submitted in its entirety, as a review article titled as ‘Potential of Raman spectroscopy for the
analysis of plasma/serum in the liquid state: Recent advances’, Analytical and Bioanalytical
Chemistry, 2019.
Chapter 9 outlines the overall conclusion of the thesis, focusing on the shortcomings and
challenges of the work presented, methods to improve the accuracy of the methodology and
potential applications of liquid Raman spectroscopy in various fields.
In the chapters which are adapted from published works, the source referencing format of the
original has been retained, but changes in figure and section numbering have been made, as
required for the thesis format. Supplementary material related to the corresponding work is
also added at the end of the chapters.
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Chapter 2
Vibrational Spectroscopic Analysis and Quantification of
Proteins in Human Blood Plasma and Serum
The following chapter reproduces the submitted book chapter entitled ‘Vibrational
Spectroscopic Analysis and Quantification of Proteins in Human Blood Plasma and Serum’,
Vibrational Spectroscopy in Protein Research, Elsevier
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2.5, 2.6 2.7 and 2.8, DRP contributed to sections 2.1, 2.2, 2.3, 2.4 and 2.5 , while MJB, HJBu
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2.1 Abstract
In this chapter, we outline current the clinical procedures for blood tests, examine the
capability of biomedical vibrational spectroscopy for disease diagnostics and monitoring, and
discuss the potentiality for the techniques to be successfully translated into the clinic.
Alterations in biomolecular components in human blood are commonly used as an indication
of disease states, namely differences in protein concentration. Unfortunately, conventional
test kits currently employed in hospitals suffer from long time delays, meaning patients often
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have to wait anxiously for their test results. Vibrational spectroscopic techniques, such as
infrared and Raman, have the ability to replace current practices, as they are label-free, costeffective, easy to operate, and require minimal sample preparation. The sensitivity to subtle
changes in biochemical composition makes them ideal diagnostic tools, and recent advances
in technology and data analytics means bodily fluids can be analysed rapidly and noninvasively to detect disease related fluctuations in protein concentration.
Keywords: Vibrational Spectroscopy, Infrared, Raman, Plasma, Serum, Diagnostics, Patient
Monitoring, Protein, Quantification

2.2 Introduction

Bodily fluids (e.g. plasma, serum, saliva or urine) are emerging as an important source of
samples for disease diagnostics and therapeutic monitoring, as their collection is largely noninvasive, cost effective and relatively simple. Analyses are performed in specialised
laboratories in hospitals or medical centres, and there is a considerable time lapse between
collection of bodily fluids from patients and delivery of the results, while the samples are
analysed for disease diagnostic biomarkers. Bodily fluids are collected from a large number
of patients in a hospital, further delaying the performance of the analysis and availability of
results, which may in turn delay the therapeutic intervention, and prolong patient anxiety to
the detriment of patient management. The accuracy of the test kits that enable point-of-caretesting is often poor and they are frequently avoided due to high cost [1], [2]. Furthermore,
some diseases are still without biomarkers for diagnosis and disease stage monitoring.
Although in recent years, global analysis techniques based on ‘omics’ have emerged, using
multi-component concentrations as specific biomarkers, there is still a need for improved,
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objective and cost effective methods capable of accurate early disease diagnosis from bodily
fluids in a point-of-care clinical setting, whilst also developing new tools for the
identification of novel biomarkers. For both these purposes, vibrational spectroscopic
techniques are appropriate, as they are non-destructive, label-free, rapid, cost-effective, easy
to operate, and require minimal sample preparation.
The vibrational spectroscopic techniques Raman and Infrared absorption, are valuable
analytical techniques available to scientists, as they provide the unique opportunity to
investigate the molecular composition of both organic and inorganic compounds. They are
routine, standard techniques used for fingerprinting and identifying chemicals, as they can
give molecularly specific chemical information without the use of extrinsic labels and
without being extremely invasive or destructive to the system studied. Since both techniques
are truly label-free, their potential for diagnostic applications has been well investigated and
demonstrated, and increasingly, interest has turned towards their application in the analysis
of bodily fluids, particularly human blood plasma and/or serum for disease diagnostics and
patient monitoring [3], [4].

2.3 Analysis of Biofluids

For many years, the field of medicine has used bodily fluids, or biofluids, for patient
monitoring and screening for disease. Within the body there are two major fluid categories;
intracellular fluid (ICF) and extracellular fluids (ECF). ICF refers to fluids contained inside
the cell plasma membrane, whilst EFC can be further differentiated into the interstitial fluid
(IF) surrounding cells (~75%), the fluid component of the blood called plasma (~25%), and
the transcellular fluids, a small specialised fraction of excreted biofluids (urine, saliva, gastric
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fluids etc.). An adult human body is composed of 50-60% water, about two thirds of which
is found in the ICF and one third in the ECF, enabling the crucial physiological process of
osmosis to take place. Described as the passage of water across a semipermeable membrane,
along a concentration gradient, osmosis is essential for cells to maintain homeostasis. Key to
this transfer of biochemical constituents between the extra and inter cellular environment is
the blood (plasma/serum), and therefore its composition can evolve over time, reflecting
changes in patient health.
However, within this complex matrix, only a limited number of molecules, or biomarkers,
have well-established symptomatic deviations from normal ranges that can be used for
diagnosing specific pathologies. As a consequence, biomarker discovery has become an
active field of research, aiming to provide tools for early diagnosis associated with better
prognosis for patients. Cerebrospinal, synovial, pleural, pericardial, peritoneal, lymphatic
fluids, the aqueous humour and mucosal secretions, such as urine, saliva, sputum, are thus
considered as part of the ECF system. These fluids derive or interact with blood and can
therefore similarly contain sentinel indicators of cellular and organ function or dysfunction.
Thus, human biofluids are considered to be powerful sources of clinical biomarkers [5], [6].
In terms of disease diagnostics and prognosis, bodily fluids are an interesting alternative to
cells and tissues [7]. It is expected that modification of the overall composition of the
biochemical state of bodily fluids could deliver crucial information about patient health and
disease states, enabling early disease diagnosis and administration of treatment [8]. Disease
diagnosis from bodily fluids could potentially be developed into a dynamic diagnostic
environment that will enable early disease diagnosis even before the disease becomes
symptomatic.
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These biofluids, which provide organ-specific information, are increasingly used for
diagnosis; however, blood is considered the largest biomarker reservoir of the body. Since
most of the clinical analytical instruments are accurate for both serum and plasma, these two
terms are used interchangeably in most clinical tests [9]. Notably, many studies that have
been reported to be carried out in serum were in fact carried out in plasma [10]-[14].

2.3.1 Blood Sample: preparation of plasma versus serum

A range of blood-based tests are routinely conducted in a clinical setting. Each analysis
protocol has strict pre-analytical requirements, according to which molecular or cell specific
analysis assays are to be used, even starting with the choice of sampling tubes. For example,
measurement of clotting factors level (by mean of factor consumption and degradation) or
complete blood cell count (through cell lysis and segregation in clot) cannot be analysed in
dry tubes (i.e. without anti-coagulant reagents) [15]. Thus, only citrate-treated tubes are
compatible with haemostasis evaluation. While plasma and serum are both cell-free fluids
obtained from blood samples by centrifugation, they differ on the basis of whether the sample
has been allowed to clot, or not (Figure 2.1).
For plasma preparation, tubes treated with anticoagulant (such as citrate- or heparin)are used
for blood collection. Routinely, refrigerated centrifugation for 10 minutes at 2,000 x g
concentrates unwanted cells and platelets. For serum preparation, whole blood is allowed to
clot at room temperature for about 15–30 minutes. The clot is removed by refrigerated
centrifugation at 1,000–2,000 x g for 10 minutes, often separated by a gel component to avoid
contamination. It is important to immediately transfer the supernatant (plasma or serum) into
a clean polypropylene tube and maintain samples at 2–8°C while handling. If the samples are
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not analysed immediately, they should be stored at –20°C or preferably lower. It is also
recommended to avoid freeze-thaw cycles, because this may have detrimental effects on
many serum components.

Figure 2.1. Obtaining (a) Plasma and (b) Serum from blood samples

2.3.2 Composition of Plasma and Serum

Blood serum and plasma are predominantly composed of water (~90%), minerals, organic
substances and gas (oxygen, carbon dioxide). Proteins are the predominant molecular
components of blood plasma, the remaining constituents being carbohydrates, lipids and
amino acids (Figure 2.2). Serum albumin, globulins, fibrinogen and a handful of other
abundant proteins account for 99% of total serum proteins, while the remaining 1% is
composed of low abundance circulatory proteins. Additionally, plasma or serum contain
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more than 114,000 known metabolites at varying concentration level (<1 nmol/L to mmol/L)
[16]-[18]. In general, to measure factors other than coagulants, serum is preferred as it is less
complex and more sensitive.

Figure 2. 2. Molecular structural figures as examples of a sugar (A), a lipid (B) and an
amino acid (C)

2.3.3 Non-Protein constituents

Electrolytes are a key constituent of blood plasma and serum that play key roles in the human
body, including maintaining pH balance and cellular communication. While sodium, chloride
and bicarbonate (approximately 140mmol/L, 100mmol/L and 25 mmol/L, respectively) are
considered highly concentrated, others such as potassium, phosphate, calcium and
magnesium (4.5 mmol/L, 2.5 mmol/L, 2.5 mmol/L and 1 mmol/L, respectively) are found
with lower contents [16]. Other minerals such as iron, copper, zinc, aluminium, lead can be
found in even lower concentrations (µmol/L).
Energy is provided to cells in the form of glucose, and thus blood contains a large amount of
glucose and its derivatives. Normal glucose levels are between 3.3-5.6 mmol/L, and is strictly
regulated by endocrine system [18]. Diabetes mellitus is a disorder where this regulation has
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failed, either due to insulin resistance or non-production, and can be identified by the glucose
concentration in the blood. Hyperglycemia is defined as above the normal range, and
hypoglycaemia as below.
Lipid concentrations also are indicators for pathological conditions and are therefore
routinely monitored. A healthy range of total cholesterol is between 100-199 mg/dL in adults,
whilst triglycerides are routinely below 150 mg/dL [16]; both are linked to risk of heart and
blood vessel disease and can be used to screen patients to prevent severe conditions leading
myocardial infarction.
Amino acids, the building blocks of peptides and proteins, are found at levels 2300-4000
µmol/L and are produced from protein catabolism. The most abundant amino acids,
glutamine and alanine, are found at concentrations of 600 µmol/L and 300 µmol/L,
respectively [16]. Amino acids metabolism is complex and depends on a thin balance
between protein anabolism and catabolism. Any dysfunction in a metabolic pathway leads to
hyperammoniemia (>400 µmol/L).
Nitrogen metabolites are also used routinely in clinics to witness body dysfunctions.
Ammonia (6-35 µmol/L) is a highly toxic substance and thus is transported in blood mostly
in the form of glutamine [16]. An increased level of ammonia can indicate hepatic
dysfunction or hyper catabolism. Urea is the end product of protein (or amino acid)
degradation and is formed in the liver. Increased blood levels above 2.5-8.3 mmol/L
generally indicate elimination dysfunction, and thus can highlight renal failure.
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2.3.4 Proteins

In total, more than 20,000 human proteins are known. Of these, more than 1,500 are
extracellular [19]. Blood born proteins form a heterogeneous group comprising more than
300 types of proteins. The total concentration of serum proteins (serum total protein) ranges
from 60-80 g/L and is dependent on many factors: rate of the synthesis and degradation,
distribution in body fluids, hydration and elimination. Physiologically higher concentrations
can be observed in the standing position and in association with increased muscle activity.
On the other hand, lower concentrations are physiological for children, pregnant women or
after prolonged fasting [20]. Some of the abundant proteins like fibrinogen and clotting
factors are only found in plasma - about 8% of total proteins - while albumin and globulins
can be measured in both plasma and serum. Albumin is the most abundant protein,
accounting for about 55% of total proteins, which, combined with globulins, represents about
90% of the overall protein content of serum in healthy patients (Table 2.1). The dynamic
range of concentrations in plasma and serum can be one of the greatest challenges in
analysing the proteome, requiring advanced and intensive methods such as mass
spectrometry-based protocols. However, for a large number of clinically relevant protein
biomarkers, routine analysis is required to enable early disease diagnosis.
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Table 2.1. Relative content of abundant proteins in plasma and serum
Sample type
Plasma

Protein type

Function

Abundance

Fibrinogen

Coagulation

7%

Clotting
Factors

Fibrin formation from fibrinogen

<1%

Albumin

Blood vessel integrity

55%-65%

Carrier for insoluble molecules
Tissue growth and healing
Serum and
Plasma

α-1 globulin

High density lipoprotein (HDL)

1-5%

α-2 globulin

Haptoglobulin binds haemoglobin (iron)

5-11%

Β globulin

Carrier and part of defence system against 7-13%
infection

γ globulin

Antibodies – immune system

10-18%

2.3.4.1 Fibrinogen

The main difference between blood plasma and serum is the removal of clotting factors,
predominantly fibrinogen, to produce the latter. Fibrinogen is a dimeric 340 kDa (0.4% in
human plasma) plasma glycoprotein synthesised by the liver and plays a major role in blood
coagulation. When blood clotting is activated, the circulating fibrinogen turns into fibrin and
a stable clot is formed [21]. The normal concentration of fibrinogen in the human body is ~3
mg/mL, and any variation in this concentration can be an indicator of disease states. Many
clinical studies have consistently shown elevated levels of fibrinogen in patients with
cardiovascular disease and thrombosis [22]-[24]. A study conducted by Aleman et al. has
shown that both elevated circulating fibrinogen (hyperfibrinogenemia) and abnormal
fibrinogen levels are observable in plasmas from patients with venous thrombosis [25].
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However, the study undertaken by Klovaite et al. indicated that elevated plasma fibrinogen
levels are associated with increased risk of pulmonary embolism rather than deep venous
thrombosis [26]. Another study conducted by Toss et al. showed that increased fibrinogen
levels are associated with persistent Chlamydia pneumonia infection in unstable coronary
artery disease [27]. A study conducted by the Emerging Risk Factors Collaboration, UK, also
predicted a positive correlation between C-Reactive Protein (CRP), fibrinogen, and
cardiovascular disease [28]. These studies and others suggest a strong correlation between
increased levels of plasma fibrinogen and heart diseases that could be used as a diagnostic
indicator [29], [30].

2.3.4.2 Albumin

In humans, albumin is the most abundant plasma protein, normally constituting about 50%
of human plasma protein, and has a molecular weight of 66 kDa. Albumin is a protein made
by the liver and its main role is to maintain the osmotic pressure of the blood compartment,
provide nourishment of the tissues, and transport hormones, vitamins, drugs, and other
substances such as calcium throughout the body [31]. The normal concentration of albumin
in the human body is 30 g/L. Acute dehydration is the only clinical situation that is found to
cause an increase in albumin concentration [8]. In the event of critical illness, the rates of
synthesis and degradation of albumin are altered, leading to an abnormal distribution of
albumin between the intravascular and extravascular compartments. The concentration of
albumin decreases dramatically in critically ill patients and does not increase until the
recovery phase of the illness [32]. Increased capillary leakage is the main reason for the
altered distribution of albumin in critical illness. This is reported to occur in sepsis and after
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major surgical stress [33], [34]. Cirrhotic patients are highly prone to suffer from septic
shock. Several studies have demonstrated that the functions of albumin, such as ligand
binding and transport of various molecules, can be applied in the treatment of cirrhotic
patients and patients suffering from other end stage liver diseases [35]. It is clear that closely
monitoring the variation in albumin concentration could act as an indicator of liver diseases
and other related pathologies.

2.3.4.3 Globulins

Globulins represent fractions of proteins identified in the plasma/serum known as alpha-1
globulins, alpha-2 globulins, beta globulins and gamma globulins (Table 2.2). Each one of
these fractions have various biological functions, including immune functions.

Table 2.2. Globulin fractions with example of encompassed proteins
Beta globulins

Gamma globulins

Range: 7-15 g/L

Range: 8-16 g/L

Very Low Density
Lipoprotein (VLDL)

Transferrin

Immunoglobulins

Alpha-1 globulins
Range: 1-4 g/L

Alpha-2 globulins
Range: 3-9 g/L

α-1 antitrypsin
α -1 acid
glycoprotein
(orosomucoid)
α -1
Antichymotrypsin

Haptoglobin

Low density lipoprotein
(LDL)

C-reactive protein
(CRP)

Alpha-2 macroglobulin

Complement protein C3

Lysozyme

High-density
lipoprotein (HDL)

Ceruloplasmin

Fibrinogen

Glycoprotein

Hemopexin

Complement protein C4

Properdin

Thyroxine-binding
globulin (TBG)
Prothrombin
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Alpha
fetoprotein

2.3.4.4 Immunoglobulins

Immunoglobulins (Ig) are gamma globulin proteins present in blood plasma and mucosal
secretions, and are delivered to sites of inflammation within tissue. They are antibodies
produced by B lymphocytes, white blood cells. They are among the most abundant proteins
in the blood, comprising 20% (by weight) of total plasma/serum proteins (Table 2.3). Based
on structure and protein composition, immunoglobulins are divided into five classes: IgG ,
IgA, IgM, IgD and IgE based on structure and protein composition (Table 2.3).

Table 2.3. Details of immunoglobulin subtypes

Molecular
weight

IgM

IgG

IgA

IgE

IgD

900 kDa

150 kDa

320 kDa

200 kDa

180 kDa

10-16 g/L

1-4 g/L

10-400 µg/L

0-0.4 g/L

Secondary
immune response:

Local
immune
response on
exposed
mucosal
surface

Immune
Antibody
responses to production
parasites
regulation

Normal
0.5-2 g/L
concentrations
Function

Secondary
immune
response:

Immune memory

Naïve
response
Abnormal
situations

Myeloma 
Immunodeficiency


Allergic
reactions 

Ig classes vary by the number of units; one unit (Ig G, IgD and IgE), two units (IgA) or five
units (IgM). The simplest antibody molecule can be represented as a Y shape (Figure 2.3),
composed of four polypeptide chains: two identical heavy chains (H) and two identical light
chains (L) oriented parallel to each other and linked by di-sulphide bonds [36]. Both light
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and heavy chains are characterised by variable and constant regions. L chains only consist of
one variable (VL = variable light) and one constant (CL = constant light) domain, while
heavy chains have one VH (variable heavy) and three to four CH (constant heavy) domains
respectively, corresponding to IgG/IgA and IgM/IgE. The terminal end of both L and H
chains present extremely variable (“hypervariable” regions), forming the antigen binding
site. There are 2 types of L chains, λ (lambda) or κ (kappa) that can be found in all types of
Ig, but never together. H chains are Ig specific and designated γ (IgG), α (IgA), μ (IgM), ε
(IgE) and δ (IgD). Each heavy chain has about twice the number of amino acids and
molecular weight (~50 kDa) compared to light chains (~25 kDa), resulting in a total
immunoglobulin monomer molecular weight of approximately 150kDa. The constant region
confers immunoglobulin its biologic activity while the variable regions form a complex,
conformational molecular arrangement for the attachment of each specific antigen.

Figure 2.3. Structure of immunoglobulins
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2.4

Pathology of plasma proteins

2.4.1 Abundant proteins

Generally, routine serological evaluation of a patient includes analysis of a panel of serum
electrolytes, total protein and glucose concentrations. Estimating total protein, globulin and
albumin content is important to assess the global and nutritional status of patients [8], [37].
The Biuret assay is the most common method used to quantify total protein levels in blood
serum [38], which is the most compatible with routine application, in terms of sensitivity and
linearity of range, as well as in terms of reaction time. Except in some known physiological
states, a low concentration is a sign of undernutrition, malabsorption or hepatic disease and
occurs in the case of severe protein loss (burn victims, renal failure). On the other hand,
hyperproteinaemia is found in conditions such as dehydration, myeloma, and systemic lupus
erythematosus.
Although total serum protein estimation has limited diagnostic potential when compared to
albumin or globulin, due to lack of specificity, its relevance in the evaluation of patients with
clinical conditions such as malnutrition, renal malfunction, liver diseases and immune
disorders cannot be ignored [37], [39]. A normal level of total serum protein between 60-83
g/L indicates healthy nutritional status and normal liver function. Reduced serum total protein
is predominantly found in patients with kidney disorders, HIV and the elderly [40], [41].
γ-globulins, produced by lymphocytes and plasma cells in lymphoid tissue, are large protein
molecules that consists of the immunoglobulins: IgM, IgA, and IgG [42]. An elevation in γglobulins is a characteristic abnormality in the serum proteins in liver diseases and carcinoma
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of the gastro-intestinal tract or breast. [43], [44]. Testing globulin levels in serum routinely
provides key information that helps diagnose various conditions and diseases that affect the
immune status. Liver diseases, chronic inflammatory diseases, haematological disorders,
infections

and

malignancies

cause

excess

Ig

levels

[45],

whereas

humoral

immunodeficiencies cause low Ig levels [46]. Radial immunodiffusion (RID) is the gold
standard method for measuring globulins [47]. All conventional methods used for testing
total protein content and globulin measurement make use of expensive disposables and are
labour intensive. With escalating medical costs and budget constraints, a cost effective
alternative technology is desirable.
Serum protein electrophoresis (SPEP) is a cost effective method for separation of proteins,
based on their net charge (positive or negative), size and shape. It enables visualisation of the
two major types of protein present in the serum: albumin and the globulin proteins.

Figure 2. 4. Disease patterns in serum protein electrophoresis (SPEP)

The largest peak, closest to the positive electrode, reflects the high concentration of albumin,
while globulins are represented by multiple smaller features (Figure 2.4). However, the
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pattern of five globulin categories (alpha-1, alpha-2, beta-1, beta-2, and gamma) contains the
most relevant information for diagnosis. A dense narrow band that is composed of a single
class of immunoglobulins is categorised as monoclonal gammopathy. It is the result of a
malignant clone producing only one type of antibody that leads to a thin peak in protein
electrophoresis. A broad-based band in the gamma region suggests a polyclonal increase in
immunoglobulins (Polyclonal gammopathy). When the β-globulins and γ-globulins do not
separate, it can be specific to liver disease (cirrhosis), but is also common in autoimmune
disease, chronic viral or bacterial infections. SPEP is a rapid technique to detect a number of
conditions based on qualitative and quantitative patterns of the serum fractions. Table 2.4
provides examples of conditions with increased or decreased levels in protein fractions.
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Table 2.4. Serum Protein Fractions and Conditions Associated with an Increased or
Decreased Level
Serum Protein

Albumin

Alpha-1

Decreased
Malnutrition
Cachexia (wasting syndrome)
liver disease
nephrotic syndrome
Impaired liver function
protein-losing enteropathies
Haemorrhage
severe burns
Alpha-1 antitrypsin deficiency
Nephrotic syndrome
Liver dysfunction
Haemolysis
Liver disease

Alpha-2

Protein malnutrition
Globulins
Beta 1-2

Agammaglobulinemia,
hypogammaglobulinemia
Gamma

Increased
Indicator
dehydration

for

Pregnancy
Inflammatory states
Nephritic syndrome
Adrenal insufficiency
Adenocorticosteroid
therapy
Advanced
diabetes
mellitus
Hyperthyroidism
Biliary cirrhosis
Hypothyroidism
Nephrosis
Polyarteritis nodosa
Obstructive jaundice
Cushing’s disease
Third-trimester
pregnancy
Iron-deficiency anemia
Cirrhosis
Multiple myeloma
Hodgkin’s disease
Chronic lymphocytic
Leukaemia
Amyloidosis
Rheumatoid

2.4.2 Low abundance proteins

Currently, there are various proteins that are often used in the diagnosis and monitoring of
different pathologies. For example hepatic function is evaluated by ASAT (aspartate amino
transferase), ALAT (alanine amino transferase), ALP (alkaline phosphatase) and GGT
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(gamma glutamyl transferase) activities. For cardiac injuries, such as acute coronary
syndrome, diagnostic and patient care is dependent on the troponin test. Recently, a number
of studies have proven that imbalances in plasma protein levels can be linked to the presence
of numerous disease states [48], [49]. A method incorporating the ability of polyethylene
glycol fractionation and immunoaffinity depletion to detect plasma biomarkers has been
reported [50]. This method successfully identified 135 low abundance proteins with
concentration levels less than 100ng/mL. A high accuracy mass spectrometry based
proteomics method has been reported to characterise proteins in the plasma of patients with
an acute bone fracture, leading to the discovery of several new proteins which were not
previously reported in plasma [51]. Addonna et al. developed a pipeline by integrating the
proteomic technologies used from the various stages of discovery of plasma biomarker
identification, to identify early biomarkers of cardiac injury [52]. Patients were allowed to be
their own controls by sampling blood directly from patient hearts before, during and after
controlled myocardia injury. Liquid chromatography mass spectroscopy – LCMS – detected
121 highly differentially expressed proteins and >100 novel candidate biomarkers for
myocardial infarction (MI) [53]. Ray et al. identified 18 signalling proteins in blood plasma
that can be used to differentiate Alzheimer's disease samples and control subjects with close
to 90% accuracy and to identify patients who had mild cognitive impairment that progressed
to Alzheimer's disease 2–6 years later. This molecular test for Alzheimer's disease could lead
to early diagnosis and better treatment [54].

2.4.2.1 Cytochrome c
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Cytochrome c is a water soluble, ~12kDa heme protein found loosely attached to the inner
membrane of the mitochondrion. Cytochrome c normally resides in the mitochondrion and
is released into the blood in the event of cell death, triggering inflammation [55]. This protein
is essential in mitochondrial electron transport and also acts as an intermediate in apoptosis
[56], [57]. More recently, it was reported that cytochrome c can be used as an indicator of
the apoptotic process in the cell [58]. This study demonstrated that cytochrome c can act as
an in vivo apoptosis indicator and prognostic marker during cancer therapy using a
cytochrome c enzyme linked immune sorbent assay (ELISA) kit that was modified to
increase sensitivity. In another study, a sandwich ELISA method was used to measure serum
cytochrome c levels to quantify the extent of apoptosis in systemic inflammatory response
syndrome (SIRS) [59]. The prognostic significance of cytochrome c concentrations was
investigated and the ability of this method to assess the severity of organ dysfunction and
help to predict the prognosis of SIRS was demonstrated. Release of cytochrome c into
circulation has been reported in patients with myocardial infarction [60] and several liver
diseases [61]. The mean cytochrome c level recorded in patients with liver diseases was found
to be 187.1 ng/mL, whereas that of healthy controls was 39.8 ng/mL. A number of studies
have been undertaken to show that cytochrome c can be used as a potential clinical marker
of molecular and cellular damage [55]. Cytochrome c was identified in mitochondrial
damage-associated molecular patterns, along with interleukin-6 (IL-6), as a marker of
inflammation in haemodialysis patients [62]. An elevated level of cytochrome c in human
plasma/serum can be indicative of the presence of various pathologies. Therefore, this
mitochondrial protein has a huge potential to be used as a clinical marker for these diseases
at an early stage.
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2.5

Vibrational spectroscopic analysis of bodily fluids

It is recognised, however, that conventional test kits commonly employed in a hospital
environment for plasma/serum analysis suffer from long time delays due to the need for
specialised laboratories, which may in turn delay the therapy, and prolong patient anxiety
[63]. The development of optical methods for biomedical applications is an emerging field
with huge potential [64], and has recently been explored through vibrational spectroscopic
approaches [65], [66]. The sensitivity to subtle changes in biochemical composition makes
vibrational spectroscopy an ideal diagnostic tool. Considering the advancement in
spectroscopic technologies, and data analysis capabilities, coupled with filtration and
fractionation techniques, bodily fluids can be analysed rapidly and non-invasively to detect
disease related fluctuations in protein concentration [67]-[70].

2.5.1

Vibrational Spectroscopy

Vibrational spectroscopy usually refers specifically to the optical techniques of Infrared (IR)
absorption and Raman scattering spectroscopy, as well as inelastic neutron scattering. It is a
subset of spectroscopy which analyses vibrations within a molecule (or material). The
vibrations are characteristic of the molecular structure and, in polyatomic molecules, give
rise to a spectroscopic “fingerprint”. The spectrum of vibrational energies can thus be
employed to characterise a molecular structure, or changes to it due to the local environment
or external factors (e.g. radiation, chemical agents).
The number of vibrational modes for a given molecule will depend on its structure. A
molecule with N number of atoms will have 3N degrees of freedom. Generally, non-linear
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molecules will exhibit 3N-6 vibrational modes, the 6 non vibrational degree of freedom
corresponding to three translational and three rotational modes around the x, y and z axes. In
contrast, as linear molecules are unable to rotate upon their axis, one of the rotational degrees
of freedom is lost, and hence they can be described as having 3N-5 vibrational modes [71].
Bond stretching and bending are the two fundamental types of molecular vibration;
symmetric or asymmetric stretching alters the bond length, while bending vibrations consist
of changing the bond angle, by twisting, rocking, wagging and scissoring (Figure 2.5).

Figure 2.5. Common vibrational modes of chemical bonds.

Vibrational energies fall within the mid - Infrared (IR) region of the electromagnetic
spectrum and are commonly probed through IR absorption spectroscopy. Following the
discovery of IR radiation by Herschel in 1800 [72], initial applications of IR absorption
spectroscopy were limited to astronomy and astrophysics [73]. In material sciences,
significant advances were made by 1900 when Abney and Festing recorded spectra for 52
compounds, correlating absorption bands with molecular structures [74]. Coblentz helped
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establish IR spectroscopy as a routine analytical tool, cataloguing the spectra of hundreds of
substances, both organic and inorganic. Technological developments post WWII aided
considerably in establishing IR spectroscopy as a routine laboratory characterisation
technique, but none more so than the development of commercial Fourier Transform IR
(FTIR) spectrometers in the 1960s and 70s [75], [76] and FTIR microscopes in the late 1980s
[77].
Raman spectroscopy is a complementary technique with origin in the discovery of the Raman
effect in 1928 [78], for which C.V. Raman was awarded the Nobel prize in physics in 1930.
In 1998 the Raman Effect was designated an ACS National Historic Chemical Landmark, in
recognition of its importance in materials and process analysis. Raman spectroscopy
remained largely a curiosity until the advent of the laser in the 1960s, and the revolution in
Charged Coupled Detector (CCD) arrays in the 1980s and 1990s added to the benefits of high
laser source intensities. In addition, the development of narrow band laser line rejection filters
meant that the huge losses in signal from traditional triple monochromator systems could be
overcome with the combination of a filter set and a single spectroscopic grating. Furthermore,
the significant reductions in acquisition time with multichannel signal detection enabled
significant improvements in signal to noise ratios [79]. The combination of technological
developments led to a new range of Raman spectroscopic microscopes in the 1990s,
establishing Raman spectroscopic microscopy as a relatively inexpensive benchtop
laboratory tool to complement conventional infrared spectroscopy.
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Figure 2.6. Depiction of light scattering by vibrating polarisation

Both IR and Raman spectroscopy entail the coupling of incident radiation with molecular
vibrations and the resultant spectrum is characteristic of the compound or material. However,
whereas IR spectroscopy involves the absorption of radiation, inducing transitions between
vibrational states, Raman spectroscopy is a scattering technique (Figure 2.6), whereby the
incident radiation couples with the vibrating polarisation of the molecule and thus generates
or annihilates a vibration. The differing underlying mechanisms gives rise to a
complementarity of the two techniques. For a vibration to be active in IR spectroscopy, a
change in dipole is required, whereas to be Raman active, a change in polarizability is
required. As a rule of thumb, vibrations of asymmetric polar bonds tend to be strong in IR
spectra, whereas Raman is particularly suitable as a probe of symmetric, nonpolar groups.
Notably, O-H vibrations of water are very strong in IR spectra, whereas they are extremely
weak in Raman spectra, rendering Raman a potentially more suitable technique for
biomedical applications, particularly in vivo.
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A further implication of the differing physical origins of the techniques is that, whereas IR
directly monitors the absorption of IR radiation, Raman scattering can be employed in the
UV, visible or near-IR regions of the spectrum. Raman scattering thus offers intrinsically
higher spatial resolution for mapping or profiling, the diffraction limit being determined by
the wavelength (<1m for Raman, ~5-10m for IR). For many applications, however, near
IR is favoured as a source for Raman analysis, to minimise interference from scattering,
fluorescence, or photodegradation of the sample [80].

2.6 Experimental approaches

2.6.1

Fourier-Transform Infrared Spectroscopy

FTIR spectrometers have replaced traditional dispersive instruments, due to their superior
speed and sensitivity [81]. They utilise a Michelson interferometer, which is a device that
splits a single beam of IR light into two paths, and then recombines them after a variable path
difference has been introduced (Figure 2.7) [82]. The interferometers are composed of a fixed
mirror, a movable mirror and a beam splitter. The purpose of the beam splitter is to reflect
some of the radiation toward the fixed mirror, meanwhile partially transmitting the rest to the
adjustable mirror. When the waves return to the beam splitter, they interact and are then
further reflected and transmitted. The split beams travel different pathlengths as a result of
the moving mirror, and hence produce waves of different of intensity when recombined [83].
As a function of time, the light field varies spectrally, and can be converted to the frequency
domain through Fourier transformation. The absorption, reflection or scattering of light by a
sample can thus be recorded in the time domain by a single detector. FTIR absorption
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spectroscopy monitors the vibrational bending and stretching modes of molecules that are
active within the infrared region. The wavelengths at which they absorb the IR radiation are
measured, and as every compound has a characteristic set of absorption bands, it results in a
unique spectroscopic fingerprint [84].

Figure 2.7. The Michelson interferometer found in FTIR instruments. Red: incident beam,
blue: reflected and purple: combined. Adapted from ref.[85]

There are three main sampling modes involved in FTIR spectroscopy; transmission,
reflection and attenuated total reflection. By default, most FTIR instruments use transmission
mode, in which traditionally IR light is irradiated through a sample on an IR transparent
window, such as calcium fluoride, and is collected by a detector on the other side [86]. The
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coupling of transmission mode to microscopy has allowed FTIR imaging to emerge in
biomedical research [87], [88]. There are, however, a number of flaws related to transmission
mode. Sample preparation can be exhaustive, and short pathlengths (<10m) are required to
prevent full absorption of the IR radiation by the sample before reaching the detector. This
limiting factor also affects aqueous samples, since water is highly IR active [89].
Furthermore, IR transparent substrates that are required for this technique are fragile and
often rather expensive to replace [90].
In transmission/reflection, or so called transflection mode, the incident IR beam initially
travels through a sample, and is then reflected back off an IR reflecting substrate, and again
passes through the sample toward the detector. It can be advantageous in comparison to
transmission, in that the substrates are generally inexpensive low emissivity (low e) slides,
and the approximate sample thickness can usually be smaller than that required for
transmission measurements (1-4m c.f. 2-8m) which can be beneficial when sample
quantity is limited. On the other hand, as the pathlength is effectively doubled there is also a
maximum thickness limitation. Transflection mode may also be prone to standing wave
artefacts that cause spectral variance, although the implications of this effect for diagnostic
applications are still being assessed [86], [91], [92].
In assessing the suitability of the measurement mode for analysis of biological samples which
are highly physically and chemically inhomogeneous, it is important to understand the
physical processes involved. When a sample is measured in reflection, or transflection, a
proportion of the light registered derives from the top surface, the reflectance of which is
governed by the real component of the refractive index of the material. The transmitted light,
measured in transmission or transflectance, can be reduced by the intrinsic absorptions of the
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constituent molecules, giving rise to the desired fingerprint of the sample, but can also be
reduced by “Mie-like” scattering from structures (cells and cell nuclei) which have
dimensions similar to the wavelength of light employed (5-20m). This scattering is
resonantly enhanced in the neighbourhood of an absorption, and can give rise to spectral
“artefacts” in reflection, transflection and transmission modes [93], [94]. These resonant Mie
effects can be ameliorated by application of specific pre-processing methods [95].
The development of attenuated total reflection-Fourier transform infrared (ATR-FTIR)
spectroscopy has attracted wide interest in the field in recent years. The technique is unique
in that the incident IR beam does not actually travel through the sample, but is directed
through a substrate with a high refractive index, such as diamond, germanium or silicon,
known as an internal reflection element (IRE). The sample must be placed in direct contact
with the IRE, as when the incident radiation reflects off the internal surface of the IRE, an
evanescent wave projects orthogonally into the sample, which then attenuates the IR beam
before exiting the IRE to the detector [89]. The refractive index of the chosen IRE and the
sample govern the basic ATR phenomenon, as shown in Eq.1, where the critical angle θc,
can be calculated from n1 and n2, which are the refractive indices of the IRE and sample,
respectively.
𝑛2
𝜃𝑐 = sin−1 ( )
𝑛1
Equation 1: Calculation of the critical angle 𝜃𝑐 , where 𝑛1 and 𝑛2 are the refractive indices of
the IRE and sample, respectively.

The IR radiation undergoes total internal reflection when the angle of incidence at the
sample-crystal interface is greater than the critical angle, hence materials with a high
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refractive index are commonly chosen to minimise the critical angle [96]. An important factor
is the depth of penetration 𝑑𝑝 of the evanescent wave into the sample (Equation 2), as it
determines how much of the sample is actually analysed [85]. The penetration depth is
dependent upon the angle of incidence, refractive indices and the wavelength; at longer
wavelengths, the evanescent wave will penetrate deeper into the sample.

𝑑𝑝 =

𝜆
2𝜋𝑛1 √𝑠𝑖𝑛2 𝜃 − (𝑛2 ⁄𝑛1 )2

Equation 2: The depth of penetration 𝑑𝑝 where  is the angle of incidence and  is
wavelength.

One limitation with this approach, is that the IRE must be kept clean to ensure there is no
cross-contamination between samples, inhibiting throughput. Traditional IREs can also be
expensive, for example a fixed diamond crystal, preventing multi-IRE systems. However,
multi-IRE systems have been developed that will enable a high throughput analysis [97].
Scratches on the surface of the IRE are known to affect the sample-IRE contact, and loss of
sensitivity is common due to the shallow penetration depths [82]. That said, ATR has become
extremely popular in FTIR spectroscopy, as it has numerous advantages over the other IR
techniques [85]. In contrast to transmission mode, for which the sample usually has to be
pressed into a pellet or thin film, the ATR-FTIR mode negates the need for time consuming
preparation, as the sample can be examined directly on to the IRE, in liquid or solid state.
The shorter pathlength makes it more applicable for aqueous samples, as there is less IR
radiation is lost through water absorbance, compared to transmission measurements [89].
Likewise, minimal scattering effects and relatively high signal-to-noise ratio (SNR) are
valuable attributes [86]. Biological samples, such as human blood serum, are well suited to
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ATR analysis as only small volumes of biofluid drops are required to dry efficiently onto the
IRE. The size of the crystal governs the volume of sample that is required, and to ensure
intimate contact occurs the sample should cover the whole IRE, allowing effective
penetration of the evanescent wave [98].

2.6.2 Instrumentation for Raman spectroscopy

A Raman spectrometer typically consists of three major components: an excitation source, a
sampling apparatus, and a detector. While these three components have evolved in varying
forms over the years, modern Raman instrumentation has developed around using a laser as
an excitation source, a spectrometer for the detector, and either a microscope or a fibre optic
probe for the sampling apparatus. Figure 2.8 shows a schematic of a typical Raman setup.
The laser sources provide a stable and intense beam of radiation. A wide range of lasers can
be used as the light source, although, for biological applications, longer wavelength, near
infrared sources are commonly employed, to minimise photodamage, scattering and/or
fluorescence [99]. Band pass “interference” filters are employed to clean the laser spectrum
and remove plasma lines. Dispersive instruments make use of a notch filter coupled with a
high quality grating monochromator. Double, or triple, grating monochromators, rejection
filters, super notch filters, holographic notch or edge filters and holographic filters are
employed to separate relatively weak Raman lines from intense Rayleigh scattered radiations
[100]. Charge transfer devices (CTDs) such as charge-coupled devices and charge-injection
devices act as detectors and are used in the form of arrays. The role of the CTD arrays are to
convert the incoming optical signal into charge which are then integrated and transferred to
readout devices [101]. CTDs are commonly made of silicon so laser wavelengths of less than
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1 μm can be detected, while laser wavelengths of greater than 1 μm use single element
detectors based on a low band-gap semiconductor, such as Germanium (Ge) or Indium–
Gallium–Arsenic (InGaAs). The grating is used to disperse the light and the groove density
determines the spectral resolution. Other factors that play a key role in determining spectral
resolution include the wavelength, shorter wavelengths having a higher spectral resolution,
and the spectrometer length, which is the distance between grating and the detector, longer
distances providing higher resolution. The objective lens both delivers the incident light and
collects the scattered light. The objective lens delivers the incident light to the sample, and
the Raman scattered light can be observed at any angle. In the commonly employed
backscattering geometry, the Raman is collected by the objective lens and delivered to the
grating. The spectrally dispersed, detected Raman scattered light is displayed as a Raman
shift from the source wavelength, which in converted to units of wavenumber (cm-1), such
that Raman spectra can easily be compared and contrasted with equivalent FTIR spectra.
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Figure 2. 8. Typical Instrumentation for Raman microspectroscopy (CCD; charge coupled
detector)

2.7 Biospectroscopy

FTIR spectroscopy has become an accepted tool in biophysics for analysis of the structure
and interactions of proteins, lipids, carbohydrates and nucleic acids [102]-[105]. Applications
to tissue samples for diagnostic applications were first reported in the early 90s, and since
this time a range of pathologies has been investigated [106]-[108]. The application of Raman
spectroscopy to biomolecules and even tissues was first demonstrated as early as the 1960s,
and by the mid 1970s biomedical applications were explored [109]-[111]. Whole cell and
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tissue studies have been carried out on a range of pathologies [112]-[114] and in vivo studies
[115], [116] have demonstrated the prospective for diagnostic applications. The potential of
vibrational spectroscopy in conjunction with multivariate analysis techniques as a diagnostic
tool has thus been well demonstrated and the concept of spectral cytopathology has been
coined [117]. In this respect, Raman and infrared can be viewed as rival technologies, but to
best advance the understanding of the potential of the techniques a combination of the two
complementary techniques is recommended.
Lipids, proteins, nucleic acids and carbohydrates are the four biomolecular groups
characteristically found in a biological spectrum, as measured using either FTIR or Raman
spectroscopy. Figure 2.9 shows, for example, the (A) FTIR and (B) Raman microscopic
spectra of human blood serum, where the protein-related bands are highlighted, while Tables
2.5 and 2.6 shows typical band assignments across the full spectra. In the "high wavenumber
region", >2500cm-1, of the FTIR spectrum, the distinctive vibrations of N-H, C-H and O-H
of lipids and proteins can be found, whereas in the "fingerprint region", <1800cm-1, the
features are typically more complex combinations, including the Amide I (1650cm-1) and
Amide II (1520cm-1) modes of proteins, nucleic acid phosphate stretching modes at 1070cm1

and 1250cm-1 and lipidic derived features at 1310cm-1 and 1750cm-1. It should be noted

that, although complementary techniques, the features in the respective spectra of FTIR and
Raman have similar origin. Thus, the Raman spectrum of the nucleus exhibits similarly
prominent signatures associated with proteins and lipids across the fingerprint region, as well
as large peaks related to DNA and RNA at 785cm-1.
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Figure 2. 9. Typical IR (A) and Raman (B) spectrum of human blood serum

A notable difference between the two spectra is the spectral range is presented (Figure 2.9).
FTIR covers the full spectral range in a single scan of the interferometer, which is recorded
by a single detector. In contrast, Raman spectroscopy is currently predominantly performed
by dispersive techniques, by which a spectral range is dispersed onto a CCD pixel array. The
range covered depends on the dispersion element (grating) and use of higher resolution
gratings means that multiple windows are required to cover the whole spectral range. Hence,
Raman spectra are frequently presented as either the fingerprint or high wavenumber region.
On the other hand, either Raman or FTIR can be limited in the lower wavenumber limit by
instrument detectors, optical elements and or substrate used. Typically, Raman spectra are
recorded as low as 400cm-1, FTIR only as low as 1000cm-2 or 600cm-1.
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Table 2.5. Tentative peak assignments for FTIR spectral data, (i)-(vii) corresponds to Figure
9A [118]-[121]
Approximate
Wavenumbers (cm1)
3300 (i)
3100 (ii)
2957
2920
2872
2850
1740
1715-1680
1650 (iii)
1645
1550 (iv)
1453
1450 (v)
1395 (vi)
1395
1380
1350-1250 (vii)
1242
1170
1150
1090
1086
1079

Vibration

Biochemical Assignments

ν(N-H)
ν(N-H)
νas(CH3)
νas(CH2)
νs(CH2)
νs(CH2)
ν(C=O)
ν(C=O)
>75%ν(C=O),
ν(C-N), (N-H)
(HOH)
~60% (N-H), ν(C-N),
(C-O), ν(C-C)
(CH2)
as(CH3)
s(CH3)
ν(C=O)
s(CH3)
(N-H), ν(C-N),
(C=O), ν(C-C),
νas(PO2-)
νas(C-O)
ν(C-O), (COH)
νs(PO2-)
ν(C-O), ν(C-C),
def(CHO)
ν(C-C)

Amide A of proteins/peptides
Amide B of proteins/peptides

Lipids
Phospholipid esters
Nucleic acids
Amide I of proteins
Water
Amide II of proteins
CH2 Scissoring
Lipid/Proteins
Lipid/Proteins
Carboxylate COOPhospholipid/triglyceride
Amide III –
peptide/protein/collagen
DNA/RNA/phospholipid
Ester
Carbohydrates
DNA/RNA/phospholipid
Carbohydrates
Glycogen

1065
DNA and RNA ribose
ν(C-O)
1050
ν(C-O)
Phosphate ester
1028
def(CHO)
Glycogen
2965
DNA and RNA Ribose
ν(PO3 )
710-620
def(O=C-N)
Amide IV
ν = stretching;  = bending;  = wagging, twisting and rocking; def = deformation; as =
asymmetric; s = symmetric
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Table 2.6. Tentative peak assignments for Raman spectral data, (i)-(viii) corresponds to
Figure 2.9B [122], [123].
Approximate
Wavenumbers
(cm-1)
785-788
1004(i)

Vibration

Biochemical
Assignments

νs (PO2-)
Nucleic Acid
ν(ring breathing)Phenylalanine
Protein
2νs (PO )
Nucleic Acid
1090(ii)
ν(C-N)
Protein
ν(C-N)
Protein
1127(iii)
ν(C-C)
Lipid
2νs (PO )
Nucleic Acid
1262
Amide III of Proteins
(N-H), ν(C-H)
Lipid/Nucleic Acid
(CH2)
1319(iv)
def(CHO)
Protein
2νs (PO )
Nucleic Acid
1341(iv)
def(C-H)
Protein/Fatty acid
1451(v)
Protein/Lipid
(CH2)
1554 (vi)
Amide II of Proteins
(N-H), ν(C-N)
1619(vii)
ν(C=C)
Protein
ν(C=O)
Amide I of Proteins
1662(viii)
ν(C=C)
Lipid
ν = stretching;  = bending;  = twisting; def = deformation; s = symmetric

2.8 Vibrational Spectroscopy of Protein

For the investigation of proteins, vibrational spectroscopy is particularly useful, as protein
related bands are dominant within biological spectra. Stretching vibrations are found in the
higher-wavenumber region (3500-2500cm-1), such as C-H, N-H and O-H stretches, whereas
bending and carbon skeleton fingerprint vibrations tend to occur in the lower-wavenumber
regions. The most important spectral region in relation to biological materials is the
information-rich fingerprint region (1800-400cm-1), wherein the Amide I and II peaks exist
(1700-1500 cm-1) [86].
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The wealth of information that exists in a vibrational spectrum of a biological sample,
detailed in Tables 2.5 and 2.6, renders the techniques as interesting tools for investigating
molecular systems ranging from amino acids, peptides and protein complexes [124]-[127].
Vibrational spectroscopy can enhance the understanding of protein function, as it is sensitive
to changes to the protonation state of amino acid side chains and the strength of hydrogen
bonding between amide bonds [128], [129]. In both IR and Raman spectra, most
characteristic bands are associated with the CONH group, referred to as Amide A (NH
stretching, ~3300 cm-1), Amide B (NH stretching, ~3100 cm-1) and Amide I to VII (I: 1600–
1700 cm-1, II: 1480–1580 cm-1, III: 1230–1300 cm-1, IV: 625–770 cm-1, V: 640–800 cm-1,
VI: 540–600 cm-1,VII: 200 cm-1) (Figure 2.10) [118], [130]. The Amide A band (~3300cm1

) originates from the NH stretching vibration, which are often present as a resonance doublet

with the weakly absorbing Amide B (~3170cm-1), arising from a Fermi resonance between
the first overtone of Amide II [118]. The Amide I, which absorbs near 1650cm-1, is primarily
caused by the C=O stretching vibrations, with smaller contributions from CN stretching,
deformation of CCN and NH in plane bending vibrations. The out-of-phase combination of
the NH bending and the CN stretching vibrations, as well as minor contributions from the
CO in-plane bend and the CC and NC stretching vibrations, give rise to the Amide II band at
~1550cm-1 [131].
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Amide A & Amide B

Amide I

Amide II

Amide III

Figure 2.10. Molecular vibrations of the amide group - Orange: Hydrogen, Red: Nitrogen,
Purple: Carbon, Blue: Oxygen. Adapted from ref [132]

Similar analyses can be performed using IR and/or Raman spectroscopy, and even Raman
Optical Activity (ROA), which is particularly sensitive to molecular chirality [133].
Although infrared absorption and Raman scattering spectroscopy probe the same physical
phenomenon of molecular vibrations, the spectral profile is discernibly richer in substructure
in the case of Raman, for similar instrumentational specifications in terms of spectral and
spatial resolution [134]. Infrared absorption involves an electric dipole transition between
two vibrational states, each of which has its own homogeneously and inhomogeneously
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broadened line width. The resultant spectral bandwidth is a convolution of these two
individual line widths. Although often represented as a transition between a real vibrational
level of the manifold of an electronic state and a virtual electronic level, Raman is a scattering
process. In the representation of the transition to a virtual state, the bandwidth of that state is
infinitesimally small, and so the scattering line width is intrinsically less than that of an
equivalent infrared absorption transition, giving rise to more distinct spectral features.
A characteristic feature of Raman spectra of many proteins, not observed in IR spectra, is the
strong and often dominant feature at ~1004 cm-1, ascribed primarily to the ring breathing
mode of the phenylalanine residue. Note, however, that its prominence in the spectrum does
not reflect a similar relative prominence over other residues in the protein structure, but rather
the large Raman scattering cross section of the highly polarisable, π-conjugated, ring
structure. Similarly, the porphyrin moieties of cytochrome c contributes strongly to the
Raman spectrum at ~1585 cm-1, and can be resonantly enhanced at source wavelengths of
<550nm (Figure 2.11) [135].

Figure 2. 11. Raman spectra of (A) Albumin, (B) Fibrinogen and (C) Cytochrome c.
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Many studies have looked at the potential of vibrational spectroscopy to predict protein
secondary structure, as the Amide I band is highly sensitive to hydrogen bonding pattern,
dipole-dipole interaction and the geometry of the polypeptide backbone [136]. A series of
overlapping components that represent different structural elements, such as -helices and
-sheets, are present in the broad Amide I band [89], [137].
Rygula et al. have reviewed the analysis of the secondary structure of proteins using Raman
spectroscopy of 26 different proteins [130]. Raman spectroscopy for analysis of protein
secondary has focused largely on the correlation of the position of the amide I and amide III
vibrations with the crystallographically determined fraction of each secondary structural
element present in the protein. Associated with the amide I and amide III modes,
wavenumbers assignments for features associated with α-helix and β-sheet structures
include: 1662–1655 and 1272–1264 cm-1 (a), 1674–1672 and 1242–1227 cm-1 (b),
respectively, and the review also classified structures as “mixed structures  s)”
and “others” [138]. The bands relating to protein secondary structure of the Amide I band are
summarised in Table 2.7.
Particularly for the case of IR studies, protein secondary structures have been studied
experimentally using both H2O and D2O. This is mainly due to the H2O absorbance
overlapping with the Amide I band, but it is also thought to be easier to obtain spectra in D2O
as the bands occur at lower wavenumbers than H2O, meaning the region between 14001800cm-1 exhibits relatively low absorbance (or scattering), providing an ideal window to
observe the weaker bands of solubilised protein [136]. That said, using H2O as a solvent is
still preferable to D2O when looking at protein structure, as D2O can slightly alter the
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flexibility of proteins; for example, D2O has been shown to increase the rigidity of most
protein structures [139].

Table 2.7. Assignment of Amide I band positions to secondary structure in H2O for both IR
and Raman [128], [130], [136], [137] and [140]

-Helix

IR band Position (cm-1) Raman band Position (cm1)
1648-1657
1650–1659

-Sheets

1623-1641 & 1674-1695

1669-1674

Turns

1662-1686

1680-1690 & 1653-1656

Disordered/Random Coil

1642-1657

1640-1651

Secondary Structure

Fourier self-deconvolution (FSD) and derivative filtering are commonly employed methods
for the investigation of protein secondary structure. FSD mathematically reduces bandwidths,
so that the overlapping bands can be resolved [141]. This can also be achieved by
differentiating the spectrum, commonly by calculating the second derivative, which exhibits
a negative peak for every band or shoulder in the spectrum. For quantification, both FSD and
second derivative spectra require curve-fitting (Figure 2.12), and the fractional areas of the
fitted components correspond to the relative quantities of the different types of secondary
structure [136]. Thus, the band areas are directly proportional to the relative amount of
secondary structure that is represented in that spectral region. The quantity of each
component is expressed as a percentage, which provides a clear picture of overall protein
structure. For example, second derivative analysis by Dong et al. predicted that
Immunoglobulin G contains mostly -sheets (64%) and turns (28%), with few random coils
55

(5%) and -helix (3%), a finding which was found to be closely correlated to the values
obtained through X-ray crystallography [142].

Figure 2. 12. Curve fitting of the Amide I band in serum, for IR (A) and Raman (B)
Spectra

Moreover, the estimation of amino acid side-chain absorption must be considered in the
analysis of protein spectra. Amino acid residues - arginine, asparagine, glutamine etc. also
absorb in the Amide I/II spectral region (Table 2.8). In the IR spectra of some globular
proteins, the contribution of side-chains can be as high as 10-30% of the overall absorbance
[137]. This can be a potential difficulty as the contribution from the amino acids will depend
on their protonation state, which can be challenging to evaluate. The quantitative estimation
of these groups can allow more refined predictions of the secondary structure of proteins and
polypeptides by FTIR [136], [143].
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Table 2.8. Summary of main amino acid side chain absorptions found in IR spectra
between the 1400-1800cm-1 region [128], [136], [144]
Side chain assignments
Asp,ν(C=O)

Approximate band position in IR
(cm-1)
1716

Glu,ν(C=O)

1712

Asn, ν(C=O)

1678

Arg, νas(CN3H+5 )

1673

Gln, ν(C=O)

1670

Arg, νs(CN3H+5 )

1633

Lys, as(NH+3 )

1629

Asn, (NH2)

1622

Gln, (NH2)

1610

Tyr, Ring-O-

1602

Asp, νas(COO-)

1574

Glu, νas(COO-)

1560

Lys, s(NH+3 )

1526

Tyr, Ring-OH

1518

Phe, Ring

1494

ν = stretching;  = bending; as = asymmetric; s = symmetric
Rygula et al. also identify features of the Raman spectra that permit the description of the
environment of numerous amino acid chains. These include the amino acid side-chain modes
(e.g. tryptophan doublet 1360/1340 cm-1, tyrosine doublet 860/833 cm-1) or the sulphurcontaining residues in the different physical states (C–S stretching with H at the trans position
of the S atom: 640–680 cm-1 and C–S stretching with C at the trans position of the S atom;
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740–760 cm-1, S–S stretching: 508–512 cm-1 (GGG), 523–528 cm-1 (TGT), 540–545 cm-1
(TGT) [138].

2.8.1 Spectroscopic signature of serum

Over the past decade, there has been a rapid increase of proof of concept publications for
spectroscopic disease diagnostics, highlighting its potential for progression into the clinical
environment. The majority of the publications in the biomedical vibrational spectroscopy
field have been based on the analysis of human tissue, with pilot studies showing it is possible
to differentiate between healthy and cancerous tissue, as well as benign and malignant
tumours [84]. Malignancies from various organs, such as breast, lung, colon and prostate
tissues, have previously been studied which has provided a platform of promising results
[145]-[147], [119], [106]. Despite the high volume of published research, the technique has
yet to make a successful transition into the clinic [70].
More recently, there has been further interest in biofluid spectroscopy due to the ease of
collection and handling, and minimal sample preparation is required. Blood components such
as serum and plasma are commonly analysed for clinical reasons, carrying information
regarding intra- and extra-cellular events. Biobanks exist as a valuable stock both serum and
plasma, with the ability to repeat analysis or monitor treatment or disease progression [69].
More specifically, blood serum is the most complex biofluid, containing over 20,000
different proteins. As it perfuses all body organs, it gains proteomes from surrounding tissues
and cells [148]. The low molecular weight fraction of serum - the peptidome - is information
rich, therefore the spectroscopic biosignature of serum is ideal for detecting disease states
[149].
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ATR-FTIR spectroscopy has been proven to be a promising screening tool for detecting
ovarian cancer from human blood, where both serum and plasma were used to discriminate
ovarian cancer patients from healthy controls with a success rate of ~95% and ~97%,
respectively [150]. Backhaus et al. used serum spectroscopy to differentiate between patients
in good health and those with breast cancer, by applying unsupervised and supervised
methods, reporting sensitivities and specificities of >92% for both [151]. Another pilot study
found that the serum biosignature for cirrhotic patients, with and without hepatocellular
carcinoma (HCC), could be successfully separated using support vector machine (SVM)
classification and leave-one-out cross validation [152]. Furthermore, patients with extensive
fibrosis in the liver have been separated from those without fibrosis, which is a common
disorder in the early developmental stages of HCC, by using their FTIR serum spectra.
Ollesch et al. introduced automated sampling for the first time, robotically spotting serum
for high throughput FTIR measurements, in their quest to identify and validate spectroscopic
biomarker candidates for urinary bladder cancer [153]. By using as little as 1l of blood
serum for ATR-FTIR analysis, Hands et al. were not only able to distinguish between serum
of brain tumour patients and controls, but could effectively predict tumour grade by
separating low grade lesions from patients with glioblastoma (high grade), highlighting the
great potential of ATR-FTIR spectroscopy of blood serum for determining the severity of
brain tumours [154]. Paraskevaidi et al. demonstrated that ATR combined with
chemometrics was capable of differentiating patients with various neurodegenerative
diseases. Alzheimer’s disease (AD) was identified with a sensitivity and specificity of 70%,
and the AD patients were further segregated from those with dementia with 90% accuracy
[155].
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In order to maximise classification accuracy, feature extraction techniques can be utilised to
pick out the most salient properties of the IR spectra. These methods isolates the features that
are most highly correlated with a target set and ranks them based on similarity, which in turn
allows discrimination between classes and maximizes the intergroup differences [156]. In a
further study, Hands et al. used feature extraction to select the most discriminatory spectral
regions in their dataset [157]. Blood serum from cohort of 433 patients, with and without a
brain tumour, were collected for ATR-FTIR analysis. This substantial dataset consisted of
control samples (non-cancer) and various brain tumour types; high- and low-grade glioma,
meningioma and metastatic tumours. The variable ranking function highlighted the
wavenumber variables that were most salient between each spectral class. This technique
proved to be effective in exposing the changes in the spectral signature between classes and
tumour grade, and was capable of differentiating between: cancer and non-cancer; glioma
and meningioma; metastatic and brain cancer; and high- and low-grade glioma, based on the
most discriminatory spectral regions; Amide I, Amide II, C-O stretch of lipids/proteins, CH2
of lipids/proteins and PO2- of DNA/RNA. Furthermore, vibrations of C-O, C=O and C-H of
lipids/proteins, as well as the PO2- stretch from nucleic material, enabled discrimination
between the three organs of origin of the metastatic cancer samples (lung, melanoma and
breast). Previous studies have also highlighted these spectral regions when analysing brain
cancer and metastatic states via tissue spectroscopy [158], [159]. To further explore the
dataset gathered by Hands et al., machine learning techniques were employed in a
computational study by Smith et al. [160]. The cancer versus non-cancer spectra were
classified by RF, which utilised a Gini impurity metric to elucidate the most important
wavenumber regions for the classification. The carbohydrate region (997-1003cm-1) was
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found to be of highest RF importance, followed by the phosphate (1290-1294cm-1), lipid CH2
(1462-1464cm-1), Amide II (1527-1533cm-1), carbohydrate (1028-1034cm-1) and protein
COO- (1387-1390cm-1) regions. 2D correlation analysis was also performed alongside RF.
The features highlighted by the 2D correlations were highly comparable to the RF results,
further clarifying the main spectral differences. The combination of these machine learning
methods permitted successful discrimination of cancer and non-cancer, with sensitivities and
specificities of 92.8% and 91.5% respectively, verifying the plausible use of orthogonal
techniques to examine salient information for more accurate and rapid diagnostics [160].
Although ATR is preferred for biofluids analysis, the strong absorbance of water is still
evident in the fingerprint region, which can obscure protein absorbance in liquid samples.
Hence, the analysis of biofluids has been predominantly performed on air dried samples,
which can lead to chemical and physical inhomogeneity. The complex patterns that arise
from dried biofluid drops have been of great interest over that past few decades, and various
models have been published in an attempt to explain the complicated drying behaviour [161].
In analysing such dried droplets using single-point transmission FTIR, Hughes et al. found
the absorbance of the Amide I/II region to be highly variable across a minute drop of blood
serum. Spectra obtained from random locations across the dried serum spot, showed evidence
of differences in sample thickness and heterogeneity. IR transmission imaging verified that
there were biochemical differences across the drop [162]. Furthermore, the loss of light due
to scattering, caused by the presence of cracks throughout the sample, along with varied drop
thickness led to the conclusion that samples need to be smooth and evenly spread for
transmission measurements [163]. Deegan et al. proposed the coffee ring effect, whereby
capillary flow forces biomolecules to move out towards a drop’s edge leaving behind dense
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ring at the periphery [164]. This is common when drying biofluid drops, which is a concern
for spectroscopists, as the centre of the drop may not be representative of the whole sample.
Specifically in blood serum, the process is known as the Vroman effect, whereby a series of
molecular displacements arise through protein exchange [165]. When a biological liquid is
applied to a solid surface, low molecular weight proteins attach to the surface first, before
being displaced by larger protein molecules over time. Therefore, the adsorption of proteins
on to the substrate surface will be based on their differing affinities [166]-[168]. Gelation and
cracking patterns have also been observed in dried biofluid drops, which are thought to be
dependent on protein concentration [88], [169]. These are the main limiting factors of using
dried biofluids, as the surface inhomogeneity can cause peak shifts and alterations in band
intensities [162]. Environmental (temperature and humidity) and experimental (volume and
concentration) conditions have been shown to affect the drying patterns, hence it is vital the
drying conditions are controlled and optimal protocols are developed in order to obtain a
more homogenous deposition across the sample [161], [170]. When measured in the ATR
mode, however, the sample deposit can be completely contained within the area of the crystal,
such that the evanescent wave measures the average of the entire drop, averaging out any
inhomogeneities.
Raman spectroscopy is a complementary tool to IR spectroscopy and is compatible with
aqueous samples. This technique allows the analysis to be carried out in the native state of
bodily fluids, and, therefore, the additional drying step can be eliminated. A comprehensive
proof of concept has been designed and conducted to detect hepatocellular carcinoma (HCC)
from patient serum using micro-Raman spectroscopy using dried and freeze-dried serum
drops [171]. The aim of the study was to discriminate serum samples of patients with HCC
62

and patients without HCC. Two groups of patients were classified with an overall accuracy
of 84.5% to 90.2% for dried serum drops and 86% to 91.5% for freeze-dried serum. Although
not specifically protein based, Mahmood et al. demonstrated the ability of Raman micro
spectroscopic analysis of dried blood serum to identify the presence of dengue infection, and
to correlate the spectroscopic response with viral load [172]. A surface-enhanced Raman
scattering (SERS) based immunoassay has been developed to monitor levels of the mucin
protein MUC4 in patient serum, which will help in the early detection and diagnosis of
pancreatic cancer [173].
Raman and surface-enhanced Raman spectroscopy (SERS) using silver nanoparticles, have
been employed to identify signatures linked to ovarian cancer in blood plasma [174]. Both
techniques provided satisfactory diagnostic accuracy for the detection of ovarian cancer,
Raman achieving 94% sensitivity and 96% specificity, and SERS 87% sensitivity and 89%
specificity. For early ovarian cancer, Raman achieved sensitivity and specificity of 93% and
97% respectively, while SERS had 80% sensitivity and 94% specificity.
As Raman microspectroscopy, by default, measures a very limited area of the sample, defined
by the spot size of the objective focus, its suitability for analysis of chemically and physically
inhomogeneously dried biofluid droplets is limited. However, an improved protocol for
Raman spectroscopic analysis coupled with fractionation of serum using centrifugal filters to
concentrate and separate low molecular weight proteins has been demonstrated [175]. FTIR
spectra were recorded in aqueous solutions of gelatin at concentrations as low as 100 mg/L,
using Raman spectroscopy, high quality spectra of gelatin solutions as low as 10 mg/L was
achieved. Spectral features of human serum were found to be weak and partially obscured by
water features. Dried deposits were shown to be physically and chemically inhomogeneous,
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resulting in unreliable results. Concentration of the serum using commercially available
centrifugal filter devices resulted in enhanced spectral intensity and quality and a hundred
per cent recovery of the analytes. Improved analysis of serum using Raman spectroscopy was
reported when the sample was analysed in the inverted geometry using the water immersion
objective with a 785nm laser as source (Figure 2.13). A drop of water is used to minimise
the differences in the refractive indexes between sample, objective and the substrate.
However, the water drop does not contribute to the data collected, as it is outside the focus
of the beam.

Figure 2. 13. The inverted geometry used to analyse the serum focused by immersion
objective

Using this analytical set up, Parachalil et al. recently reported on a systematic investigation
of sample preparation considerations and data processing, for the analysis of blood plasma
and serum [176]. In a solution of proteins, mixed in physiologically relevant concentrations,
it was clearly seen that the poorly water soluble fibrinogen presented significant challenges
to measurement in the liquid phase, as it caused extensive Mie scattering of the source laser
as well as the Raman scattering from itself, and the other protein constituents, preventing any
64

quantitative measurement. This is a strong indication that the analysis of blood serum rather
than plasma is favourable for optical based techniques. In cases where the determination of
fibrinogen levels is desired, the study showed that fibrinogen aggregates were broken down
through mild sonication of the mixture, which significantly reduced the scatter.

2.8.2 Quantitative analysis

The ability of vibrational spectroscopy to quantify levels of biomolecules in blood serum has
enabled various clinical studies over the past few decades [177]. In recent years, the
technique has been introduced for potential disease screening and monitoring for numerous
health conditions, including arthritis, diabetes, heart disease and a variety of cancers [178][180]. The development of a robust spectroscopic protocol could enable the replacement of
the quantification methods currently used in medical practice.
An early study reported the quantitative analysis of dried serum films provided high accuracy
for total protein, triglycerides, cholesterol, urea and glucose, although the protocol was found
to be less suitable for creatinine and uric acid [177]. Another demonstrated that both low
density lipoprotein and high density lipoprotein cholesterol can be independently quantified
using IR spectroscopy of dried serum films [181]. A later study showed patients with multiple
myeloma are distinguishable from healthy patients through FTIR analysis of serum
immunoglobulins, where the band intensity ratios in the spectral profile of the myeloma
patients were higher than those with normal immunoglobulin levels [182].
Perez-Guaita et al. published an extensive quantitative study, using ATR-FTIR and partial
least squares regression (PLSR) to determine the concentration of various proteins in human
serum [183]. They established models for albumin and immunoglobulin, as well as total
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globulin and the albumin/globulin ratio, which are routinely determined in clinical practice
as they can be indicative of diseased states [184]. As the selected proteins exhibit different
secondary structures, their analysis was focused on the behaviour of the Amide I/II bands.
Their findings suggest that this technique could be useful in clinical practice as a routine
assay for protein determination, as their prediction capability was extremely high for both
albumin and total globulin, the root mean square error of prediction (RMSE) being lower
than 5% for both. The RMSE for immunoglobulin and the albumin/globulin coefficient were
slightly higher, between 7-14%, but the authors highlighted the ATR-FTIR method, coupled
with PLSR, provides a promising quantification tool, especially at screening level [183].
Similar quantitative models using ATR-FTIR were constructed using PLSR in a recent study
by Spalding et al., whereby human pooled serum was spiked with commercial human serum
albumin (HSA) and immunoglobulin G (IgG). The spiked serum was analysed in both liquid
and dried state to determine the optimal experimental protocol. In this particular study, in
order to maintain reproducible spotting of the sample, the 10% air dried sample preparation
was deemed to be the preferred approach. Using the same method, they analysed serum
gathered from 20 patients, to test the predictive power of the PLSR model when looking at
more complex samples. The model was tested by two validation method; leave one patient
out cross validation (LOPOCV) and k-fold cross validation. For the prediction of total protein
concentration, both models produced excellent results; the k-fold cross validation produced
an RMSE of 1.986  0.778mg/mL and an R2 value of 0.934, whereas there was an RMSE of
1.534  1.14mg/mL and an R2 value of 0.926 for the LOPOCV model. Both blind testing
methods produced similar trends, with the prediction of the individual HSA and IgG
concentrations not as effective as the total protein. The prediction of IgG concentration was
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inferior to that of HSA, which Spalding et al. suggested could be due to the inability of FTIR
to distinguish between the variable contributions of five major types of immunoglobulins that
are present in human serum (IgA, IgD, IgE, IgG and IgM) [185].
In comparison, Raman spectroscopy has been used for the quantitative analysis of blood to a
lesser extent. Berger et al. used Raman microscopic analysis of liquid whole human blood
and serum samples to quantify the content of six analytes, namely glucose, cholesterol,
triglyceride, urea, total protein and albumin [186]. Rohleder et al. undertook a comparison
of mid-infrared and Raman spectroscopy for the quantitative analysis of serum, based on
mid-infrared and Raman spectra of the sera obtained from 247 blood donors [187]. PLSR
analysis was used for the quantification of total protein, cholesterol, high- and low-density
lipoproteins, triglycerides, glucose, urea and uric acid. IR measurements were performed on
dried samples, whereas Raman was performed on liquids. For all analytes, comparable
RMSEC (calibration) and RMSEV (validation) were achieved.
Centrifugal filtration devices have been utilised to improve the sensitivity of quantitative
analysis by both Raman and IR spectroscopy, by separating the molecules according to their
molecular weight. The proteins that are highly abundant in serum dominate the spectral
profile, and through the removal of these proteins (albumin and globulins) the ability to
monitor changes in the lower molecular weight fraction (LMWF) is enhanced. Note,
however, the importance of following a strict rinsing protocol to remove residual glycerine
has been highlighted [67]. The centrifugal fractionation of human serum using both ATRFTIR and Raman spectroscopy was evaluated by Bonnier et al. [188]. In this study, whole
human serum was spiked with a wide range of known concentrations of glycine, between 0.5
mg/mL and 50 mg/mL, in order to examine the capabilities of both ATR-FTIR and Raman
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spectroscopy in human serum monitoring. As glycine has a molecular weight of 75Da,
existing as the smallest amino acid, it can freely diffuse through the 10kDa centrifugal filter
membrane, making it an ideal target for quantitative analysis of the filtrate. Small aliquots
(0.5l) of each concentration was measured, in both liquid and dry state, after air drying for
10 minutes. Bonnier et al. used principal component analysis (PCA) to explore and quantify
the spectral variability caused by the adulteration of glycine to the human serum.
Interestingly, the liquid samples produced a linear model (R2 = 0.9993), whereas the results
from the dried drops deviated from linearity above 10 mg/mL, and the relationship between
the glycine concentration and spectral variations were expressed by a polynomial expansion
(R2 = 0.9978). In order to test the predictive power of both regression models, the lowest
concentration, 0.5 mg/mL, was used as a blinded sample. The average predicted values for
the liquid and dry models were 0.45 mg/mL  0.16 mg/mL and 0.383 mg/mL  0.007 mg/mL,
respectively. Using the same protocol, more clinically relevant concentrations of glycine
(0.01-2.5 mg/mL) were added to a centrifugal filtered LMWF stock solution for further
analysis. Similar to the model for whole serum in the dried state, the LMWF model followed
a polynomial fit achieving an R2 value of 0.9981. In this case, the depletion of the abundant
HMW proteins greatly enhanced the sensitivity of the regression model for the detection of
glycine, delivering a predictive value of 0.011 mg/mL  0.006 mg/mL for the 0.01 mg/mL
serum sample [188]. In the same study, it was demonstrated that the concentrate of the
centrifugal process has been considerably concentrated (by factors up to x10 depending on
the filter pore size), greatly enhancing the signal to (water) background levels for liquid phase
Raman analysis. This indicates the potential for the prediction of other biomolecules that
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exist within the LMWF with this method, and with further research, such techniques could
be translated into the clinical environment as a rapid tool for screening and monitoring.

2.9 Clinical Translation

The high volume of research in the field of biomedical vibrational spectroscopy has indicated
the potential utility of vibrational spectroscopy in a clinical environment. Numerous
diagnostic and disease monitoring studies have reported extremely promising results, in some
cases achieving sensitivity and specificity values greater than 90%. However, the techniques
have not yet been successfully translated into the clinic [65]. The major hurdle to successful
translation is arguably acceptance by health technology regulatory agencies, who determine
which technologies are made available for public health. Criteria for successful acceptance
require statistically verified clinical trials to prove clinical utility, but also clear understanding
of the current clinical pathway in order to determine the economic and clinical impact of new
technologies.
While promising proof-of-principal studies have supported clinical suitability, there have
been few reported clinical trials employing either IR or Raman spectroscopy to confirm the
utility in a prospective patient population. One of the examples closest to translation is the
analysis of whole blood for the detection of malarial infection, currently being tested in a
prospective cohort in Papua New Guinea [189]. This application of ATR-FTIR spectroscopy
also looks to quantify levels of parasitaemia in blood, providing clinically relevant
information more rapidly than current methods [190]. The analysis of blood serum using
ATR-FTIR spectroscopy for the early detection of brain cancer is also approaching clinical
use, currently analysing a prospective patient cohort. This application is also significant due
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a clearly defined health economic study recently published, highlighting the clinical and
economic benefits of such a test into the current diagnostic pathway for brain cancers [191].
In summary, this study shows that a serum blood test at the primary care level could prioritise
patients for neuroimaging, improving patient survival and quality of life, whilst also
providing cost savings by reducing unnecessary brain scans. Another benefit of this
application is the potential of a seamless transition into the current clinical pathway. Blood
tests at the primary care level are commonly ordered, and the addition of a triage test into the
clinical pathway would not significantly disrupt current clinic practices.
Current advances in technology may also facilitate the uptake of vibrational spectroscopy
into standard clinical practice in the near future. Automated or high-throughput
instrumentation would be best suited to clinical settings so as to minimise pressure on
personnel resource. High-throughput technologies are available in IR transmission (or
transflection) systems, largely attributed to the development of multichannel detectors and
IR sources for discrete frequency spectroscopy, as well as the use of sample substrates which
can be batch processes. This could have specific impacts on the translation of tissue imaging
applications which have the potential to complement histopathology [107]. On the other
hand, ATR-FTIR spectroscopy is inherently limited to a single point of analysis, the IRE,
which restricts the overall sample throughput, particularly when taking into account cleaning
the crystal between measurements as well as background subtraction. However, the
development of low cost IREs may provide a disposable substrate for ATR-FTIR
spectroscopy, similarly enabling batch processing of samples and high-throughput spectral
acquisition alongside the development of novel instrumentation [192]. High throughput
systems have similarly been explored for Raman analysis and measurement in the liquid form
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avoids any further delay in the clinical work flow [193], [194]. Although the impact of
reduced sampling times, and consequent signal to noise ratio, on classification and
quantification accuracies have not yet been systematically explored.
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Chapter 3
Materials and Methods
3.1 Introduction

In the previous chapter, the background and aims of the study are discussed and the
importance of liquid Raman spectroscopy for detection and monitoring plasma/serum
analytes is highlighted. This chapter is designed to provide more information about the
methodology which were employed throughout the study. Further details on sample
preparation and general methodology are provided in the relevant chapters.

3.2 Raman spectroscopy

A Horiba Jobin-Yvon LabRam HR800 spectrometer with a 16-bit dynamic range Peltier
cooled CCD detector was used to record the Raman spectra throughout this work. The
spectrometer was coupled to either an Olympus BX41 upright or an Olympus 1X71 inverted
microscope and a x10 (UMPlanFL N, Olympus) or a x60 water immersion objective
(LUMPlanF1, Olympus) was employed. In the following experiments, two laser lines,
532nm and 785nm were used with the 600 lines/mm grating and 300 lines/mm grating
respectively and the backscattered Raman signal was integrated for 3×80 seconds over the
spectral range from 400-3500cm-1.
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3.3 Sample substrates

A range of substrates was tested, including a polystyrene 96 well cell culture plate, a quartz
96 well plate, and Lab-Tek plate. The polystyrene 96 well cell culture plate was purchased
from True Line, USA. The quartz well plate was purchased from Hellma Analytics,
Germany. The Lab-Tek plate (154534) has a 0.16-0.19mm thick, 1.0 borosilicate cover glass,
and was purchased from Thermo Fischer Scientific, Ireland.

3.4 ATR-FTIR

A comparative study was conducted to investigate the potential of ATR-FTIR to detect
similar variations in protein concentrations. ATR-FTIR spectra were recorded with the
Perkin Elmer (MA, USA) Spotlight 400N Universal Attenuated Total Reflectance accessory
of the spectrometer. A germanium crystal with a refractive index of 4.0 was employed for
this analysis. In ATR mode, spectral data is the result of 16 scans from each sample with a
spectral resolution of 2 cm-1, over the spectral range from 600cm-1 – 4000cm-1. 2 µl of the
different liquid samples were deposited on the crystal and left to dry for 10-15 minutes before
recording the spectra. Prior to recording, a background spectrum was also recorded from the
crystal and automatically subtracted by the software.

3.5 Preparation of stock protein

Albumin (A9511) was purchased from Sigma Aldrich, Ireland. A 100mg/mL stock solution
of albumin was prepared in distilled water. Fibrinogen (F3879) was purchased from Sigma
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Aldrich, Ireland. A 100mg/mL stock solution of fibrinogen was prepared using warm
phosphate buffered saline. For some experiments, a Sonics VCX-750 Vibra Cell Ultra Sonic
Processor (Sonics & Materials Inc., USA), equipped with a model CV33 Sonic Tip was used
to sonicate the fibrinogen stock solution for 5-10 seconds at 30% amplitude to improve the
dispersion of the fibrinogen. Cytochrome c (C2506) was purchased from Sigma Aldrich,
Ireland. A 1mg/mL stock solution of cytochrome c was prepared in distilled water. Vitamin
B12 (V2876) was purchased from Sigma Aldrich, Ireland. A 10mg/mL stock solution of
vitamin B12 was prepared in distilled water. The stock solutions of albumin, cytochrome c
and vitamin B12 were stored at 4ºC. A fresh stock of fibrinogen was prepared before each
experiment, as it was observed to be susceptible to precipitation when stored. Individual
protein solutions of varying concentration were prepared for spectroscopic analysis, to
explore the limit of detection of each protein and sensitivity of vibrational spectroscopic
techniques to subtle changes in the protein concentrations in its native state.

3.6 Impact of centrifugal filtration

Amicon Ultra 0.5mL centrifugal filter devices (Merck, Germany) of various cut off points, 3
kDa, 10 kDa, 50 kDa and 100 kDa, were employed to concentrate and separate the proteins
in the simulated plasma, based on their molecular weight. The centrifugal filtration procedure
that was previously reported by Bonnier et al. was followed [1]. Pre-rinsing of the filter
devices with 0.1M NaOH prior to plasma analysis is essential to avoid glycerine interference
in the analysis [2]. The optimised washing and rinsing procedure includes spinning 0.5mL
0.1M NaOH at 14000×g for 30 minutes followed by three rinses with distilled water by
spinning 0.5mL distilled water for 30 minutes at 14000×g. Every 30 minute wash and rinse
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must be followed by spinning the device in the inverted position at 1000×g for 2 minutes, to
remove the residual solution contained in the filter. After washing, 0.5mL sample is
transferred to the 100kDa filter and centrifuged at 14000×g for 30 minutes. The solution that
flows out from the 100kDa filter is the filtrate, which contains mostly water and molecules
smaller than 100kDa. The remainder of the sample, known as the concentrate, is collected by
placing the filter device upside down and spinning for 1000×g for 2 minutes. The resultant
concentrate, ~50µL, contains molecules with molecular weight larger than 100kDa, and is
concentrated by a factor of ~10. The filtrate is transferred to the 50kDa centrifugal filter
device and is spun at 14000×g for 30 minutes. The same steps are repeated with the 10kDa
and 3kDa filters. The final filtrate that flows out of the 3kDa filter contains mostly water and
molecules that are smaller than 3kDa. Raman spectra of all the four concentrates and filtrates
were recorded.

3.7 Observing the optimum volume to record spectra

Bio-fluid samples collected from patients are usually limited in volume, so it is crucial to be
able to record the Raman spectra from such minute amounts of sample. In optimising the
measurement protocol, the aim is to standardise the amount of sample volume required for
obtaining Raman spectra. In order to perform such optimisation, water and stock solutions of
fibrinogen were analysed in volumes from 1µL to 1mL.
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3.8 Data Analysis of the recorded spectra

It is necessary to remove the background signal as much as possible from the raw Raman
spectra in order to be able to distinctly visualise the Raman peaks, and in particularly to
obtain accurate predictions for the purpose of disease detection. Spectral data processing and
analysis are therefore critical considerations [3].

3.8.1 Spectral Pre-processing

The main contributing components of the spectra recorded using Raman spectroscopy are the
Raman signal of the analyte, the background signal and noise. Pre-processing techniques are
essential to remove the background signal and reduce the noise, before further analysis.
Initially, protein spectra were analysed with no preprocessing. Smoothing of the raw data
was done by Savitzky–Golay at a polynomial order of 5 and window 13. Then, preprocessing steps were applied to subtract the background from the data and the effects of
these algorithms on subsequent regression analysis (Section 3.8.2) were investigated.

For the sake of comparison, two pre-processing techniques, Extended Multiplicative Signal
Correction (EMSC) [4] and the “rubberband” method [5], were trialed on the raw dataset of
the proteins. The rubber band method can be explained as a ‘rubberband’ of a defined length
wrapped around the ends of the spectrum to be corrected by fitting against the curved profile
of the spectrum. By assuming the convex polynomial configuration, the rubber band is
wrapped around the curve profile of the spectrum from below and has the ability to exactly
fit the real data with a line shape on both the sides of the spectrum [6], [7]. Rubberband
correction was performed in Matlab. EMSC was developed in the 1980s for applications to
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near IR analyisis in food science [4]. EMSC is reported to be effective in removing the
background signal of glass and water from Raman spectra of single cells [8], as well as having
the additional benefit of baseline correcting the spectra, a step that is required prior to
performing data analysis. In this study, EMSC was employed for the pre-processing of
protein data to remove the underlying water spectrum. The EMSC algorithm uses a water
spectrum generated upon illumination with 532nm, a spectrum of the relevant protein with
minimum amount of water as reference, and a baseline of chosen polynomial order N as
input; resulting in a modelled background consisting of water signal and a slowly varying
baseline curve which can be subtracted to obtain spectra that are free from water signal. The
reference was prepared by adding a few drops of distilled water to the known concentration
of analyte powder and a thick paste is made. A Raman spectrum of the paste is recorded by
focusing 532nm laser is used as the reference spectrum The EMSC algorithm was
implemented based on the algorithm of Kerr et al. [8] incorporating Matlab’s polyfit function.

3.8.2 Partial Least Squares Regression

Partial Least Squares Regression (PLSR) is a multivariate statistical method which aims to
establish a model that relates the variations of the spectral data to a series of relevant targets.
This method can be used to improve the limit of detection of Raman bio-sensing [9].
The PLSR model attempts to elucidate factors which account for the systematic majority of
variation in predictors ‘X’ (spectral data) versus associated responses ‘Y’ (target values of
analyte concentration) [10]. The spectral data (X matrix) is thus related to the targets (Y
matrix) according to the linear equation Y = XB +E, where B is a matrix of regression
coefficients and E is a matrix of residuals.
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The PLSR algorithm allows for the construction of a regression model which can be used to
predict the outcome in varying concentration of proteins, and the performance of the PLSR
model in predicting varying protein concentration was evaluated in this study. In this case,
the examples used are concentration and Raman signal, and therefore the algorithm can be
used to predict the detection of Raman signal for a particular protein concentration. Leave –
One - Out Cross Validation (LOOCV) or 20 fold cross validation was applied to assess the
validity of the model. The number of latent variables was assessed, enabling the assessment
of the performance of a model when applied to an unknown data set.
In the LOOCV method, a single element from the data set is used as a ‘test’ set and the
remaining elements are used as the training set. This process is repeated until every single
observation in the data set is used once as the ‘test’ set. The number of latent variables used
for building the PLSR model is optimised by finding the value that is equivalent to the
minimum of the Root Mean Square Error of Cross Validation (RMSECV) and percent
variance explained by the latent variables. The spectral data obtained from the samples were
split as 20% training and 30% test sets and the RMSECV was calculated. The training values
are used to construct the model and its efficacy to predict the values from the test data set
determines the quality of the fit. RMSECV is used to evaluate the predictive capacity of the
constructed model [11]. The percent variance plot explains the number of components
required for maximum variation in the input data.
The 20 fold cross-validation approach involves randomly dividing the set of observations
into approximately equal size, ~50% of the spectral data were randomly selected as test set,
while the remaining ~50% is used as the training set [12]. Spectra were divided into two
groups of test and training spectra. The cross-validation process is then repeated 20 times
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(the folds), whereby all observations are used for both training and testing, and each
observation is used for testing exactly once. The results from the folds can then be averaged
to produce a single estimation. The RMSECV is calculated from the 20 iterations to measure
the performance of the model for the unknown cases within the calibration set. The
correlation between the concentration and spectral intensity is given by the R 2 value. The
standard deviation was calculated to find the variation between each spectrum calculated
from the same sample.
The appropriateness of various pre-processing methods can be determined through the
performance of the PLSR model. In this study, PLSR analysis was performed on the preprocessed data as well as raw data. To improve the performance of PLSR model, outlier
samples were removed from the original data set. The outlier samples are the ones which
look completely different compared to other samples and cannot present the same (X, Y)
linear relationship as other samples.

3.9 Standardisation of measurement protocol

Most of the screening methods for disease diagnosis are dependent on invasive procedures
that might cause discomfort to the patients [13]. The major advantage of using body fluids
as a screening target, specifically blood, urine, or saliva, is that their collection is significantly
less invasive than the conventional screening methods, such as biopsy. The relatively weaker
water signal in Raman spectroscopy allows the Raman spectral measurements to be taken of
aqueous samples, for example those of bodily fluids. Liquid bio-spectroscopy is possible and
the requirement of drying the samples can be eliminated with the use of Raman spectroscopy
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[1]. Moreover, the spectra of the biomolecules can be recorded in their native state, without
any additional sample preparation steps.
A challenge of Raman spectroscopy measurements is choosing the optimum configuration
for the experiment, in terms of laser line, substrate, sample volume, and instrument geometry.
An ideal substrate should produce low background signals, be compatible with the test
samples, and be cost effective. Many studies have reported the use of substrates such as
aluminium, calcium fluoride and quartz [14]. However, a good substrate that produces
minimal background signals is often expensive and can produce variable results in Raman
measurements [8]. The main objective of the current work is to establish the optimal
measurement settings in terms of cost and performance for liquid bio-spectroscopy
experiments. To study the performance of each substrate systematically, Raman spectra of
distilled water were recorded in the following substrates; polystyrene 96 well plate, quartz
well plate and Lab-Tek plate, in the upright and inverted geometry, using the 532nm and
785nm laser lines of the Horiba Labram HR800 system described in Section 3.2.

3.9.1 Substrate selection

As they are commonly employed in a laboratory and clinical setting, 96 well polystyrene
plates were initially tested as a suitable substrate for body fluid measurement, in the upright
geometry. Distilled water was used as the sample and Raman spectra were recorded using
the 532nm laser line focused by a x10 objective. When a 96 well polystyrene plate was used
to record the spectrum of water using the 532nm laser line, two strong peaks were observed
at ~1640cm-1 and ~1000cm -1 (Figure 3.1A). The broad peak at ~1640cm-1 is attributed to the
OH bending of water, whereas the sharp band at ~1000cm-1 corresponds to a ring breathing
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mode of the phenyl ring in the polystyrene. The same peak at ~1000cm-1 can be seen when
the Raman spectrum of an empty 96 well polystyrene well plate was recorded (Figure 3.1B).
Therefore, the spectrum of Figure 3.1A indicates a significant contribution from the
polystyrene substrate to the Raman spectrum of water. Such contributions may interfere with
the analysis of subtle changes in the spectrum of the body fluids.

Figure 3.1: (A) Raman spectrum of water in the 96 polystyrene well plate and (B) an empty
polystyrene well plate recorded using the 532nm laser line in the upright geometry with the
x10 objective. This study indicates that 96 well polystyrene plates cannot be used as the
substrate, as polystyrene peaks are observed superimposed on the water peaks

The Raman spectrum of distilled water in the quartz 96 well plate substrate shows a strong
water band at ~1640cm-1 (Figure 3.2). No other additional bands are seen, which makes the
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quartz substrate an ideal substrate to use for Raman measurements. However, despite its
advantages as an ideal substrate, the quartz substrate is very expensive and is not suitable for
day-to-day lab experiments, or ultimately for translation to the clinical environment.

Figure 3.2: Raman spectrum of water recorded in the quartz well plate in the upright
geometry using the 10x objective and the 532nm laser line. A strong water peak at 1650cm1
can be seen, with minimal background noise.

As an alternative, a glass bottomed Lab-Tek plate was explored as substrate. The plates are
also commonly employed in the laboratory setting, and the thin glass bottom, of 0.16 - 0.19
mm thickness, may not contribute significantly to the Raman signal. Figure 3.3A shows the
Raman spectrum of water recorded using the 532nm laser, focused by the x10 objective, and
Figure 3.3B is the Raman spectrum of an empty Lab-Tek plate recorded by focusing the laser
on the glass bottom. The spectrum recorded from the empty Lab-Tek plate was that of only
glass, which has a strong Raman band at 850cm-1, attributed to the presence of orthosilicate
[15]. Figure 3.3A demonstrates that, since the bottom of the Lab-Tek plate is made of thin
glass; it does not influence the Raman spectrum of the sample. Therefore, the Lab-Tek plate
was chosen as the appropriate substrate for the further Raman measurements.
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A

B

Figure 3.3: (A) Raman spectra of water recorded in the Lab-Tek plate and (B) empty LabTek plate recorded using the 532nm laser line in the upright geometry with the x 10 objective.
No interference from glass peaks at 850cm-1 can be seen in A. Therefore, the Lab-Tek plate
can be used as an ideal substrate for Raman measurements.

3.9.2. Wavelength selection

Another major challenge in Raman measurements is the selection of a suitable wavelength
that is compatible with the substrate and gives maximum Raman signal of the samples used.
The objective here is to select the best laser line which provides high quality Raman spectra
with enhanced spectral details. From the results so far, it is clear that the 532nm laser line is
compatible with Lab-Tek plate substrates and provides a strong Raman signal of water with
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minimal background interference. It is always desirable to use a short wavelength with high
excitation power source, as there is a linear relationship between the power of the scattered
light and the intensity of the incident light and the power of the scattered light is inversely
proportional to the fourth power of wavelength. In order to gauge the performance of a higher
power longer wavelength laser, with a liquid sample and Lab-Tek plate as substrate, the
Raman spectrum of distilled water was recorded using the 785nm laser line focused by the
x10 objective.

Figure 3.4: Raman spectrum of water recorded using the 785nm laser line in the Lab-Tek
plate in the upright geometry with the x 10 objective. Strong fluorescence background is
observed due to absorption by glass impurities at 785nm

Figure 3.4 presents the Raman spectrum of water recorded with the 785nm laser line using a
Lab-Tek plate as substrate. The Lab-Tek plate exhibits a strong fluorescence background
signal which will swamp the Raman measurements of the sample. Since impurities in glass
are absorbing and highly fluorescent in the NIR region, a laser line in the visible region of
the spectrum is more desirable when working with glass substrates [16]. In terms of source
wavelength, the 532nm laser line was chosen as the ideal laser line for further measurements,
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as it gives no background fluorescence and a high quality Raman signal can be recorded from
the sample
3.9.3 Geometry selection

The next step in the experimental set-up is to choose the geometry of Raman measurements.
The objective here is to identify the best instrumental set up that enables an increase in the
overall spectral intensity accompanied by an improved signal to noise (S/N) ratio with small
sample volume.

A

B

Figure 3.5: (A) Raman spectrum of the distilled water recorded in the upright geometry with
x10 objective (B) enhanced Raman spectrum of the distilled with considerably lower
background and improved S/N, recorded in the inverted geometry focused with x60 water
immersion objective
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Bonnier et al. have already reported the advantages of the inverted Raman set up [1]. To
verify, the Raman spectrum of water was recorded using both the upright geometry using the
x10 objective and the inverted geometry using the x60 water immersion objective. From the
results shown in Figure 3.5 A and B, it is notable that an enhanced water spectrum with
considerably lower background was recorded in the inverted geometry. Higher collection
efficiency of Raman signals could be obtained in the inverted geometry when focused with
the water immersion objective.

Figure 3.6: The inverted geometry used to analyse the serum focused by immersion
objective. [1]

An improved protocol of Raman spectroscopy set up, coupled with fractionation of serum
using centrifugal filters to concentrate and separate the low molecular weight proteins, was
demonstrated by Bonnier et al. [1]. Better analysis of serum using Raman spectroscopy was
reported when the sample was analysed in the inverted geometry using a water immersion
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objective with 785nm laser line and CaF2 substrate (Figure 3.6). In this study, a x60 water
immersion objective is used with 532nm laser line and the substrate used is a Lab-Tek plate.
A drop of water is used to minimise the differences in the refractive indexes between sample,
objective and the substrate. However, the water drop does not contribute to the data collected,
as it is outside the focus of the beam.

3.9.4. Protein measurement in the upright and inverted geometry

The stock solutions of albumin (100mg/mL), fibrinogen (100mg/mL), cytochrome c
(1mg/mL) and vitamin B12 (10mg/mL) were prepared and Raman spectra were recorded in
the optimised inverted geometry with the Lab-Tek plate as the substrate. The raw spectra of
the proteins were baseline corrected suing the rubberband method and smoothed using the
Savitzky–Golay algorithm (polynomial 5, window 13). Figure 3.7 shows the Raman spectra
of the fingerprint region of the stock solution of proteins recorded in the inverted geometry
using the water immersion objective. In comparison to the measurements taken in the upright
geometry, the spectral features are well defined and significantly enhanced. Therefore, the
inverted microscope set-up with the x 60 water immersion objective is ideal for liquid biospectroscopy measurements. Characteristic Raman peaks of the proteins are listed in Table
3.1. [11], [17]–[19]
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Figure 3.7: Raman spectra of the stock solutions of albumin, fibrinogen, cytochrome c and
vitamin B12 recorded in the finger print region in the inverted geometry focused by water
immersion x60 objective. Well-defined Raman peaks with minimum background were
obtained.
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Table 3. 1 Peak assignments for the Raman spectra of plasma proteins [11], [17]–[19]

Plasma Proteins

Peak position (cm-1)

Albumin

828
899
940
1002
1089
1102
1336
1450
1655

Fibrinogen

758

Tyrosine
ν (CN)
ν (CCN)sym, ν(CC)
Phenylalanine band
ν (CN)
ν (CN)
C-H deformation
C-H deformation
Amide I (C=O stretching
mode of proteins, α -helix
conformation)
Symmetric ring breathing of
tryptophan
Arginine
Phenylalanine band
Amide III (C–N stretching
mode,
mainly
α-helix
conformation)
C-H deformation
C-H deformation
Tryptophan
Amide I (C=O stretching
mode of proteins, a helix
conformation)
Heme breathing
ν(CH3)
All bonds of heme
C=C
5,6-Dimethylbenzimidazole
Corrin ring
5,6-Dimethylbenzimidazole
Corrin ring

878
1003
1250

1336
1450
1552
1659

Cytochrome c

Vitamin B12

Assignments of Raman
Vibrational Modes

750
1127
1314
1585
722
1160
1197
1498
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The spectra of albumin and fibrinogen shown in Figure 3.7 clearly reveal the common Raman
peaks of these two proteins. These include the amide I band around ~1659cm-1, a relatively
sharp band at 1003cm-1 associated with phenylalanine, intense bands at ~1336cm-1 and
~1450cm-1 due to C-H deformation, and a vibration band at ~940cm-1 related to C-C
stretching mode backbone of α-helix structure. The signature peaks of albumin that
differentiate it from fibrinogen are bands at 899cm-1 and 1102cm-1, that can be related to
ν(CC) and ν(CN). The signature peaks of fibrinogen are sharp bands observed at 758cm-1 and
1552cm-1 that can be assigned to tryptophan. Raman bands of cytochrome c and vitamin B12
are unique and can be easily distinguished; as evidenced in Figure 3.7.

3.9.5 Observing the optimum volume to record spectra

In order to determine the smallest volume that can be measured efficiently with the inverted
microscope set up, Raman spectra of distilled water and a stock solution of fibrinogen were
recorded from varying volumes of 1 μL to 1mL, in the Lab-Tek plate. The raw spectra ware
baseline corrected using the rubberband method.
The intensity of the water spectrum varied slightly for different volumes, even though the
variation is not large (Figure 3.8A). The intensity of the water peak at ~1640cm -1 was
measured and plotted against the volume (Figure 3.8C). From both the graphs, it is
noteworthy that the variation in intensity is negligible as no signal is lost when the volume is
reduced from 1mL to 1μL. The key point here is that high quality, consistent Raman spectra
were obtained from a sample volume as low as 1μL. Freshly prepared fibrinogen stock
solution was also measured as a function of volume. To maintain a level of consistency,
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Raman spectra were always recorded as soon as the sample was transferred to the middle of
the Lab-Tek plate to prevent drying of the sample and the acquisition time was 120 seconds
for 3 accumulations. From the results (Figure 3.8A), is it clear that the intensity of the
fibrinogen spectra did not vary significantly with volumes. In order to perform a quantitative
evaluation of each of the recorded fibrinogen spectra, the intensity of the phenylalanine peak
at 1003cm-1 was measured for all the volumes and a graph was plotted (Figure 3.8D).

Figure 3.8: (A) Raman spectra of distilled water recorded from 1 μL to 1mL volume, (B)
Raman spectra of fibrinogen solution recorded from 1 μL to 1mL volume, (C) Intensity
versus volume graphs of distilled water and (D) Intensity versus volume graphs of fibrinogen
stock. This shows a strong Raman signal can be recorded from a volume as small as 1µL in
the inverted geometry using Lab-Tek Plate as substrate.

The results in this section demonstrate that enhanced Raman spectra with defined spectral
features can be obtained from samples of volume as low as 1μL. This method is potentially
advantageous in a clinical set up, where the sample volume is usually very low.
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3.10 ATR-FTIR analysis of varying concentrations of fibrinogen – A comparative
study

The application of ATR-FTIR to collecting high quality spectra from highly concentrated
bodily fluids such as plasma has been previously investigated [20], [21]. This is a reliable,
rapid and convenient approach to analyse the bodily fluid samples, but suffers from a major
drawback of the Vroman effect. The objective of this study is to explore the dependence of
the absorbance on the concentration of the sample. A physiologically relevant concentration
range of fibrinogen from 1mg/mL to 50mg/mL was analysed in the ATR mode from 6504000cm-1. 2μL samples were deposited directly onto the crystal and were air-dried prior to
the measurements to remove the water content completely. Despite the rich composition of
fibrinogen in higher concentrations, the intense water contribution from the liquid samples
obscured the spectral features of the protein. Hence, air-drying is important to visualise all
the spectral details clearly in the ATR-FTIR measurements. A drying time of 4-6 minutes
was required for the highest concentration (50mg/mL) and about 8-10 minutes for the lowest
concentration (1mg/mL). Following the air drying, the fibrinogen samples display numerous
well defined peaks at 1536cm-1 (amide II band), 3280cm-1 (H-O-H stretching), 2957cm-1
(asymmetric CH3 stretching), 1080 cm-1 (C-O stretch) and 1453 cm-1 (CH2 scissoring)
(Figure 3.9A). Figure 3.9A shows that higher concentrations yield high intensity peaks and
the low concentrations give low intensity peaks. However, a plot of absorbance vs
concentration (Figure 3.9 B) shows that the linearity of the plot is lost after 30mg/mL, due to
saturation of the IR absorbance. According to the Lambert-Beer law, when the thickness of
the deposit from the sample droplet exceeds the penetration depth of the ATR evanescent
wave, an increase in solution concentration results in a linear correlation between the sample
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concentration and signal intensity. However, linearity is lost above 30mg/mL, when the
thickness of the dried fibrinogen sample exceeds the depth of penetration of evanescent wave.
No further increase in the absorbance after 30mg/mL suggests loss of Lambert-Beer type
dependence of the absorbance. Thus, a linear dependence of the absorbance and the intensity,
and therefore quantitative potential, is observed only at lower concentration range [1].
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Figure 3.9: (A) ATR-FTIR spectra of varying concentration (1mg/mL to 50mg/mL) of
fibrinogen in distilled water collected after depositing 2μL of the sample on the ATR crystal.
(B) Intensity vs concentration plot of the Amide 2 peak shows a steady increase in the
intensity until 30mg/mL and remains constant for 40 and 50mg/mL
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Therefore, sample drying is a major obstacle in the ATR-FTIR measurements as it leads to
chemical and physical inhomogeneity and saturation of the absorbance at higher
concentrations. Since Raman can perform spectroscopy in aqueous solutions, it is the best
choice for liquid bodily fluid measurements.

3.11 Summary

Raman spectroscopy is a reliable, label free, rapid and cost effective technique, delivering a
molecular fingerprint of the sample. In the present study, an optimised protocol for recording
Raman spectra from small volumes of liquid protein samples has been demonstrated. An
improved spectral quality with significant reduction in the background signal is achieved by
using a water immersion objective in the inverted geometry, rather than the upright geometry.
Using the water immersion objective has the additional advantage of minimising the
refractive index differences between substrate, sample and objective without adding to the
signal collected. A Lab-Tek plate was found to be the appropriate substrate as it provided
strong Raman spectra using the 532nm laser line, focused with a water immersion objective,
with negligible background in the inverted geometry. Additionally, in the inverted geometry,
Raman spectra can be recorded from a sample volume which can be as small as 1 μL, which
increases the potential of using this method in clinical applications. The limitations of
performing ATR-FTIR of dried deposits have also been demonstrated. The demonstrated
protocol for Raman analysis of protein samples in the liquid form can be applied to a wide
range of body fluids and has huge potential in clinical applications.
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Chapter 4
Raman spectroscopic analysis of High Molecular Weight
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drafting and proofing of the manuscript.

4.1 Abstract

This study explores the potential of Raman spectroscopy, coupled with multivariate
regression and protein separation techniques (ion exchange chromatography), to
quantitatively monitor diagnostically relevant changes in high molecular weight proteins in
liquid plasma. Measurement protocols to detect the imbalances in plasma proteins as an
indicator of various diseases using Raman spectroscopy are optimised, such that strategic
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clinical applications for early stage disease diagnostics can be evaluated. In a simulated
plasma protein mixture, concentrations of two proteins of identified diagnostic potential
(albumin and fibrinogen) were systematically varied within physiologically relevant ranges.
Scattering from the poorly soluble fibrinogen fraction is identified as a significant
impediment to the accuracy of measurement of mixed proteins in solution, although careful
consideration of pre-processing methods allows construction of an accurate multivariate
regression prediction model for detecting subtle changes in the protein concentration.
Furthermore, ion exchange chromatography is utilised to separate fibrinogen from the rest of
the proteins and mild sonication is used to improve the dispersion and therefore quality of
the prediction. The proposed approach can be expeditiously employed for early detection of
pathological disorders associated with high or low plasma/serum proteins.

4.2 Introduction

Raman spectroscopy has emerged over the past 20 years as an increasingly routine analytical
technique for a wide range of applications, as it provides specific biochemical information
without the use of extrinsic labels. This technique can provide intrinsic vibrational signatures
of the material of interest in a non-destructive fashion, and its potential for diagnostic
applications has been well demonstrated, notably in human serum and plasma [1]–[4]. Raman
spectroscopy provides a vibrational signature of a complex biological mixture which is a
result of the contributions from all the major components from that mixture, and changes in
the concentrations of the components will give rise to notable changes in the Raman signal.
However, although both Raman and Fourier-Transform Infrared (FTIR) spectroscopy have
been widely explored to study bodily fluids over the last two decades, most of these studies
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have been carried out on air dried samples, in order to avoid the water contribution in the
case of FTIR, and to increase the concentration of the analytes in the case of Raman [5]–[9].
The major limiting factor in the use of dried samples is the so-called “coffee-ring” effect, or,
specifically in terms of blood serum, the Vroman effect [10]–[12], whereby different analytes
precipitate from solution at different rates, giving rise to variations in the spectral features
due to chemical and physical inhomogeneity. This leads to spatially varying chemical
compositions and sample thicknesses, and unreliable results[13]. Ultimately, it is desirable
to undertake the analysis in the native state of bodily fluids, in which the chemical
composition is averaged out by molecular motion over the measurement time, and additional
drying steps can be eliminated. This aim naturally favours Raman analysis, as water is a
relatively weak Raman scatterer.
In this paper, the sensitivity of Raman spectroscopy to detect subtle changes in a simulated
plasma protein-mixture concentration is explored, specifically for the higher molecular
weight proteins. Albumin is the most abundant plasma protein, normally constituting about
50% of the plasma protein and has a molecular weight of 66kDa [14]. The normal
concentration of albumin in the human body is 30mg/mL, although it dramatically decreases
in critically ill patients and does not increase again until the recovery phase of the illness
[15]. Several studies have demonstrated that the functions of albumin, such as ligand binding
and transport of various molecules, can be applied to the treatment of cirrhotic patients and
patients suffering from other end stage liver diseases [16]–[18]. It is clear that closely
monitoring the variation in albumin concentration could act as an indicator of liver diseases
and other related pathologies. Fibrinogen is a 340kDa (0.4% in human plasma) dimeric
plasma glycoprotein synthesised by the liver and plays a major role in blood coagulation [19].
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The normal concentration of fibrinogen in human body is ~3mg/mL, and any variation in this
concentration can be an indicator of disease states [20]–[22]. Many clinical studies have
consistently shown elevated levels of fibrinogen in patients with cardiovascular disease and
thrombosis [22]–[25].
The conventional test kits available in a hospital for plasma/serum analysis suffer from long
time delays for the availability of results due to the need of specialised laboratories, which
may in turn delay the therapy, and prolong patient anxiety. The potential of vibrational
spectroscopy techniques coupled with multivariate analysis techniques have been previously
investigated for a range of clinical applications [1]–[9], [26]–[29]. This paper evaluates the
potential of Raman spectroscopy as a diagnostic tool to detect minute changes in the plasma
protein concentrations in aqueous samples and systematically explores the challenges to such
liquid based biopsy techniques, including sample scattering and abundance of individual
constituent components, while presenting some potential solutions to improve the protocols
of liquid biopsy monitoring using Raman spectroscopy.
A simulated plasma protein mixture of high and low molecular weight proteins, i.e. albumin,
fibrinogen, cytochrome c and vitamin B12, at physiologically relevant concentrations, was
prepared and variations were made to these concentrations over physiologically relevant
ranges. Separation of proteins in the solution was performed by ion exchange
chromatography to separate high molecular weight proteins from low molecular weight
proteins, and high molecular weight fraction proteins from each other. The efficiency of data
pre-processing methods (rubberband and Extended Multiplicative signal Correction
(EMSC)) in removing the background, to build an accurate prediction model, was explored
and mild sonication was used to improve the dispersion of fibrinogen. The standardisation of
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measurement protocol and other experimental parameters is detailed and the results of
concentration dependence study of proteins, in isolation and protein mixtures, and the
chemometric methods used to build the prediction model are presented.

4.3 Materials and Methods

4.3.1 Preparation of stock protein and protein mixture
Albumin (A9511), fibrinogen (F3879), cytochrome c (C2506) and vitamin B12 (V2876)
were purchased from Sigma Aldrich, Ireland. Solutions of individual proteins of varying
concentration were prepared, to initially explore the accuracy of detection of each protein
and sensitivity of vibrational spectroscopic techniques to subtle changes in the protein
concentrations in its native state. Furthermore, in order to assess the ability of Raman
spectroscopic techniques to detect subtle changes in the concentration of the protein in a more
complex mixture, potentially usable as biomarkers of various disease states, varying
concentrations of each protein in the protein-mixture were prepared. Concentrations of
albumin and fibrinogen, were varied in the protein mixture in the physiologically relevant
ranges, from 5mg/mL to 50mg/mL [15] and 0.5mg/mL to 5mg/mL [22] respectively while
maintaining the concentrations of cytochrome c and vitamin B12 constant. The stock
solutions and the protein-mixture solutions and analysed in the liquid form using Raman
spectroscopy.
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4.3.2 Ultrasonication

A Sonics VCX-750 Vibra Cell Ultra Sonic Processor (Sonics & Materials Inc., USA),
equipped with a model CV33 Sonic Tip was used to sonicate the fibrinogen stock solution
for 5-10 seconds at 30% amplitude at room temperature to explore the effect of improved
dispersion of the fibrinogen on the measurement procedure. Previous studies have
demonstrated negligible effects of ultrasonication on the integrity of the fibrinogen structure
[30].

4.3.3 Ion exchange chromatography

Carboxymethyl-cellulose (C9481) was purchased from Sigma Aldrich, Ireland. It acts as a
weak cationic exchanger and binds to the positively charged molecules [31]. Glycine
(G8898) was purchased from Sigma Aldrich, Ireland and glycine buffer of pH 10 was
prepared as the elution buffer [32]. 1mL of the protein-mixture was pipetted into a centrifuge
tube and 0.08g of carboxymethyl-cellulose. The solution was mixed for 10 minutes on a
Spira-mix roller and then centrifuged at 14000g for 5 minutes. The unbound material was
present in the supernatant and was transferred to a fresh tube. The pellet was washed using
2mL glycine buffer by repeated inversion, followed by centrifugation at 14000g for 5
minutes. The supernatant that contains the fibrinogen was carefully transferred to a fresh
centrifuge tube and Raman analysis was performed.
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4.3.4 Raman spectroscopy

A Horiba Jobin-Yvon LabRam HR800 spectrometer with a 16-bit dynamic range Peltier
cooled CCD detector was used to record the Raman spectra throughout this work. The
spectrometer was coupled to Olympus 1X71 inverted microscope and a x60 water immersion
objective (LUMPlanF1, Olympus) was employed. In all the following experiments, a 532nm
laser of 12mW at the sample was used with the 600 lines/mm grating and the backscattered
Raman signal was integrated for 3 accumulations and a total acquisition time of 80 seconds
over the spectral range from 400-1800cm-1.

4.3.5 Sample substrates

The Lab-Tek plate (154534) was chosen as the optimal substrate for this study. It has a 0.160.19mm thick glass bottom, 1.0 borosilicate cover glass, and was purchased from Thermo
Fischer Scientific, Ireland.

4.3.6 Spectral preprocessing

Pre-processing techniques are essential to remove the background signal and reduce the
noise, before further analysis. Smoothing of the raw data was done by Savitzky–Golay at a
polynomial order of 5 and window 13. Two pre-processing techniques, Extended
Multiplicative Signal Correction (EMSC) and the rubberband method, were trialed on the
raw dataset of the proteins in Matlab, at different stages of the study. EMSC was employed
for the pre-processing of protein data to remove the underlying water spectrum [33], which
has an OH bending vibration at ~1640cm-1 [34] which can obscure the protein signals at low
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concentrations. The reference for EMSC was prepared by adding a few drops of distilled
water to the known concentration of protein powder and a thick paste is made (~10mg/mL).
A Raman spectrum of the paste was recorded using the 532nm laser as source and used as
the reference spectrum. Rubberband correction was carried out in Matlab by wrapping a
‘rubberband’ of defined length around the ends of the spectrum to be corrected and fitting
against the curved profile of the spectrum [35].

4.3.7 Partial Least Squares Regression

The Partial Least Squares Regression (PLSR) algorithm was applied to construct a regression
model that can be used to predict the outcome in varying concentration of proteins, and the
performance of the model in predicting varying protein concentration was evaluated [36].
The PLSR model attempts to elucidate factors that account for the systematic majority of
variation in predictors ‘X’ (spectral data) versus associated responses ‘Y’ (target values of
protein concentration). The spectral data (X matrix) is thus related to the targets (Y matrix)
according to the linear equation Y = XB +E, where B is a matrix of regression coefficients
and E is a matrix of residuals. Leave – One - Out cross validation was applied to assess the
validity of the model. In this case, the number of latent variables was assessed, enabling the
assessment of the performance of a model when applied to an unknown data set. The number
of latent variables used for building the PLSR model is optimised by finding the value that
is equivalent to the minimum of the Root Mean Square Error of Prediction (RMSEP) and
percent variance explained by the latent variables. The spectral data obtained from the 30
samples were split as 20% training and 30% test sets and the RMSEP was calculated. RMSEP
is used to evaluate the predictive capacity of the constructed model [37]. The percent variance
121

plot explains the number of components required for maximum variation in the input data.
The appropriateness of various pre-processing methods can be determined through the
performance of the PLSR model. In the following, for each aspect of the study, the optimum
conditions for model development are detailed.

4.4 Results

4.4.1 Standardisation of measurement protocol

For the analysis of liquid protein samples, an optimised inverted set-up, previously
demonstrated by Bonnier et al. [13] was used. Better analysis of serum using Raman
spectroscopy was reported when the sample was analysed in the inverted geometry using a
water immersion objective with a 785nm laser and CaF2 substrate. In this study, a x60 water
immersion objective is used with a 532nm laser and the substrate used was a Lab-Tek plate.
The 532nm laser was chosen as it is compatible with (thin glass bottomed) Lab-Tek plate
substrates and provides a strong Raman signal of water with minimal background
interference. A drop of water is used to minimise the differences in the refractive indexes
between sample, objective and the substrate. However, the water drop does not contribute to
the data collected, as it is outside the focus of the beam. This set-up also has an added
advantage of providing high quality, consistent Raman spectra from a sample volumes as low
as 1μL.
Figure 4.1 presents the spectra of the fingerprint region of the stock solutions of proteins
recorded in the inverted geometry. The raw spectra of the proteins were baseline corrected
using the rubberband method and smoothed using the Savitzky–Golay algorithm (polynomial
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5, window 13). Measurement in the inverted geometry, using a water immersion objective,
is found to be the best instrumental set up that enables an increase in the overall spectral
intensity accompanied by an improved signal to noise (S/N) ratio with small sample volume.

Figure 4.1: Raman spectra of the stock solutions of albumin, fibrinogen, cytochrome c and
vitamin B12 recorded using the 532nm laser in the finger print region in the inverted
geometry focused by water immersion x60 objective. Well-defined Raman peaks with
minimum background were obtained.

The spectra of albumin and fibrinogen shown in Figure 1 clearly reveal the common Raman
peaks of these two proteins. These include the amide I band around ~1659cm-1, a relatively
sharp band at 1003cm-1 associated with phenylalanine, intense bands at ~1336cm-1 and
~1450cm-1 due to C-H deformation, and a vibration band at ~940cm-1 related to C-C
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stretching mode backbone of α-helix structure. The signature peaks of albumin that
differentiate it from fibrinogen are bands at 899cm-1 and 1102cm-1, that can be related to
ν(CC) and ν(CN) [38]. The signature peaks of fibrinogen are sharp bands observed at 758cm1

and 1552cm-1 that can be assigned to tryptophan [39]. Raman bands of cytochrome c and

vitamin B12 are highly specific and can be easily distinguished, as evidenced in Figure 4.1
[40], [41].

4.4.2 Monitoring the concentration dependence of proteins in aqueous solution

Albumin. Protein solutions were prepared by varying the concentration of albumin in order
to achieve the physiologically relevant range from 5mg/mL to 50mg/mL. Figure 4.2A show
the raw unpre-processed spectra, which exhibit a steady increase in the spectral intensity
when the concentration is increased from 5mg/mL to 50mg/mL. The spectrum of the highest
concentration clearly shows albumin features, whereas those of the lower concentrations are
dominated by water, which has a characteristic OH bending mode at ~1640cm-1. As the
concentration of albumin increases, a notable increase in the background can also be
observed, which can be attributed to scattering. Although many studies suggest that the broad
background present in Raman spectra is due to fluorescence [42], albumin is optically
transparent at 532 nm, so the background is rather due to scattering of the source laser as well
as the Raman scattered light, which enters the spectrometer as stray light, and is dispersed
across the CCD in a wavelength independent fashion [43]. In order to analyse the spectral
variations and the albumin concentrations, the PLSR algorithm was applied. The percent
variance plot in Figure 5.2B gives a rough indication of how the algorithm progressively fits
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the spectral data, showing that nearly 68% of the variance is explained by the first component,
while as many as four additional components make significant contributions.

Figure 4.2 (A): Raw Raman spectra of varying concentrations of albumin (5mg/mL –
50mg/mL) in distilled water, recorded using the 532nm laser (B): Percent variance explained
by the components, (C): plot of PLSR coefficient with Albumin features, (D): Linear
predictive model built from the PLSR analysis

Based on the percent variance explained by the latent variables and the minimum value of
RMSEP, the optimum number of latent variables to reach the best model is determined. The
PLSR coefficient plot displayed in Figure 5.2C, confirms the correlation of the data in Figure
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5.2D is based on albumin features, such as the peaks at ~1665cm-1, ~1448cm-1 and ~1337cm1

. Finally, after selecting the optimum number of components for the data set analysed, a

predictive model is built from the PLSR analysis (Figure 4.2D), to compare the observations
to the known concentrations of albumin in the samples with the estimated concentrations
from the spectral data sets. Figure 4.2D indicates that a good linear model could be obtained
with the raw data set. However, the PLSR coefficient is not a clean albumin spectrum and
has a large background due to scattering, indicating that scattering could have influenced the
model. Furthermore, the minimum value of RMSECV was found to be 22.59mg/mL,
indicating a poor accuracy of prediction over the range 5mg/mL to 50mg/mL. Analysis of
the raw albumin concentration dependence serves as an initial illustration of some of the
issues presented by measurement of high molecular weight macromolecules in solution.
Appropriate pre-processing steps could help to minimise the background from scattering
effects. Hence, rubberband pre-processing steps were performed on the data set before PLSR
analysis and the model obtained is displayed in Figure 4.3.
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Figure 4.3 (A): Rubberband corrected Raman spectra of varying concentrations of Albumin
(5mg/mL – 50mg/mL) in distilled water, (B): % variance explained by the latent variables,
(C): plot of PLSR coefficient with Albumin features, (D): Linear predictive model built from
the PLSR analysis

Figure 4.3A shows the albumin data set after background correction using the rubberband
method. Figure 4.3B shows the percent variance explained by the latent variables, indicating
that three components accounted for the majority of the variance. Five latent variables were
chosen for this model and the resultant PLSR coefficient exhibits strong albumin features, as
shown in Figure 4.3C. A linear predictive model can be defined from the rubberband
corrected data set of varying concentration of albumin in water Figure 4.3D. The RMSEP
was found to be 1.58mg/mL after applying the rubberband pre-processing steps for the same
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data set. The results suggest that there is a significant improvement in the predictive capacity
of the constructed model when rubberband pre-processing steps are applied to the data set.
Simulated “pathological” plasma protein mixtures were prepared by varying the
concentration of albumin in order to achieve the physiologically relevant range from 5mg/mL
to 50mg/mL and by maintaining the concentrations of fibrinogen, cytochrome c and vitamin
B12 constant at the concentrations of the “healthy” human plasma. The concentrations for
hypoalbuminaemia (>30mg/mL) and hyperalbuminemia (<30mg/mL) have been deliberately
included in the set of samples being prepared. Based on the results of Figure 4.3, rubberband
correction was applied to the dataset in an attempt to improve the accuracy of the prediction
by performing baseline correction. Notably, the Raman spectral features of the protein
mixture were seen to decrease with increasing albumin concentration (Figure 4.S1A in
supplemental material), and the PLSR coefficient obtained from this data shows inverse
albumin features (Figure 4.S1C), indicating that the model built from this dataset is not
reliable, as the high degree of scattering is effecting the dataset and the prediction model is
not based on the albumin features. Hence, the EMSC based algorithm was applied to the data
set in an attempt to eliminate the scattering associated with the albumin data in the simulated
plasma and subsequently improve the prediction model. EMSC of polynomial order 4 was
performed on the data set of varying concentration of albumin in simulated plasma protein
mixture. It has previously been shown that the reference used for EMSC does not have to be
a precise match to the sample of interest [44] and therefore a spectrum of albumin recorded
with 532nm was used, as it is the most abundant protein in the mixture. To minimise any
scattering, but also contribution of water, the powder has been diluted with a minimum
amount of water (~1mL to 10mg).
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Figure 5.4A displays the albumin spectra after performing background correction using the
EMSC algorithm. The amide 1 band at 1665cm-1 and CH2 deformation band at 1445cm-1 can
be clearly seen in the corrected spectra. Based on the percentage variance explained by the
latent variables (Figure 4.4B) and the minimum value of RMSEP, seven latent variables were
found to be optimal for this model. The PLSR coefficient shows albumin features (Figure 4.4
C), indicating that the prediction is now based on the variation in the albumin peak intensity.
A linear prediction model was achieved from this model (Figure 4.4D). The minimum value
of RMSEP is 1.5844mg/mL, indicating an improved prediction capacity. This value is the
same as the minimum value of RMSEP recorded for the varying concentration of albumin in
distilled water, indicating that the PLSR model of EMSC corrected simulated plasma spectra
is as accurate as the PLSR model of rubberband corrected spectra of varying concentrations
of pure albumin in water. The results demonstrated in this section suggest that this model can
be effectively used to detect variations in the concentration of albumin in human plasma, as
a result, for example, of liver disorders at an early stage. A strong reduction in the RMSEP
indicates that the EMSC algorithm can efficiently subtract the background without altering
the albumin features, which in turn improves the prediction of the model.
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Figure 4.4 A: EMSC corrected of varying concentrations of albumin in simulated plasma,
and B: Percent variance explained by the latent variables, C: PLSR coefficient showing
albumin features, and D:Linear prediction model defined from the dataset

Fibrinogen. Fibrinogen solutions were prepared by diluting the stock solution of 100mg/ml
to the more physiologically relevant range of 0.5mg/mL to 5mg/mL. Raman spectra were
recorded from the protein samples and smoothed using Savitzky–Golay (polynomial 5,
window 13). When the rubberband method was applied on this dataset to perform baseline
correction, the PLSR coefficient spectrum obtained was an inverse water spectrum, as shown
in supplementary information (Figure 4.S2). Fibrinogen is poorly soluble in water, such that
the fibrinogen solution is visually cloudier than the albumin solution. This significant
problem of lack of solubility due to the protein aggregation leads to scattering of the more
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pronounced Raman signal of the water, in a concentration dependent fashion. Hence, EMSC
with a polynomial of order 4 was performed on the same data set to pre-process the data prior
to PLSR analysis. The reference spectrum was obtained under similar conditions as the
albumin reference, from a fibrinogen paste with minimal amount of water. A polynomial of
order 3 resulted in the best correction. The output, however, is a very noisy spectral data set
with some indication of fibrinogen features in the spectra, notably at ~758cm-1, ~1650cm-1,
~1450cm-1, ~1336cm-1 and ~1250cm-1 (Figure 4.S3 in supplemental).
In an attempt to overcome the lack of solubility of the protein, the stock solution was
ultrasonicated to enhance the dispersion of fibrinogen and obtain a clear solution.
Ultrasonication for approximately 10 seconds at 30% amplitude resulted in a clear solution
of fibrinogen with a significantly improved Raman signal (Figure 4.S4 in supplemental).
Varying concentrations of fibrinogen samples in the physiologically relevant range were
prepared using the ultrasonicated fibrinogen stock.
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Figure 4.5 A: Raman spectra of varying concentration of sonicated fibrinogen background
corrected using EMSC algorithm B: Percent variance explained by the latent variables
C:PLSR coefficient plotted from the sonicated fibrinogen data set shows strong fibrinogen
features, D: Linear predictive model built from the PLSR analysis showing correlation
between concentration and peak intensity.

The spectrum of sonicated fibrinogen after background correction using the EMSC algorithm
with polynomial of order 3 displays strong fibrinogen features with higher intensity over the
same concentration range, compared to the non-sonicated fibrinogen samples (Figure 4.5A).
Applying PLSR, it is clear from Figure 4.5B that a total of six components made significant
contributions to explain the variance in the sonicated fibrinogen spectra. Based on the percent
variance explained, six latent variables were used to build the prediction model. The PLSR
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coefficient plot shows signature peaks of fibrinogen, indicating that the prediction was based
on variation in the fibrinogen spectral intensities (Figure 4.5C). A linear prediction model
was defined from the data set, showing correlation between the Raman peak intensity and
concentration (Figure 4.5D). The minimum value of RMSEP is found to be 0.0615mg/mL.
The reduction in the RMSEP value recorded for fibrinogen data after sonication indicates
that the accuracy of the model increases as a result of the improved solubility following
sonication. Hence, it can be concluded that sonication improves the solubility of the
fibrinogen and increases the spectral intensity, in turn leading to a considerable improvement
in the predictive capacity of the model.
Simulated “pathological” plasma protein-mixture was prepared by varying the concentration
of fibrinogen stock in order to achieve the physiologically relevant range from 0.5mg/mL to
5mg/mL and by maintaining the concentrations of albumin, cytochrome c and vitamin B12
constant at the normal concentrations in healthy human plasma. The concentrations for heart
disorders (<3mg/mL) and liver disorders (<3mg/mL) have been deliberately included in the
concentration range. The raw spectra of varying concentrations of fibrinogen in simulated
plasma were smoothed by Savitzky–Golay, polynomial of 5, window 13 (Figure 5.6).
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Figure 4.6:Smoothed spectra of varying concentration of fibrinogen in simulated plasma
(0.5mg/mL to 5mg/mL). The arrow indicates the order of increasing concentration.

The arrow indicates that both the background and spectral features themselves decrease with
increasing concentration of fibrinogen. However, noting that albumin is the dominant
contributor to the Raman signal, and that fibrinogen is the dominant scatterer, this can be
understood as a (fibrinogen) concentration dependent loss of (albumin) Raman scattering.
The PLSR coefficient obtained after pre-processing the data using the EMSC based algorithm
shows an inverse spectrum of albumin rather than fibrinogen, as shown in figure 4.S5 in
supplemental. As in the case of the water dispersions, the dominant effect of increasing
concentrations of the poorly soluble fibrinogen is the scattering of the dominant Raman
spectrum. Hence, although the predictive model built from this dataset shows a good
correlation with fibrinogen concentration, it is not based on the characteristic spectroscopic
signature of fibrinogen, and the variation of the albumin signal could equally be due to any
other scatterer.
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Ultra-filtration using 100kDa centrifugal filters failed to separate fibrinogen from the rest of
the protein in the protein mixture. Figure 4.S6 shows that the Raman spectrum of the
concentrate obtained has pronounced characteristic albumin features at 899 cm-1 and 1102
cm-1. Ion exchange chromatography was therefore explored as an alternative method for
fibrinogen separation from the protein mixture, based on its charge. Carboxymethyl-cellulose
acts as a weak cationic exchanger and fibrinogen is eluted out by altering the net charge of
the bound protein, and thus its matrix binding capacity. Fibrinogen was detected in the
unbound fraction. Albumin was not detected in the unbound fraction by Raman spectroscopy
and it is concluded adsorption of the albumin fraction to the carboxymethyl cellulose resin
occurred at the pH values employed. Other studies have shown carboxymethyl cellulose may
form insoluble complexes with serum albumin [45].
Fibrinogen was extracted from the protein mixtures over the full concentration range, and
Raman spectra were recorded from the separated fibrinogen and EMSC was performed on
the data set before doing PLSR analysis. In the absence of sonication the prediction model
performed poorly, due to the high degree of scattering, as seen in figure 4.S7. Mild sonication
can be employed to improve the solubility of and reduce the scattering from fibrinogen, and
thus the performance of the prediction model.
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Figure 4.7A: EMSC corrected data of varying concentrations of fibrinogen separated by ion
exchange chromatography, and B: Percent variance explained by the latent variables, C:
PLSR coefficient showing fibrinogen features and D: Linear prediction model defined from
the dataset

The spectrum of sonicated fibrinogen separated by ion exchange chromatography after
background correction using the EMSC algorithm displays strong fibrinogen features. In
Figure 4.7B, it is clear that nine components made significant contributions to the variance
in the sonicated fibrinogen spectra. The minimum value of RMSEP is found to be
0.0568mg/mL. The PLSR coefficient plot shows the signature peaks of fibrinogen (Figure
4.7C), indicating that the linear prediction model obtained was based on the correlation
between the Raman spectral intensities of fibrinogen and concentration (Figure 4.7D). Hence,
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it can be concluded that ion exchange chromatography can successfully separate fibrinogen
for Raman analysis from the protein mixture within 30 minutes and an accurate prediction
model can be built from the Raman data to detect subtle changes in the fibrinogen
concentration. Early detection of fibrinogen concentration could help to prevent disorders
that are associated with increased fibrinogen level in plasma such as thromboembolism [46],
various cardiovascular events and post-surgical arterial re-occlusion [47].

4.5 Discussion

In monitoring biological molecules in their native aqueous state in biofluids, Raman
spectroscopy offers the potential advantage over other spectroscopic techniques such as
infrared absorption, that water was a relatively low scattering cross section. However,
applications of the technique face several challenges related to detection of relatively low
concentrations and variations of concentrations of analytes, and low quality signals from
poorly dispersed components, and there remains a considerable number of issues relating to
the fundamental process of recording and extracting the spectral details using chemometric
techniques.
Raman analysis in the inverted geometry using a water immersion objective is found to be
the optimal method to record well defined spectra with minimal background, and notably
samples of volumes as low as 1µL can be measured. In a sample set of varying concentrations
over physiologically relevant ranges, the albumin contributions to the spectrum dominate
over those of the water, and, after minimal preprocessing, PLSR can be employed to establish
a regression model whose predictive performance shows a close correlation between the
concentrations of the proteins and the Raman spectral profile. However, in a the more
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complex simulated plasma mixture of proteins, improved data preprocessing techniques are
required to account for the increased spectral background.
Although the broad background to Raman spectra is often attributed to fluorescence, this
cannot be the case for materials with are nonresonant at the Raman source wavelength.
Proteins such as albumin and fibrinogen can, however, contribute to stray Mie scattered light
by causing diffusely scattered radiation that is not well collimated by the collection objective
of the Raman microscope, enters the spectrometer effectively as stray light, and is dispersed
across the detector [21]. The rubberband pre-processing method appeared to efficiently
remove the background from the data set of varying concentration of albumin in water, but
failed to satisfactorily deal with the background of varying concentrations of albumin in the
simulated plasma protein mixture. The more sophisticated EMSC based algorithm helped
eliminate the scattering associated with the albumin data in the simulated plasma, improving
the prediction model, and also helped to extract the spectral features of fibrinogen from water.
In both cases, before subtraction, the primary effect of varying the protein concentrations was
to decrease the contribution of the dominant Raman scatterer, which can be understood in
terms of the presence of the poorly soluble, highly Mie scattering fibrinogen component. This
proposed method can be efficiently used to detect albumin as a standard biomarker for
detecting diseases associated with hypoalbuminemia (<30mg/mL), such as liver diseases,
gastrointestinal protein loss, edema and hyperalbuminemia (>30mg/mL), such as severe
dehydration and abnormal increase in body fat [48], [49]. The accuracy of the proposed
method is comparable to that of the most commonly used method for detecting albumin from
biological fluids, the enzyme linked immunosorbent assay (ELISA) [50][51], which is
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sensitive and selective but is very time consuming and requires extensive sample preparation
steps.
In varying concentrations of fibrinogen in aqueous solution, the Raman signal of the water
itself is diffusely scattered, increasingly so with increasing fibrinogen concentration, and thus
the PLSR identifies a decreasing Raman contribution of water as the dominant concentration
dependent effect. In the case of albumin in the simulated protein mixture, a concentration
dependent Mie scattering of the Raman signal of albumin itself is the dominant effect of
increasing albumin concentration. While one would expect a linear concentration dependent
increase in the Raman signal of albumin, the inability of the ultra-filtration technique to
separate the two high molecular weight proteins may suggest an interaction between the
albumin and fibrinogen, such that increased albumin Raman scattering is overwhelmed by
increased Mie scattering.
Mild sonication is seen to improve the dispersion of fibrinogen in aqueous solutions, and
significantly improve the Raman signal. Removing the water contribution using EMSC is
seen to significantly improve the predictive model (Figure 4.5).
Separation of the fibrinogen by ion exchange chromatography from the plasma protein
mixture and application of the ultrasonication technique to reduce aggregation helped to
detect fibrinogen features from the plasma solution even at a concentration as low as
0.5mg/mL. The RMSEP of 0.0568mg/mL compares favourably with similar observations,
for example for attenuated total reflection – Fourier transform infrared absorption monitoring
of glucose in blood serum [29]. The accuracy of this study is closer to that of the most
commonly used gold-standard method i.e, the Clauss assay, which has a detection limit of
~0.4 mg/mL[52]. The Clauss assay is relatively time consuming and suffers from
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inconsistencies in the results due to calibration standards, methodologies and variation in the
reagents from various manufacturers [46]. These steps are relevant only in the case of human
plasma and can be avoided while working with human serum as fibrinogen is absent in the
serum. Notably, although this study has targeted the HMWF proteins to highlight the
associated challenges, the optimised protocol can be adapted to detect low molecular weight
proteins or other biomarkers in bodily fluids, which may have additional diagnostic potential,
after depletion of the abundant proteins [13].
Ion exchange chromatography is a quick method to separate the proteins from each other by
altering their net surface charge, making it an ideal tool for separating all the protein
constituents and a better alternative to ultra-filtration. In this case, ultra-filtration failed to
separate HMWF proteins from one another, as they tend to form hydrophobic bonds and
nonspecific binding interactions with the membrane material (Fig 4.S6). However, the ion
exchange chromatographic method has to be tailored to the specific protein, depending on its
charge, and cannot be applied as a ‘one-for-all’ separation kit for all the proteins.
It is worth noting that PLSR seeks to correlate systematic variations in the spectroscopic
profiles with the external target variable, in this case protein concentration. As such the
method is not inherently specific to any molecular variations, in the case where multiple
species vary simultaneously over the same range. It has been demonstrated, in Raman
microspectroscopic studies of the action of drugs in cells in vitro, that independent regression
of the same dataset against the applied dose and resultant viability of the cell population
yielded could be employed to yield information about independent processes in the cells [53],
[54]. However, where the study of two simultaneously varying molecular species may require
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further analysis of the PLSR co-efficient, and/or regression over different spectral regions,
which contain specific markers of the respective species of interest.

4.6 Conclusions

The potential advantages of using vibrational spectroscopy for disease diagnosis based on
bodily fluids have been extensively explored over the last two decades. However, little
consideration has been given to date to the optimisation of a Raman analysis protocol
involving proteins in their native aqueous state, leading to irreproducible results due to high
complexity of the plasma proteins. This study is a proof of concept that Raman spectroscopy
can be successfully used to detect subtle changes in individual plasma protein concentration
from simulated plasma samples to disease diagnostics purposes.
It has been shown that measurement in the inverted geometry using a water immersion
objective yields high quality spectra and the sample volume can be as small as 1μL. This
experimental set up is advantageous for clinical purposes where the volumes of patient
samples are minimal. In the simulated plasma protein mixture, the poorly soluble fibrinogen
component was seen to obscure the systematic variations of the protein concentrations, due
to the high degree of scattering. Extraction of the fibrinogen by ion exchange
chromatography is seen to be more specific than by ultra-filtration, such that the variations
of fibrinogen levels themselves can be quantified. In general, the scattering problems caused
by fibrinogen favour the use of blood serum for the analysis of the remaining lower molecular
weight fractions.
However, to further ensure relevancy and consistency of these results, experiments need to
be carried out in pooled plasma/serum. The use of Raman spectroscopy coupled with
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chemometric techniques not only gives a mere estimate of whether the protein levels are high
or low but also gives higher accuracy of quantification. Once appropriate experimental
methods are established, a hypothesised point-of- care device that can be used in real clinical
applications for spectroscopic analysis of body fluids can be realised. The proposed approach
can be expeditiously employed for early detection of pathological disorders associated with
high or low plasma proteins.
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4.8 Electronic Supplementary information:

Figure 4.S1. A: Raw Raman spectra of varying concentrations of albumin in simulated
plasma (5mg/mL – 50mg/mL). The arrow indicates the order of increase in concentration, B:
Percent variance explained by the latent variables, C: PLSR component showing the inverse
albumin features and D: Linear predictive model built from the PLSR analysis

149

Figure 4.S2A: Raman spectra of varying concentrations of fibrinogen in distilled water
corrected using the “rubberband” method (0.5mg/mL – 5mg/mL), B: Percent variance
explained by the latent variables, C: PLSR coefficient plotted from the data set shows
negative peaks and no fibrinogen features, D: Linear predictive model built from the PLSR
analysis
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Figure 4.S3A: Spectra corrected by EMSC algorithm of varying concentration of fibrinogen
(0.5mg/mL – 5mg/mL), B: Percent variance explained by the latent variables, C: PLSR
coefficient showing strong fibrinogen features, D: Linear predictive model built from the
PLSR analysis.
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Figure 4.S4.Raman spectra of fibrinogen stock recorded before (Black) and after (Red)
sonication. Sonication helped to increase the overall intensity of the Raman signal by
increasing the solubility of the protein.

Figure 4.S5 A: EMSC corrected data of varying concentrations of fibrinogen (0.5mg/mL to
5mg/mL), B: percent variance explained by the latent variables, C: PLSR coefficient showing
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the inverse peaks of albumin (1089cm-1 and 1102cm-1), and D: The predictive model built
from the dataset

Figure 4.S6. Raman spectrum of the concentrate obtained after ultra-filtration of simulated
plasma using 100kDa filters showing albumin features (899cm-1 and 1102cm-1)
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Figure 4.S7A: EMSC corrected spectra of varying concentrations of fibrinogen separated by
ion exchange chromatography (0.5mg/mL to 5mg/mL), in the absence of sonication B:
percent variance explained by the latent variables, C: PLSR coefficient showing inverse
fibrinogen peak, and D: The predictive model built from the dataset
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5.1 Abstract

Analysis of biomarkers present in the blood stream can potentially deliver crucial information
on patient health and indicate the presence of numerous pathologies. The potential of
vibrational spectroscopic analysis of human serum for diagnostic purposes has been widely
investigated and, in recent times, infrared absorption spectroscopy, coupled with ultrafiltration and multivariate analysis techniques, has attracted increasing attention, both clinical
and commercial. However, such methods commonly employ a drying step, which may hinder
the clinical work flow and thus hamper their clinical deployment. As an alternative, this study
explores the use of Raman spectroscopy, similarly coupled with ultra-filtration and
multivariate analysis techniques, to quantitatively monitor diagnostically relevant changes of
glucose in liquid serum samples, and compares the results with similar analysis protocols
using infrared spectroscopy of dried samples. The analysis protocols to detect the imbalances
in glucose using Raman spectroscopy are first demonstrated for aqueous solutions and spiked
serum samples. As in the case of infrared absorption studies, centrifugal filtration is utilised
to deplete abundant analytes and to reveal the spectral features of Low Molecular Weight
Fraction analytes in order to improve spectral sensitivity and detection limits. Improved Root
Mean Square Error of Cross Validation (RMSECV) was observed for Raman prediction
models, whereas slightly higher R2 values were reported for infrared absorption prediction
models. Summarising, it is demonstrated that the Raman analysis protocol can yield
accuracies which are comparable with those reported using infrared absorption based
measurements of dried serum, without the need for additional drying steps.
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5.2 Introduction

Human bodily fluids (e.g. blood serum/ plasma, urine, saliva, tears and cerebrospinal fluid)
are considered to be a rich reservoir of clinical biomarkers and are an interesting alternative
to cells and tissues in terms of disease diagnosis and prognosis, owing to advantages such as
minimal invasiveness, low cost, and rapid sample collection and processing (1–4). The
biochemical composition of human serum can provide crucial information on patient health
and indicate the presence of numerous pathologies, as it encompasses a vast range of proteins
and biochemical products accumulated while perfusing various organs (5). Moreover,
alterations in the biochemical composition of the serum/plasma could reflect changes of
physiological states due to disease, enabling early disease diagnosis and treatment (6–8). For
example, it is reported that carcinoembryonic antigens, CA 15-3 and CA 27.29, can be
considered as serum biomarkers for breast cancer (9), KL-40 and MMP-9 have been found
to be potential serum biomarkers for high grade gliomas (10), prostate specific antigen was
found in higher levels in the serum of patients with prostate cancer (11,12), and
carcinoembryonic antigen has been reported to be serum biomarker for colorectal cancer
(13). In recent decades, extensive studies have explored the detection of serum biomarkers
for various diseases, and quite naturally the reference tools used are the conventional,
complex analytical techniques such as chromatography, electrophoresis or mass
spectroscopy (14–18). More recently, the field of serum proteomics has exploded in the
literature, as this emerging field has gained world-wide attention due to its potential to reveal
important information regarding the pathogenesis or progression of diseases (19–22).
Analysis of serum biomarkers based on protein content is inherently challenging, because of
the low concentrations and the vast variety and dynamic range of protein abundance. The
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complex nature of the serum poses as a huge problem for the detection of small molecule
biomarkers (2,23). Human serum contains more than 10,000 different proteins, with an
overall concentration ranging from 60-80mg/mL. Furthermore, circulating species present in
the serum, such as metabolites, peptides, sugars, and lipids, add to its complexity.
Conventional proteomic methods struggle to handle large dynamic range of abundances of
its constituent components (17). The characteristics of serum are usually dominated by the
high molecular weight fraction (HMWF) of proteins, which includes albumin (57-71%) and
globulin (8-26%) and masks the features of low molecular weight analytes which are present
in trace amounts (<5%) (24). Chromatographic fractionation can significantly enhance the
sensitivity and specificity of the data recorded, and coupling with spectroscopic analysis
techniques such as IR absorption in hybrid techniques such as Liquid Chromatography (LCIR) or Gas Chromatography (GC-IR) (25) can improve the performance further. Such
chromatographic techniques, although extensively used in pharmaceutical, chemical or food
science applications are time consuming and costly, however (26–28), and commercially
available centrifugal filters have been employed to deplete the HMWF before analysis to
facilitate analysis of the low molecular weight fraction (LMWF), including proteins and
molecular biomarkers (29).
Vibrational spectroscopic techniques, both Raman and infrared absorption, have emerged
over the past 20 years as increasingly routine analytical techniques for a wide range of
applications, as they reveal specific biochemical information without the use of extrinsic
labels. Although they are often considered complementary techniques (30) there are also
specific considerations for each, for specific applications such as measurement of bodily
fluids, as described by Bonnier et al. (31). They provide intrinsic vibrational signatures of
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the material of interest in a non-destructive fashion, and the potential for diagnostic
applications has been well demonstrated, notably in human serum and plasma (7,32–34).
However, although both Raman, Fourier-Transform Infrared (FTIR) and Attenuated Total
Reflectance-FTIR (ATR-FTIR) spectroscopy have been widely explored to study bodily
fluids over the last two decades, most of these studies have been carried out on air dried
samples, in order to avoid the water contribution in the case of FTIR, and to increase the
concentration of the analytes in the case of Raman (35–40). Two major limiting factors in
the use of dried samples are the drying time (41) and also the so-called “coffee-ring” effect,
or, specifically in terms of blood serum, the Vroman effect (42–44), whereby different
analytes precipitate from solution at different rates, giving rise to variations in the spectral
features due to chemical and physical inhomogeneity. Previous studies have clearly shown
that the IR spectrum of dried (aggregates of) molecular species is not the same as that in
solution (45). It has further been shown that, for dried deposits from solutions of varying
concentrations of analyte, the linearity of the Beer-Lambert law, and therefore the
quantitative nature of the measurement is compromised as the concentration of the analyte is
increased (45). In the case of the “coffee ring effect”, the thickness, and therefore the
quantitative accuracy of the measurement is spatially inhomogeneous, and the technique is
not ideally suited for quantitative measurements, such as those considered here. Notably,
Spalding et al. have used a serum dilution technique to improve the reliability of the
technique for quantitative measurement (46). The issues with inhomogeneity can potentially
be overcome by micropipetting and sampling the whole drop, and there have been studies
that show excellent specificity/sensitivity of classification of diseased state using dried
samples (40,47,48). A study conducted by Hands et al. have shown that a 1 µL spot of serum
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on an ATR-FTIR crystal takes 8 minutes to dry to a state where excellent spectra can be
collected (49). Nevertheless, in terms of clinical translation, the requirement of a drying step
adds considerably to the sampling time and complexity of the workflow (41).
Protocols for monitoring changes in HMWF serum proteins in their native liquid form using
Raman spectroscopy have recently been demonstrated, however, without the need for drying
(50). Analysing in the native liquid state, the chemical composition is averaged out by
molecular motion over the measurement time, greatly reducing the variability of the
measurement. Bonnier et al. compared FTIR and Raman for measuring gelatin in solution
and described protocols for isolation of LMWF from serum (31). This study indicated that
Raman in the liquid form could deliver similar sensitivities to ATR-FTIR for measurement
of LMWF species.
The aim of this study is to investigate the sensitivity and accuracy of Raman spectroscopy in
the liquid state, coupled with centrifugal filtration, as a biochemical tool to detect clinically
relevant changes in the biochemical composition of serum and compare to the ATR-FTIR
technique, using the specific example of glucose. The study is specifically designed
according to the ATR-FTIR study of glucose in serum by Bonnier et al., using identical
parameters and protocols of ultra-filtration and multivariate regression analysis, such that a
direct comparison of the two techniques can be made (29). The protocol is first demonstrated
using aqueous solutions and human serum spiked with systematically varied concentrations
of glucose, before exploring the sensitivity and accuracy of the technique in patient samples.
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5.3 Materials and Methods

5.3.1 Preparation of varying concentration of glucose in distilled water model

D-glucose (G8769) was purchased from Sigma Aldrich, Ireland and 6 glucose solutions were
prepared over the concentration range 100mg/dL to 1000mg/dL. Amicon Ultra 0.5mL
centrifugal filter devices (Millipore- Merck, Germany), with 10kDa cut off point, were
employed to concentrate and fractionate the serum samples. The centrifugation procedure
previously reported by Bonnier et al. was followed (31). A further study published by
Bonnier et al. reported 100% recovery of LMWF using 10kDa, hence only 10kDa cut off
filtration has been used in the present study (45). Pre-rinsing of the filter devices with 0.1M
NaOH prior to plasma analysis is essential to avoid glycerine interference in the analysis
(32). The optimised washing and rinsing procedure includes spinning 0.5mL 0.1M NaOH at
14000×g for 30 minutes followed by three rinses with distilled water by spinning 0.5mL
distilled water for 30 minutes at 14000×g. Every 30 minute wash and rinse must be followed
by spinning the device in the inverted position at 1000×g for 2 minutes, to remove the residual
solution contained in the filter. After washing, 0.5mL of glucose solution is transferred to the
10kDa filter and centrifuged at 14000×g for 30 minutes. The solution that passes through the
10kDa filter is the filtrate, which contains mostly water and molecules smaller than 10kDa.
The remainder of the serum, known as the concentrate, is collected by placing the filter device
upside down and spinning for 1000×g for 2 minutes. The resultant concentrate, ~50µL,
contains molecules with molecular weight larger than 10kDa, concentrated by a factor of
~10, and can be employed for study of the HMWF (50). All the filtrate solutions were
analysed using Raman spectroscopy and five replicate measurements from different positions
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have been performed for each sample of ~50µL. In subsequent analysis, each patient is
represented by all the spectra recorded from that patient, rather than the mean.

5.3.2 Preparation of glucose spiked in serum model

Sterile, human serum (H6914) and D-glucose (G8769) were purchased from Sigma Aldrich,
Ireland, for the preparation of in vitro spiked models. The commercial human serum was
spiked with glucose in the concentration range that matches of the study of Bonnier et al.
(29). Since glucose is already present in normal human serum at concentrations of 70110mg/dl (51), the final concentration of the spiked samples covers the physiologically
relevant ranges of normal (80-120mg/dL) (52), and hyperglycaemia (>120mg/dL). The
centrifugal processing step described in Section 2.1 was performed on the spiked serum
samples to obtain the filtrate. Note, in the analysis of Figure 3, the regression is performed
over spiked, rather than total glucose concentration, consistent with the approach of Bonnier
et al. (29).

5.3.3 Glucose levels in patient serum samples

Patient serum samples were donated by the University Hospital CHU Bretonneau de Tours
(France) and the ethical procedures were followed. The blood samples were collected from
the individuals as routine blood check-ups and 1 mL per patient was provided for
spectroscopic analysis. A total of 25 patient samples were included in the present study.
Samples were collected by personnel of the University Hospital CHU Bretonneau de Tours,
under standard clinical protocols and ethical procedures approved by the hospital. The
samples were serologically profiled, for other purposes, and the anonymised, residual discard
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samples, along with their serological profiles were donated to the Université FrançoisRabelais de Tours, for further study. No further specific ethical approval or patient consent
is required. Glucose concentrations were obtained by routine biochemical analysis using a
COBAS analyser, following the in house guidelines for routine biochemical analysis. The
principle of the test is based on the enzymatic reference method with hexokinase, which
catalyses the phosphorylation of glucose to glucose-6-phosphate by ATP methods (53,54).
Subsequently, glucose-6-phosphate is oxidised by glucose-6-phosphate dehydrogenase, in
the presence of NADP, to gluconate-6-phosphate. This reaction is specific, with no other
carbohydrate being oxidised. The rate of NADPH formation during the reaction is directly
proportional to the glucose concentration and is measured photometrically in the UV.
Measured glucose levels in the patient samples are listed in Table 6.1, and can be seen to
cover the range 55-435 mg dL-1. Note, that the distribution of glucose levels covers a broader
range than that of the study of similar (n=15) patients by Bonnier et al. (61-208 mg dL-1)
(29).
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Table 5. 1. List of measured glucose levels in patient samples. Glucose blood levels are
quoted in terms of the SI unit of mmol L-1 as well as mg dL-1, commonly used in serology
literature and in the study of Bonnier et al.(29)
Sample number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

mmol L-1
2.9
3.1
3.9
3.9
4.2
4.2
4.3
4.5
5.1
5.1
5.2
5.7
6
6.1
6.4
6.4
7.2
8.8
9.9
11.5
11.7
13.4
15.7
15.8
24.1
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Glucose blood levels
mg dL-1
52.25
55.85
70.27
70.27
75.67
75.67
77.47
81.08
91.89
91.89
93.69
102.70
109.10
109.90
115.31
115.31
129.72
158.55
178.37
207.20
210.81
241.44
282.88
284.68
434.23

5.3.4 Data collection using Raman spectrophotometer

The measurement conditions used for screening HMWF proteins in solution have recently
been detailed (50). Raman spectra of all the liquid samples were recorded at stabilised room
temperature (18ºC) using a Horiba Jobin-Yvon LabRam HR800 spectrometer with a 16-bit
dynamic range Peltier cooled CCD detector. The spectrometer was coupled to an Olympus
1X71 inverted microscope and a x60 water immersion objective (LUMPlanF1, Olympus)
was employed. The substrate used was a Lab-Tek plate (154534) with a 0.16-0.19mm thick
glass bottom, 1.0 borosilicate cover glass, and was purchased from Thermo Fischer
Scientific, Ireland. Since the scattering efficiency is inversely proportional to the fourth
power of the wavelength, it is always desirable to use a short wavelength Raman source. In
the filtered serum, there are no molecular species which are resonant with 532nm, and
therefore neither fluorescence nor photodamage are limiting factors.

5.3.5 Data pre-processing and analysis

The raw spectra were subjected to pre-processing techniques in Matlab before further
analysis, to remove the background signal and reduce the noise. Smoothing of the raw data
was done using the Savitzky–Golay method, with a polynomial order of 5 and window 13
and the Extended Multiplicative Signal Correction (EMSC) algorithm was applied to the
smoothed spectra to remove the underlying water spectrum, whose OH bending feature at
1640 cm-1 can interfere with the protein spectra, particularly at low concentrations (55).
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The principle of EMSC for subtraction of a specific measureable background spectrum and
the associated Matlab codes have previously been published by Kerr and Hennelly, 2016
(55), and their description has been adapted in the following. In the case of measurement in
aqueous solution, the raw sample spectrum, S, consists of Raman spectrum of the analyte of
interest, R, a baseline signal, B, and the water signal, W.
S = R + B + W (55)

(1)

The Raman spectrum of interest can be represented by a reference spectrum of the analyte of
interest, r, and it can be assumed that R is the product of this reference spectrum and a certain
scalar weight, Cr, which describes the concentration dependence (56,57).
R ~ Cr x r (55)

(2)

Similarly, a spectrum, w, is recorded from water directly in order to represent the spectral
contribution of water in W, as the product of pure water spectrum and a certain scalar weight.
W = Cw x w (55)

(3)

The baseline, B, is now represented by a polynomial:
BN = C0 + C1X + C2X +……+ CNXN

(55)

(4)

where N is the order of polynomial and Cm for m = 0  N represents various coefficients of
polynomial (58). The EMSC algorithm is used to obtain estimates of the scalar values Cr, Cm
and Cw. These estimates are obtained from an optimal fit of the various vectors in Equation
5.
𝑚
S~ [𝐶𝑟 × 𝑟] + [𝐶𝑤 × 𝑤] + [∑𝑁
𝑚=0 𝐶𝑚 𝑋 ] (55)

(5)

The background corrected, concentration dependent analyte spectra, T, can be represented
as:
S−[𝐶𝑤 ×𝑤]−[∑𝑁
𝑚=0 𝐶𝑚𝑋𝑚 ]

T=

𝐶𝑤

(55)

(6)
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Note, that division by Cw has the effect of scaling the analyte spectra, assuming a constant
water contribution to all sample spectra. The Raman spectrum of the stock glucose solution
(450g/L) is used as the reference for EMSC, and polynomial of order 5 was used in all cases.
The glucose reference spectrum and water spectrum used in EMSC were recorded using the
532nm laser line and Lab-Tek plate as substrate. The x60 objective brings the laser to a focus
within the liquid, beyond the thin (0.16mm-0.19mm) glass substrate. No significant
contribution from the glass to the recorded spectrum was apparent, and therefore no
correction was required. The Rubberband method (59) was used to baseline correct the
glucose reference spectrum after smoothing it using the Savitzky–Golay method.

5.3.6 Partial Least Squares Regression

Partial Least Squares Regression (PLSR) was employed to establish a model that relates the
variations of the spectral data to a series of concentrations. This regression model can be used
to improve the limit of detection of Raman bio-sensing (60). Constructed based on the
spectra of samples of known glucose content, either solutions of varying concentrations of
glucose (in water or in commercial serum), or those of the patient serum, the model is then
validated using a rigorous cross validation procedure which evaluates its performance in
accurately predicting glucose concentrations. A 20 fold cross validation approach has been
employed to validate the robustness of the method. This approach involves randomly
dividing the set of observations into approximately equal size, 50% of the spectral data were
randomly selected as test set, while the remaining 50% is used as the training set (61). In the
current case, (5 x 25 spectra) were divided into two groups of 65 (test) and 60 (training)
spectra. The cross-validation process is then repeated 20 times (the folds), with all
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observations are used for both training and testing, and each observation is used for testing
exactly once. The results from the folds can then be averaged to produce a single estimation.
The Root Mean Square Error of Cross Validation (RMSECV) is calculated from the 20
iterations to measure the performance of the model for the unknown cases within the
calibration set. The correlation between the concentration and spectral intensity is given by
the R2 value. The standard deviation was calculated to find the variation between each
spectrum calculated from the same sample. The number of latent variables used for building
the PLSR model is optimised by finding the value that is equivalent to the minimum of the
RMSECV

5.4 Results

In this study, Raman spectra of the samples were recorded in the inverted geometry using a
x60 water immersion objective with a 532nm laser and the Lab-Tek plate was used as the
substrate. The 532nm laser was chosen as it is compatible with the thin glass bottomed LabTek plate and provides a strong Raman signal of the sample with minimal background
interference. This set-up was previously reported by Bonnier et al. (31) to yield better
analysis of serum using Raman spectroscopy when the sample was analysed in the inverted
geometry using a water immersion objective with a 785nm laser and CaF2 substrate. The
added advantage of this setup is that it provides high quality, consistent Raman spectra from
sample volumes as low as 1μL. The protocol using 532nm was more recently further explored
for analysis of HMWF serum proteins (50).
Figure 5.1 presents the spectra of the fingerprint region of the pure glucose solution recorded
in the inverted geometry. The raw spectra of the glucose were baseline corrected using the
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rubberband method and smoothed using the Savitzky–Golay algorithm (polynomial 5,
window 13). Example signature peaks of glucose (indicated by asterisks) appear at ~450cm1

, associated with an endocyclic δ(C-C-O) ring mode, δ(C1-H1) vibration at 911cm-1, a peak

at 1060cm-1 due to ν(C1-OH) stretching, a relatively sharp peak at 1125cm-1 which can be
assigned to the δ(C-O-C) angle-bending mode and the sharp peaks at 1340cm-1 and 1460cm1

, related to the δ(C-C-H) vibration and pure CH2 group vibration, respectively(62).

*

*

*
*

*

*

Figure 5.1. Raman spectrum of an aqueous glucose solution, concentration 450g/L. Example
signature peaks at 450cm-1, 911cm-1, 1125cm-1, 1340cm-1 and 1460cm-1 are labelled in the
figure.

5.4.1 Monitoring the concentration dependence of glucose in distilled water

In order to establish the analysis protocol for the patient samples, a PLSR prediction model
was first built and applied to the set of varying concentrations of glucose in distilled water,
as well as spiked into serum. The first step in this study was to optimise the measurement
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protocol and also to evaluate the efficacy of the centrifugal filtration technique in separating
and concentrating glucose from the HMWF proteins. For this, different amounts of pure
glucose were spiked into the distilled water. The normal glucose concentration and the
concentration and hyper-glycaemia were deliberately included to simulate physiologically
relevant concentrations.
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Figure 5.2 (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal filtration
with 10kDa filters of varying concentrations of glucose (5 x100mg/dL, 5 x 450mg/dL and 5
x 1000mg/dL, offset for clarity), in distilled water and signature peaks of glucose are
highlighted with asterisks, (B): Evolution of the RMSECV on the validation model, (C): plot
of PLSR coefficient with glucose features, (D): Predictive model built from the PLSR
analysis. The value displayed in the PLSR model is an average of the concentration predicted
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with the corresponding standard deviation calculated from the 20 iterations of the cross
validation. The RMSECV and R2 values were calculated as 10.93mg/dL and 0.9705
respectively.

Figure 5.2 A displays examples of the EMSC (polynomial order 5) corrected low (5
x100mg/dL), medium (5 x 450mg/dL) and high (5 x 1000mg/dL) datasets, showing glucose
features (indicated by asterisks) of greater intensity at higher concentration, whereas the
lower concentrations shows weaker features of glucose. The groups of spectra are off set for
clarity. The concentration 1000mg/dL was deliberately included in the dataset to evaluate the
consistency of the glucose spectral features as the concentration increases from 100mg/dL to
1000mg/dL. In order to analyse the spectral variations and the glucose concentrations, the
PLSR algorithm was applied.
Based on the percent variance explained by the latent variables and the minimum value of
RMSECV (Figure 5.2B), the optimum number of latent variables to reach the best
performance is determined to be 4. The PLSR coefficient plot displayed in Figure 5.2C
confirms the correlation of the data in Figure 5.2D is based on glucose features, such as the
peaks at ~1060cm1, ~1125cm1, 1450cm-1 and ~1340cm-1. Finally, after selecting the
optimum number of components for the data set analysed, a predictive model is built from
the PLSR analysis (Figure 5.2D), to compare the observations to the known concentrations
of glucose in the samples with the estimated concentrations from the spectral data sets. Figure
5.2D indicates that a satisfactory linear model could be obtained with the raw data set and
that the concentration dependence of the sample set is conserved by centrifugal filtration.
From the results shown in figure 5.2, it is evident that the predicted values are in good
agreement with the reference concentrations and the corresponding correlation coefficient
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(R2) is calculated as 0.9705. Note, each concentration point has five independent
measurements, and the mean standard deviation of each measurement is 4.8mg/dL. The
RMSECV calculated from the 20 iteration of cross validation is 10.93mg/dL,, thereby
indicating that PLSR provides accurate predictions for the glucose Raman data over the entire
concentration range of 100mg/dL to 1000mg/dL.

5.4.2 Monitoring the glucose concentration in spiked serum

In an attempt to extend the optimised protocol to a more complex environment, PLSR
analysis was performed on the EMSC corrected data set recorded from the filtrate of the
serum samples with spiked glucose concentrations varying from 0mg/dL to 220mg/dL. When
the entire fingerprint region was selected for PLSR analysis, the resultant PLSR coefficient
displayed a negative peak at ~1000cm-1 which could potentially derive from other LMWF
species such as urea (63) (Figure 5.S1C in Supplemental). Therefore, the spectral region from
1030cm-1 to 1400cm-1, which contains strong glucose features at ~1050cm-1 and at~1340cm1

but minimal interference from urea, has been chosen for PLSR analysis (62). Figure 5.3A

shows the glucose data set after background correction using the EMSC algorithm (offset for
clarity by 5.0 units). The optimum number of latent variables were chosen by calculating the
lowest value of RMSECV (Figure 5.3B). Six latent variables were chosen for this model and
the resultant PLSR coefficient exhibits strong glucose features, as shown in Figure 5.3C. A
linear predictive model can be defined from the EMSC corrected data set of varying
concentration of glucose in serum Figure 5.3D. The RMSECV was found to be 1.66mg/dL
and R2 value was calculated as 0.9914. The mean standard deviation of each measurement
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from 20 iterations of cross validation was calculated to be 3.2mg/dL. The results suggest that
this optimised protocol can be applied to the patient samples to build a quantitative model.
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Figure 5.3. (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of glucose spiked in serum (spiked concentrations 5 x 0mg/dL,
5 x 120mg/dL and 5 x 220mg/dL, offset for clarity) and the signature peaks of glucose are
highlighted by asterisks, (B): Evolution of RMSECV of the data set (C): plot of PLSR
coefficient with glucose features, (D): Predictive model built from the PLSR analysis. The
value displayed in the PLSR model is an average of the concentration predicted with the
corresponding standard deviation calculated from the 20 iterations of the cross validation.
The RMSECV and R2 values were calculated as 1.66mg/dL and 0.9914
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Bonnier et al. have previously illustrated the strategy of centrifugal filtration to fractionate
the samples to eliminate the influence of HMW in order to screen potential LMWF
biomarkers using glucose as a model analyte, measured by ATR-FTIR [33]. The results of
the analysis of similarly centrifugally filtered, glucose spiked samples of commercial serum
are reproduced in Table 5.2, and directly compared to the results of the current study using
Raman spectroscopic analysis in the native liquid state. Although each method yields similar
R2 values, the RMSECV of Raman spectroscopic analysis is significantly lower, which
indicates an increased accuracy of the measurement protocol in the liquid state.
Table 5. 2. Comparison of the results of ATR-FTIR and Raman spectroscopic analysis of
human serum spiked with varying concentrations of glucose.
Measurement
type

Concentration
range (mg/dL)

RMSECV(mg/dL)

Standard
deviation

R2

FTIR (MinMax
normalised)

0-220

2.199

0.250

0.995

Raman
spectroscopy

0-220

1.665

3.2

0.991

5.4.3 Monitoring the glucose concentration in patient samples

Figure 5.4A displays the Raman spectra from patient samples after performing background
correction using the EMSC algorithm, in the reduced spectral range of 1030-1400 cm-1. The
spectra are offset for clarity by 5.0 units. The glucose bands at 1120cm-1 and 1340cm-1,
related to the δ(C-C-H) vibration and pure CH2 group vibration, and the peak at 1060cm-1
due to ν(C1-OH) stretching can be clearly seen. Based on the minimum RMSECV value

174

(Figure 5.4B), 12 latent variables were found to be optimal for constructing a PLSR based
model. The PLSR coefficient clearly shows glucose features (Figure 5.4C), indicating that
the prediction is based on the variation in the glucose peak intensities.
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Figure 5.4. (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of patient samples (5 x 52.25mg/dL, 5 x 75.67mg/dL, 5 x
93.69mg/dL, 5 x 210.81mg/dL and 5 x 434.35mg, offset for clarity) and the signature peaks
are marked by asterisks, (B): Evolution of RMSECV of the data set, (C): plot of PLSR
coefficient with glucose features, (D): Predictive model built from the PLSR analysis. The
value displayed in the PLSR model is an average of the concentration predicted with the
corresponding standard deviation calculated from the 20 iterations of the cross validation The
RMSECV and R2 values were calculated as 1.84mg/dL and 0.84 respectively.
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In the prediction model of Figure 6.4D, the minimum value of RMSECV is 1.84mg/dL and
the R2 value is calculated as 0.82, indicating a high prediction capacity. The mean standard
deviation was determined to be 3.48mg/dL, indicating acceptable repeatability between the
cross validation iterations.

Table 5. 3. Comparison of the results of ATR-FTIR (29) and Raman spectroscopic analysis
of patient sample set for monitoring the glucose levels. FTIR results are normalised.
Measurement
type

Concentration
range (mg/dL)

RMSECV(mg/dL) Standard
R2
deviation(mg/dL)

ATR-FTIR
(Min-Max
normalised)

61.25-210

3.1

1.90

0.9957

Raman
Spectroscopy

52.25-210

1.6

2.31

0.91

52.25-440

1.84

3.48

0.84

Table 5.3 directly compares the results of analysis of a similar patient sample-set, with
glucose levels which varied over the range 0-210mg/dL, similarly centrifugally filtered and
analysed using ATR-FTIR (29) and the results of the current study of patient samples over
the same (patients 1-21, Table 5.1) and extended (patients 1-25, Table 5.1) range using
Raman spectroscopic analysis in the native liquid state. It is noteworthy that Raman
spectroscopy yields significantly lower values of RMSECV for all the Raman prediction
models, suggesting higher sensitivity and accuracy. However, the standard deviation was
found to be higher and the R2 value was found to be considerably lower for the shorter as
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well as larger concentration range. The reduced R2 value and higher standard of deviation
could be attributed to the variability in the spectral response of the patient samples.
Nevertheless, the precision of the model expressed by the RMSECV values indicates the
suitability of this technique to discriminate patients with very close concentrations of blood
glucose. The results demonstrate that Raman spectroscopy is able to detect subtle variations
in the glucose concentrations with similar accuracy in the native liquid state, to the ATRFTIR method in dried samples.
In order for a glucose detection method to be viable, it should be able to detect glucose in the
clinically relevant range (10-450mg/dL). Post PLSR analysis, the dataset is presented in the
Clarke’s error grid (Figure 5.5), the most common standard for evaluating the performance
of a glucose detection method used since 1987 (64).

Figure 5.5. PLSR validation of patient samples on Clarke’s error grid. The RMSECV was
found to be 1.84 mg/dL and R2 value was calculated as 0.84
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Data points that fall in zone A and B are acceptable values. Values that fall outside A and B
result in erroneous diagnosis. On the Clarke’s error grid of patient samples (Figure 5.5), 98%
of the PLSR validation dataset falls within zone A and B, which is the zone of clinical
accurate measurement with no effect on clinical actions. Error can be attributed to the
intrinsic variability of patient samples which reflects their physiological state on the day.
However, the results from this study are promising, indicating that Raman spectroscopy
coupled with multivariate analysis and centrifugal filtration techniques can be used as a
biochemical tool for detecting potential small biomarkers from human serum/plasma.

5.5 Discussion

The potential advantages of using vibrational spectroscopy for biomarker assessment in
bodily fluids have been extensively explored in the last two decades. However, little
consideration has been given so far to protocols involving Raman analysis in the native liquid
state of proteins. Liakat et al. reported the in vitro prediction of physiologically relevant
concentration of glucose using mid-IR transmission light with respect to a Clarke error grid
(52). Near IR and Raman spectroscopy was also used for measurement of glucose from
artificial plasma with high precision and accuracy (65). Although these are initial steps
towards developing Raman spectroscopy into a biochemical tool for serum/plasma analysis,
measurements should be performed on patient samples in order to ensure the relevancy of
these methods. Using Raman spectroscopy as a biochemical tool, it has been possible to
detect differences in peak intensities of altered serum compared to normal ones for glucose
and lipid compounds (66), multicomponent blood analysis (67) and also to determine blood
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glucose concentration of blood samples with above-physiological levels of glucose within 5
min (68).
Using glucose as a model analyte, this study successfully demonstrated the feasibility of
employing Raman spectroscopy for detecting small biomarkers in serum after depletion of
HMWF proteins. It has been shown that optimal experimental set up for Raman analysis for
this experiment is Lab-Tek plates as substrate and measurement in the inverted geometry
using water immersion objective and the sample volume can be as small as 1μL. This
experimental set up is advantageous for clinical purposes where the volumes of patient
samples are minimal. After the depletion of the abundant proteins, the dominant water peak
from the filtrate collected after centrifugal filtration using 10kDa can be removed by using
the EMSC algorithm, and PLSR analysis applied to obtain a prediction model relating the
glucose concentrations and the intensity of glucose features. Even though the EMSC
algorithm removed the underlying water spectra effectively, there could be interference from
other LMWF analytes, namely, urea (7-20mg/dL). Thus, as presented in the present study,
the spectral range from 1030cm-1 to 1400cm-1 was chosen for data analysis, as this region
does not contain signature peaks of urea.
The depletion of HMWF proteins using centrifugal filtration to detect glucose in serum using
ATR-FTIR was previously reported by Bonnier et al. (29). While the work carried out by
Bonnier et al. showed excellent results, the requirement of a drying step is potentially a major
drawback. Indeed, the drying process required for ATR-FTIR has been identified by
Cameron et al. as a potentially significant impediment to translation of the technique to
clinical applications (41). Since Raman is compatible with aqueous samples, sample drying
can be avoided and data can be recorded from the native environment, which makes the
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proposed method an ideal alternative to IR. The results summarised in Table 5.2 and Figure
5.3 suggest that Raman spectroscopy maintained high level of accuracy and predictive power
and the relationship between spectral variation and protein concentrations is linear, with
minimal standard deviation. The PLSR model built on varying concentration of glucose
spiked in serum provided an accurate prediction model (R2=0.9914, RMSECV= 1.66mg/dL)
after applying pre-processing steps using the EMSC based algorithm. Having established the
optimal sample preparation and analysis protocol using the spiked serum model, the same
protocol was applied to patient samples. In the case of patient samples, RMSECV and R2
values were calculated to be 1.84mg/dL, and 0.84 respectively. Although ATR-FTIR
provides better standard deviation and higher R2 value, the Raman prediction model gives
lower a RMSECV value, indicating higher accuracy. The PLSR coefficient plot shows clear
features of glucose, indicating the prediction model is built on variations in glucose
concentrations. The added advantage of Raman spectroscopy is that the analysis can be
performed on liquid samples and no additional time delays associated with sample drying are
introduced. Although the quantitative capability of Raman can be easily demonstrated using
glucose spiked with a pooled serum model, the analysis of patient samples can be more
complicated, the reason being the intrinsic variability of individual samples depending upon
the physiological state of the individual on that day.
For the purposes of a direct comparison of the two techniques, glucose concentration in
human serum was chosen, and the results detailed in Table 5.3 indicate that Raman in the
liquid state provides higher accuracy than FTIR-ATR. Although vibrational spectroscopic
techniques are unlikely to replace current techniques for routine glucose monitoring, in a
more general sense, an argument for serological applications of vibrational spectroscopic
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techniques has been made (28, 37). The advantages of using Raman spectroscopy over
common biochemical assays to quantify urea and creatinine has previously been reported
(63). Moreover, Raman spectroscopy as a biochemical tool for serum analysis is cost
effective, rapid and a non-destructive method as compared to currently employed gold
standard clinical methods such as spectrophotometric analysis ( e.g. COBAS analyser) (69).
The COBAS analyser has a standard deviation of 0.04 mmol.L-1 (which is equivalent to 0.721
mg.dL-1), as mentioned in the Material and Methods section, and the lower detection limit is
2mg/dL (70) with a correlation coefficient of 0.975 reported for immunoassays (71) and R2
of 0.990 for urea, creatinine, sugar, total protein and calcium (72). Similar R2 values were
calculated for pure glucose solutions and glucose spiked serum solutions using Raman
spectroscopy, suggesting that Raman spectroscopy is well-suited for routine use as a
biochemical tool for glucose analysis. However, the analysis using COBAS analyser is
complex and uses various enzymatic reagents, increasing the cost and chance of inaccuracy
in the results obtained. Employing well trained personnel to operate the equipment enhances
the reliability but increases the cost. Hence, Raman spectroscopy offers several advantages
as it is a onetime investment, easy to operate and provides rapid results with wider
information without destroying the medium. This could be translated as an alternative method
for glucose monitoring, especially in the case of hyperglycaemia. Further studies need to be
conducted to investigate other LMWF metabolites from human serum using Raman
spectroscopy. However, to further ensure relevancy of the results, the study should ultimately
be conducted on large number of patient samples.
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5.6 Conclusion

Summarising, the work presented showcases the development of an optimal methodology for
the detection of LMWF analytes from human serum using Raman spectroscopy with minimal
sample preparation steps and without the use of any extrinsic labels. The proposed approach
can be expeditiously employed for early detection of pathological disorders associated with
high or low serum/plasma proteins/biomarkers. Disease diagnosis from bodily fluids can be
developed into a dynamic diagnostic environment that will enable early disease diagnosis
even before the disease becomes symptomatic. Thus, analysis of bodily fluids has emerged
as one of the promising approaches to deliver crucial information about patient health and
monitor disease progression and/or therapy. Given the remarkable advances in the field over
the last two decades, including sample preparation, protein fractionation, quantitation and
chemometrics, it is conceivable that vibrational spectroscopic techniques can be developed
as a point-of-care disease monitoring system. Ultimately, the proof of concept presented in
this study can be easily transferable to any other low molecular weight biomarkers or
therapeutic drugs.
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5.8 Supplementary information

1. When the entire fingerprint region was selected for PLSR analysis, the resultant
PLSR coefficient displayed a negative peak at ~1000cm-1 which could potentially
derive from other LMWF species such as urea (1)

A

B

C

D

Figure 5.S1 (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of serum samples, (B): Evolution of the RMSECV on the
validation model, (C): PLSR coefficient shows a negative peak ~1000cm-1, (D): Predictive
model built from the PLSR analysis.
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Chapter 6
Raman spectroscopic screening of High and Low
molecular weight fractions of human serum
The following chapter has been adapted from the published journal article titled as ‘Raman
spectroscopic screening of High and Low molecular weight fractions of human serum’,
Analyst, 2019, DOI: 10.1039/C9AN00599D.
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6.1 Abstract

This study explores the suitability of Raman spectroscopy as a bioanalytical tool, when
coupled with ultra-filtration and multivariate analysis, to detect imbalances in both high
molecular weight (total protein content, γ-globulins and albumin) and low molecular weight
(urea and glucose) fractions of the same samples of human patient serum, in the native liquid
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form. Ultra-filtration was employed to separate and concentrate the high and low molecular
weight fractions of the serum. Initially, aqueous solutions of the respective molecular species,
covering physiologically relevant concentration ranges, were analysed to optimise the
measurement protocols. An adapted Extended Multiplicative Signal Correction (EMSC)
algorithm was applied to raw spectra to remove water background signal and spectral
interferents (β-carotene). Using a validated partial least squares regression modelling
method, R2 values, Root Mean Square Error of Cross Validation (RMSECV) and standard
deviations were established for the quantification of γ-globulin, total protein, albumin, urea
and glucose content of the patient serum samples. The study demonstrates that Raman
spectroscopy in the liquid form is a viable alternative and/or adjunct to current clinical
practice for the parallel analysis of high and low molecular weight fractions, and
simultaneous analysis of multiple analytes in the low molecular weight fraction, of human
serum for diagnostic applications.

6.2 Introduction

Increasingly, medical diagnostic tests are performed on bodily fluids, as sample collection is
minimally invasive, compared to histology or cytology based techniques. However,
conventional methods for biofluid analysis can be inconsistent and are associated with high
cost and long-time delays (1,2). Therefore, there is a need for more sensitive and cost
effective methods with higher accuracy for early disease diagnosis from bodily fluids in a
point-of-care clinical setting. Vibrational spectroscopic techniques, both Infrared absorption
and Raman scattering, are among the most important analytical techniques available to
scientists, as they provide detailed molecularly specific fingerprints of both organic and
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inorganic compounds, without the use of extrinsic labels and without being extremely
invasive or destructive to the system studied. Since both techniques are truly label-free, their
potential for medical diagnostic applications has been well investigated and demonstrated
(3–7). Such techniques are particularly attractive for routine analysis of biofluids, as they are
easy to apply, require minimal sample preparation and are readily adaptable to analysis of
various bodily fluids (1-5). Notably, it has been demonstrated that, whereas IR analysis of
biofluids usually requires a drying step (8–10), Raman spectroscopic analysis can be applied
to bodily fluids in their native liquid state (11,12). As water is a relatively weak scatterer,
Raman spectroscopy is much more amenable than IR for analysis of biofluids in their native
aqueous state (10, 11), and its potential has been well demonstrated, notably in human serum
and plasma (13–16).
Estimating serum total protein, γ-globulin and albumin content is important to assess the
nutritional status of patients (17,18). Although total serum protein estimation has limited
diagnostic potential when compared to albumin or globulin, its relevance in the evaluation
of patients with clinical conditions such as malnutrition, renal malfunction, liver diseases and
immune disorders cannot be ignored (18,19). A normal level of total serum protein (60008300 mg/dL) indicates healthy nutritional status and normal liver function. Reduced serum
total protein is predominantly found in patients with kidney disorders, HIV and aging in the
elderly (20,21). The biuret assay is the most common method used to quantify total protein
levels in blood serum (1).
γ-globulins (<150kDa (22), ~38% of serum proteins), produced by lymphocytes and plasma
cells in lymphoid tissue, are large protein molecules that include the immunoglobulins: IgM,
IgA, and IgG (23). The most characteristic abnormality in serum proteins in liver diseases
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and carcinoma of the gastro-intestinal tract or breast is an elevation in γ-globulins (24,25).
Testing globulin levels in serum routinely provides key information that helps diagnose
various conditions and diseases that affect the immune status. Liver diseases, chronic
inflammatory diseases, haematological disorders, infections and malignancies cause excess
globulin levels (>1600mg/dL) (26), whereas humoral immunodeficiencies cause low
globulin levels (<700mg/dL) (27). Radial immunodiffusion (RID) (28) is the gold standard
method for measuring globulins. All the conventional methods used for testing total protein
content and globulin measurement make use of expensive disposables and are labour
intensive. With escalating medical costs and budget constraints, a cost effective alternative
technology is desirable.
Albumin is the most abundant high molecular weight fraction (HMWF) serum protein,
normally constituting about 50% of the total serum content, and has a molecular weight of
66 kDa (29). The normal concentration of albumin in the human body is 3000 mg/dL,
although it dramatically decreases in critically ill patients and does not increase again until
the recovery phase of the illness (17). Several studies have demonstrated that the functions
of albumin, such as ligand binding and transport of various molecules, can be applied to the
treatment of cirrhotic patients and patients suffering from other end stage liver diseases (30–
32). Strong correlation between cardiovascular disease and the level of albumin
concentration have also been reported (33–38), which means a normal concentration of
albumin in bodily fluids is considered a sign of good health. It is clear therefore that closely
monitoring the variation in albumin concentration could act as an indicator of liver diseases
and other related pathologies. Conventional methods used to determine the level of albumin
include absorption spectroscopy or electrochemical based assays, immunoassays and high
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performance liquid chromatography (HPLC) and can be time consuming and very expensive
(20, 26–32). Therefore, a sensitive, rapid, cost-effective method such as Raman spectroscopy
is highly desirable to quantitatively analyse albumin.
Urea is a colourless crystalline compound of molecular weight 60.056 g/mol (60.056 Da) and
is the main nitrogenous by-product produced by the liver when the body metabolises proteins
(45). The normal concentration of urea in human blood serum is 5-20 mg/dL. The kidneys
normally filter out this waste from the body, and therefore it is important to monitor blood
urea as higher (<20 mg/dL) or lower levels (>5 mg/dL) could indicate various pathologies
such as kidney or liver malfunction (46–49). The standard technique for assessment of urea
from blood or urine is based on colorimetric measurement, by which a specific reagent reacts
with the sample and absorption at a given wavelength is used to identify urea concentration
(48,50).
Glucose is a low molecular weight carbohydrate that must be monitored on a regular basis in
the case of diabetes patients (51). The normal concentration of glucose in blood is 70 to
130 mg/dL and changes in this level would lead to hyper (>130 mg/dL) or hypoglycaemia
(<70 mg/dL) (51). While currently available methods of routinely self-monitoring blood
glucose have become low cost, such glucose meters often suffer from significant errors that
can lead to unreliable results (52,53). Hence, there is an unmet need for an accurate glucose
monitoring tool, notably in a clinical setting.
Over the past decades, there have been numerous studies of analytes in biofluids using
vibrational spectroscopy, and, in recent years, attenuated total reflection (Fourier Transform)
IR (ATR-FTIR) has become popular for rapid screening of biofluids, particularly blood
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serum (54). Multianalyte serum analysis has previously been reported using mid-infrared
spectroscopy, for the simultaneous quantitation of eight serum analytes: total protein content,
albumin, triglycerides, cholesterol, glucose, urea, creatinine and uric acid (55) and for
simultaneous quantification of glucose and urea analytes along with malaria parasitemia
quantification using ATR-FTIR (56). Notably, however, both the analyses were conducted
on dried serum samples. Berger et al., as long ago as 1999, used Raman microscopic analysis
of liquid whole human blood and serum samples to quantify the content of six analytes,
namely glucose, cholesterol, triglyceride, urea, total protein and albumin (57). Rohleder et
al., performed a direct comparison of Raman and FTIR spectroscopies of multiple analytes
in human serum, concluding that the techniques produced similar accuracies(58). More
recently, Parachalil et al., demonstrated that, using the same serum fractionation and
regression analysis protocols, Raman microspectroscpic analysis in the liquid state
performed at least as well as ATR-FTIR of dried samples, in the quantification of glucose
levels in human serum (11).
This study aims to further evaluate the potential of Raman spectroscopy for the analysis of
blood serum in the liquid state to simultaneously detect and quantify subtle variations in the
whole serum (total protein content and γ-globulins), HMWF (albumin) and LMWF (urea and
glucose) as specific biomarkers linked to numerous pathologies, adding improved sampling
techniques, sample fractionation and selected spectral ranges to improve over the previous
work using ATR-FTIR and Raman spectroscopy.
Human serum is highly complex and diverse, however, due to its heterogeneous nature,
consisting of dynamic range of biomolecules such as proteins, lipids, carbohydrates etc. (59).
Raman spectra of serum are dominated by features of the abundant proteins (notably
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globulins and albumin) and water, making it difficult to visualise the spectral features of less
abundant analytes and small molecules which can act as biomarkers. Both urea and glucose
are classified as Low Molecular Weight Fraction (LMWF) analytes, and their low abundance
makes it harder to detect these analytes from the full serum samples. Therefore, measures are
taken to make data interpretation easier, such as fractionation of serum using centrifugal
filters prior to Raman analysis, followed spectral pre-processing.

6.3 Materials and Method

6.3.1 Sample Preparation

γ-globulins (G4386), albumin (A9511), urea (F3879) and β-carotene (C9750-5G) were
purchased from Sigma Aldrich, Ireland. Individual solutions of varying concentrations of
urea (1-1000 mg/dL) were prepared in distilled water by varying the concentrations over a
physiologically relevant range.
Patient serum samples were donated by the University Hospital (CHRU) Bretonneau de
Tours (France) and the ethical procedures were followed. The blood samples were collected
from the individuals as routine blood check-ups and 1 mL per patient was provided for
spectroscopic analysis. A total of 25 patient samples were included in the present study.
Samples were collected by personnel of CHRU, under standard clinical protocols and
approved ethical procedures (Comité de Protection des Personnes, Tours Region Central Oest
1- PP/ANSM- PHAO15-HB-METABOMU, registered internationally: ClinicalTrials.gov
ID: NCT02670226). The samples were serologically profiled, for other purposes, and the
anonymised, residual discard samples, along with their serological profiles were donated to
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the Université de Tours, for further study. No further specific ethical approval or patient
consent is required. Albumin, γ-globulins (IgG, IgM and IgA), total protein, urea and glucose
concentrations were obtained by routine biochemical analysis using a COBAS analyser,
following the CHRU guidelines for routine biochemical analysis. The principle for the test
of albumin utilises the formation a blue-green complex to test for albumin, and a purple‑
coloured biuret complex to test for total protein. While albumin displays a sufficiently
cationic character to be able to bind with an anionic dye, Bromoscresol green (BCG), at a pH
of 4.1 (60) and divalent copper reacts in alkaline solution with protein peptide bonds in the
case of total protein (61). The urea test is based on a coupled enzyme reaction (urease,
followed by glutamate dehydrogenase), whereby measurement of NADH (converting to
NAD+) is made at 340 nm (62). γ-globulin concentrations were obtained using
immunoturbidometric assays, and were summed to provide a value for total γ-globulin
content (63). Measured analyte levels in the patient samples are listed in Table 6.1.
Concentrations are expressed in mg/dL for consistency with other studies (9). Notably, no
correlation was found between the concentrations of HMWF and LMWF analytes in the
patient serum samples (Figure 6.S1 and 6.S2 in supplemental).
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Table 6. 1. Measured analyte levels in patient samples
Sample
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Total
Protein
(mg/dL)
6300
6900
6400
6700
5800
5600
7600
6700
6000
6200
6900
7500
5800
6100
4200
7900
6600
7600
7700
6500
7400
7600
6600
6500
7100

γ-globulin
(mg/dL)

Albumin
(mg/dL)

Urea (mg/dL)

Glucose
(mg/dL)

1327
1010
2254
1259
404
670
1395
712
875
1164
1409
1843
726
840
541
1478
1187
1201
1484
1396
1663
924
1556
1171
1236

3130
4510
2710
3580
3050
3120
4220
4450
3690
2970
3690
3910
3880
3340
2600
3890
3950
4780
4420
3380
4360
4250
3150
3750
4140

78.99
15.97
21.85
7.00
8.40
5.88
50.14
75.63
59.38
5.88
2.52
29.41
21.57
10.64
11.20
17.65
10.92
17.28
26.33
52.94
8.12
39.50
19.05
8.12
25.49

108.0
81.0
91.8
115.2
241.2
207.0
115.2
210.6
75.6
282.6
75.6
102.6
129.6
93.6
178.2
77.4
91.8
70.2
158.4
52.2
109.8
70.2
284.4
55.8
433.8

Amicon Ultra 0.5 mL centrifugal filter devices (Merck, Germany), of cut-off point 100 kDa,
50 kDa and 10 kDa, were employed to concentrate and separate the analytes of interest from
the individual solutions and patient samples. The centrifugation procedure that has been
previously reported by Bonnier et al. was followed (13). The optimised washing and rinsing
procedure includes spinning 0.5 mL 0.1 M NaOH at 14000×g for 30 minutes followed by
three rinses with distilled water by spinning 0.5 mL distilled water for 30 minutes at 14000×g.
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Every 30 minute wash and rinse must be followed by spinning the device in the inverted
position at 1000×g for 2 minutes, to remove the residual solution contained in the filter.

Figure 6.1. Schematic overview of steps in fractionation of patient serum samples to
separate γ-globulin, albumin, and urea/glucose

Figure 6.1 is a schematic representation of the patient serum fractionation steps employed in
this study. Non-fractionated serum was directly analysed to collect data for total protein
content and γ-globulin. In order to fractionate the patient serum samples, 0.5 mL sample was
first spun for 30 minutes using 100 kDa filters to remove the analytes larger than 100 kDa
(γ-globulin) in the concentrate and the transmitted filtrate, which contains molecules smaller
than 100 kDa, was used for further fractionation. For albumin isolation, the filtrate obtained
was spun using 50 kDa filters for 30 minutes and the resultant concentrate was collected for
Raman analysis. The filtrate transmitted by the 50 kDa filter was collected and was spun
using 10 kDa filter for 30 minutes and the resultant filtrate was collected for Raman analysis
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to detect the presence of urea/glucose. Using a model sample based on glycine spiked serum,
Bonnier et al. demonstrated the reproducibility of the HMW proteins depletion to be quite
efficient and acceptable (8).

6.3.2 Data collection using Raman spectrometer

The measurement conditions used were the same as those recently reported for screening
HMWF proteins (11) and glucose (64) in solution. Raman spectra of the liquid samples were
recorded at stabilised room temperature (18ºC) using a Horiba Jobin-Yvon LabRam HR800
spectrometer with a 16-bit dynamic range Peltier cooled Charged Coupled Device. The
spectrometer was coupled to an Olympus 1X71 inverted microscope and a x60 water
immersion objective (LUMPlanF1, Olympus) was employed. A 532nm laser was used,
which had a power of ~30 mW at the sample, with a 600 lines/mm grating and the
backscattered Raman signal was integrated for 3×80 seconds over the spectral range from
400-1800 cm-1. The substrate used was a Lab-Tek plate (catalog number 154534) with a 0.160.19 mm thick glass bottom, 1.0 borosilicate cover glass, and was purchased from Thermo
Fischer Scientific, Ireland.

6.3.3 Data pre-processing and analysis

The raw spectra were subjected to pre-processing techniques in Matlab before further
analysis, to remove the background signal and reduce the noise. Smoothing of the raw data
was done using the Savitzky–Golay method (polynomial order of 5 and window 13) and the
rubberband method (11) was found to be appropriate to baseline correct the smoothed
reference spectra of all the analytes and the smoothed spectra of varying concentrations of
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albumin spiked in distilled water (11). The ‘rubberband’ correction was carried out by
wrapping a ‘rubberband’ of defined length around the ends of the spectrum to be corrected
and fitting against the curved profile of the spectrum. An adapted Extended Multiplicative
Signal Correction (EMSC) algorithm (65) with a 5th order polynomial was applied to the raw
dataset to remove the spectral interferents from the data. EMSC is applied to remove the
underlying water spectrum from all the dataset, whose OH bending feature at 1640 cm-1 can
interfere with the protein spectra and also scales the analyte spectra, assuming a constant
water contribution to all sample spectra (65). The principle of EMSC for subtraction of a
specific measureable background spectrum and the associated Matlab codes have previously
been published by Kerr and Hennelly, 2016 (65), and their description is adapted in the
following. The raw spectrum, S, consists of Raman spectrum of interest, R, a baseline signal,
B, and the water signal, W.
S = R + B + W (65)

(1)

The Raman spectrum of interest can be represented by a reference spectrum of the material
of interest, r, and it can be assumed that R is the product of this reference spectrum and a
certain scalar weight, Cr, which describes the concentration dependence (66,67)
R ~ Cr x r

(65)

(2)

Similarly, a spectrum, w, is recorded from water directly in order to represent the spectral
contribution of water in W, as the product of pure water spectrum and a certain scalar weight.
W = Cw x w

(65)

(3)

The baseline, B, is now represented by an appropriate order of polynomial (N) as:
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BN = C0 + C1X + C2X +……+ CNXN

(65)

(4)

where N is the order of polynomial and Cm for m = 0  N represents various coefficients of
polynomial. The EMSC algorithm is used to obtain estimates of the scalar values Cr, Cm and
Cw. These estimates are obtained from an optimal fit of the various vectors in Equation 5.
𝑚
S~ [𝐶𝑟 × 𝑟] + [𝐶𝑤 × 𝑤] + [∑𝑁
𝑚=0 𝐶𝑚 𝑋 ]

(65)

(5)

The background corrected, concentration dependent analyte spectra, T, can be represented
as:
S−[𝐶𝑤 ×𝑤]−[∑𝑁
𝑚=0 𝐶𝑚𝑋𝑚 ]

T=

𝐶𝑤

(65)

(6)

Note, that division by Cw has the effect of scaling the analyte spectra, assuming a constant
water contribution to all sample spectra.
In the case of total protein, γ-globulins and albumin, EMSC is also applied to remove the βcarotene. Since the Lab-Tek plate is made up of thin glass bottom, no glass correction was
required. Raman spectra of the pure serum, γ-globulin (~100 mg/mL), albumin (~100
mg/mL), glucose (45mg/mL) and urea (~100 mg/mL) prepared with minimal amount of
water are used as the reference for EMSC.

6.3.4 Partial Least Squares Regression

Partial Least Squares Regression (PLSR) is a multivariate statistical method which aims to
establish a model that relates the variations of the spectral data to a series of relevant targets.
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The PLSR model attempts to elucidate factors which account for the systematic majority of
variation in predictors ‘X’ (spectral data) versus associated responses ‘Y’ (target values of
protein concentration) (68). The spectral data (X matrix) is thus related to the targets (Y
matrix) according to the linear equation Y = XB +E, where B is a matrix of regression
coefficients and E is a matrix of residuals. The PLSR algorithm allows for the construction
of a regression model which can be used to predict the outcome in varying concentration of
analytes, and the performance of the PLSR model in predicting varying analytes
concentration was evaluated in this study. In this case, the examples used are concentration
and Raman signal, and therefore the algorithm can be used to predict the detection of Raman
signal for a particular analytes concentration. The performance of the regression model in
predicting varying concentrations of the analyte over a particular range was evaluated and
this method can be employed to improve the limit of detection of Raman bio-sensing (68).
Constructed based on the spectra of samples of known analyte content, either solutions of
varying concentrations in distilled water or those of the patient serum, the model is then
validated using a rigorous cross validation procedure which evaluates its performance in
accurately predicting analyte concentrations. For consistency with previous studies (64), a
20 fold cross validation approach has been employed to validate the robustness of the method.
This approach involves randomly dividing the set of observations into approximately equal
size, ~50% of the spectral data were randomly selected as test set, while the remaining ~50%
is used as the training set (69). In the current case, (5 x 25 spectra) were divided into two
groups of 65 (test) and 60 (training) spectra. The cross-validation process is then repeated 20
times (the folds), whereby all observations are used for both training and testing, and each
observation is used for testing exactly once. The results from the folds can then be averaged
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to produce a single estimation. The Root Mean Square Error of Cross Validation (RMSECV)
is calculated from the 20 iterations to measure the performance of the model for the unknown
cases within the calibration set. The correlation between the concentration and spectral
intensity is given by the R2 value. The standard deviation was calculated to find the variation
between each spectrum calculated from the same sample. The number of latent variables used
for building the PLSR model is optimised by finding the value that is equivalent to the
minimum of the RMSECV.

6.4. Results and discussion

Figure 6.2A shows the mean spectra of the whole serum samples derived from patients. For
comparison, Figure 6.3 shows the spectra of globulin and albumin. Unexpectedly, additional
strong Raman bands at 1167 cm-1 and 1535 cm-1 (12,70) are observed, which dominate the
protein features of serum, which can be ascribed to the presence of β-carotene (Figure 6.S3).
β-carotene is a red-orange-coloured carotenoid widely distributed in fruits and vegetables
and plays a major role in the maintenance of normal healthy skin, vision, immune system and
mucous membranes (71,72). Regular intake of β-carotene rich foods results in higher levels
in blood serum/plasma (73,74) and is also associated with decreased risk of cardiovascular
disease, heart disease, cancer, and other causes of mortality (75,76). As shown by a
community-based study of French adults, serum β-carotene and vitamin C concentrations are
useful biomarkers of vegetable and fruit consumption in the French diet (77). β-carotene
features became less apparent in the spectra recorded from the concentrate of 50kDa
filtration, as shown in Figure 6.2B and no β-carotene features were found in the spectra
collected from the filtrate of 10kDa filtration, as seen in Figure 6.2C. The molecular size of
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β-carotene is less than 10 kDa (~537Da) (78), and therefore the presence of β-carotene in the
concentrate of 50 kDa rather than filtrate of 10kDa must be attributed to the binding of βcarotene to albumin (79). Some studies have shown high binding affinity of β-carotene to
albumin due to its identical left-right symmetric structure that has great potential for
association of albumin molecules and protects β-carotene against oxidative degradation
(79,80). In terms of quantitative analysis of the high molecular weight constituents, the strong
contribution of the β-carotene is undesirable. Therefore, EMSC was applied to subtract the
water signal, β-carotene signal as well as background noise from the initial serum data, and
from that of the 50 kDa filtered data.

A

B
C

Figure 6.2. Raman spectra of patient serum collected using Raman spectroscopy. (A) whole
serum, (B) concentrate from 50 kDa filtration and (C) filtrate from 10 kDa filtration. Spectra
have been off set for clarity.

205

*
*
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Figure 6.3. Spectra of γ-globulins (red- ~38% of serum) and albumin (blue - ~50% of serum)
showing similar spectral features. Identifying signature peaks of γ-globulins at 1240 cm-1 and
1553 cm-1 and of albumin at 940cm-1 are highlighted with asterisks.

6.4.1 Quantification of total protein concentration and γ-globulins in whole serum

A total serum protein test analysis measures the total amount of protein in the serum, as well
as the amount of two major proteins in the serum; albumin and globulin. The normal
concentration of total protein content in human serum is between 6000-8300mg/dL and a
reduced serum protein level is an indication of kidney disorders, HIV and aging in the elderly
(20,21). A pure serum spectrum was used as the reference for the EMSC correction (Figure
6.S4), along with spectra of pure β-carotene and water, measured under identical conditions.
Figure 7.4A presents the EMSC corrected Raman spectra of all the 25 patients from unfiltered
serum samples. As expected, the characteristic bands of both globulin and albumin,
highlighted in Figure 6.3, can be observed, as indicated by the asterisks (81,82). Notably, the
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strong bands of β-carotene are no longer as prominent. The background-subtracted, smoothed
spectra of the whole patient serum from the range 400 cm-1 to 1800 cm-1 were provided to
the PLSR algorithm, regressed against total serum protein concentrations of Table 6.1, and a
prediction model for total protein concentrations was built. The RMSECV plot of the PLSR
model shows a steady decrease within the first 10 components and stabilises after 12th
component, indicating the data is well modelled (Figure 6.4B). Note that the data range is
not well balanced, and particularly that there is only one patient with total serum content
below 5500 mg/dL. Nevertheless, the PLSR co-efficient of Figure 6.4C shows spectral
features at 940 cm-1, 1553 cm1 and 1176 cm-1, indicating the prediction model (Figure 6.4D)
was built on the spectral features of albumin (50% of total protein) and γ-globulin (38% of
total protein). The RMSECV, R2 and standard deviation values were calculated as 114.7
mg/dL, 0.82 and 5.69 mg/dL. For comparison, the prediction accuracy achieved by Berger et
al., for measuring total protein using near infrared Raman spectroscopy with 830nm was
reported to be 190mg/dL(57), whereas Shaw et al., (55) and Rohleder et al., (83) reported
prediction accuracies of 310mg/dL, 176mg/dL using Mid-IR spectroscopy of dried films
indicating that the present method is more feasible for total protein analysis from serum.
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Figure 6.4. (A) EMSC corrected Raman spectra of total protein content from patient serum
samples (4200 mg/Dl, 5800 mg/dL, 6400 mg/dL and 7900 mg/dL). The spectra have been
offset for clarity (B): Evolution of RMSECV of the data set (C): plot of PLSR coefficient for
regression against total serum protein, (D): Linear predictive model for total serum protein
built from the PLSR analysis. The RMSECV, R2 and standard deviation values were
calculated as 114.7 mg/dL, 0.82 and 5.69 mg/dL
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Figure 6.5. (A) EMSC corrected Raman spectra of γ-globulin of patient serum samples (329
mg/dL, 690 mg/dL, 836 mg/dL and 1404 mg/dL), the spectra has been offset for clarity. (B):
Evolution of RMSECV of the data set (C): plot of PLSR coefficient for regression against γglobulin concentration shows the signature peaks of γ-globulin (highlighted by asterisk), (D):
Linear predictive model for γ-globulin concentration built from the PLSR analysis. The
RMSECV, R2 and standard deviation values were calculated as 126 mg/dL, 0.88 and 4.62
mg/dL

In the case of determination of γ-globulin content in patient serum, the backgroundsubtracted and smoothed fingerprint region of the unfiltered serum spectra was also analysed,
but regressed this time against the γ-globulin concentration. As expected, the RMSECV
prediction plot (Figure 6.5B) shows a steady decrease until the 12th component, indicating
that 12 components should be utilised in this model. The lowest value of RMSECV was
recorded as 126 mg/dL and the linearity of the model was calculated as R2=0.88. However,
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it should be noted that the spectral profile of the regression co-efficient of Figure 6.5C is not
strikingly similar to the spectrum of γ-globulin in Figure 6.3, and the characteristic features
of at 1240 cm-1 and 1553 cm-1 are not prominent. γ-globulin is composed of IgG, IgM and
IgA, the relative contributions of which are seen to vary considerably from patient to patient.
Immunoglobulin G (IgG), itself, for example, is well known for its heterogeneity, which in
itself makes it an excellent biomarker of a person's general state of health (84,85). Regression
against each of the individual components did not produce a good correlation. The spectrum
of each of them, and the composite g-globulin can also be influenced by protein/protein and
any other interactions in the complex serum mixture, which can give rise to conformational
changes in the immunoglobulin structure. Thus, it may not be surprising that the individual
patient globulin spectral contributions are variable from patient to patient, and that the
regression co-efficient of Figure 6.5C, effectively an average of them all, does not exactly
match the spectral of the commercial sample in Figure 6.3. Nevertheless, the R2 of this model
is comparable to that of the method reported by Guaita et al. (86) to detect total globulin
using ATR-FTIR from blood serum, and it should be noted that no correlation between
globulin content and that of the other major protein, albumin was observed (Figure 6.S1).
The background-subtracted and smoothed fingerprint region of the unfiltered serum spectra
was also analysed over a reduced spectral region (1150 cm-1 to 1600 cm-1) to avoid spectral
interference from albumin, but regressed this time against the γ-globulin concentration.
Analysis over this reduced range failed to produce an improved performance, however
(Figure 6.S5). Excess globulin levels (>1600mg/dL) are usually an indicator of liver diseases,
chronic inflammatory diseases, haematological disorders, infections and malignancies (26),
whereas humoral immunodeficiencies cause low globulin levels (<700mg/dL) (27).
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As shown in Figure 6.3, the Raman spectra of albumin and γ-globulin are extremely similar
and, since the concentrations of albumin and γ-globulin are not correlated (Figure 6.S1 in
supplemental), PLSR cannot predict both from the same dataset; invalid correlation for the
entire population from which the training set is drawn would lead to spurious prediction
models (57). Hence, patient serum was spun using 100kDa centrifugal filter tubes to separate
and remove the γ-globulins in the concentrate and the remainder filtrate was transferred to
50kDa filter tubes for further concentration of albumin. The spectra recorded from the
concentrate of 50 kDa filtrate was used for building a PLSR prediction model for albumin
from patient samples.

6.4.2 Quantification of albumin from the HMWF concentrate

For albumin determination, the spectra recorded from albumin paste (Figure 6.3 blue) and βcarotene (Figure 6.S3) were used as the reference spectrum for the EMSC algorithm to
perform background correction and the background-corrected and smoothed spectra were fed
into the PLSR algorithm to build the prediction model by regressing against albumin
concentration (Table 6.1). The signature albumin bands that can be seen are the amide I band
around ~1659 cm-1, a relatively sharp band at 1003 cm-1 associated with phenylalanine,
intense bands at ~1336 cm-1 and ~1450 cm-1 due to C-H deformation, bands at 899 cm-1 and
1102 cm-1, which can be related to ν(CC) and ν(CN) and a vibration band at ~940 cm-1,
related to C-C stretching mode backbone of α-helix structure (87). The absence of the Raman
peaks at 1240 cm-1 and 1553 cm-1 confirms that there is no interference from γ-globulin.
PLSR analysis of aqueous solutions of albumin over the range (500-5000 mg/dL) has
previously been reported, and the results of the prediction model are summarised by Figure
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6.S6 in the supplemental material. Leave-One-Out cross validation was used to test the
robustness of this model and the RMSECV value calculated was 158 mg/dL (11).
EMSC successfully subtracted the background without altering the albumin features (Figure
6.6A), such as bands at ~1336 cm-1 due to C-H deformation and a vibration band at ~940 cm1

, related to C-C stretching mode backbone of α-helix structure. The strength of the albumin

features is, however, seen to vary considerably from patient to patient, as expected, due to
the variation in albumin content from 2710 mg/dL to 4780 mg/dL (Table 6.1). The normal
level of albumin in human blood is 3000mg/dL (17), any decrease in this level could be an
indicator of liver diseases (30-32). Applying PLSR to the dataset, a strong decrease in the
RMSECV is observed within the first 8 latent variables, as shown in Figure 6.6B, which is
followed by a stabilisation of the values after 12 latent variables, indicating that 12 latent
variables should be used to build the prediction model. The PLSR coefficient plot displayed
in Figure 6.6C shows visible albumin features, indicating that the prediction model was built
on their variation. Finally, a linear predictive model is built from the PLSR analysis (Figure
6.6D) to compare the observations to the known concentrations of albumin in the samples
with the estimated concentrations from the spectral data sets, yielding an R2 value of 0.9072
and RMSECV value of 90.097 mg/dL. The prediction accuracy of the present method for
measuring albumin from serum is higher than the prior studies on Raman (120mg/dL) (57)
and Mid IR spectroscopy (220mg/dL)(55). The overall standard deviation is calculated to be
1.1692 mg/dL. These values are comparable to the previously reported values obtained from
varying concentration of pure albumin in water (11).
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Figure 6.6. (A): EMSC corrected Raman spectra of concentrate obtained after filtration with
50 kDa filters of patient sample (2710 mg/dL, 3580 mg/dL, 4140 mg/dL and 4780 mg/dL),
the spectra have been offset for clarity (B): Evolution of RMSECV of the data set (C): plot
of PLSR coefficient from regressing against albumin concentrations, (D): Linear predictive
model for albumin built from the PLSR analysis. The RMSECV, R2 and standard deviation
values were calculated as 90.097 mg/dL, 0.9072 and 1.1692 mg/dL.

6.4.3 Quantification of glucose and urea from the LMWF filtrate

Glucose and urea are both present in the filtrate obtained after depletion of the HMWF of
human serum using filtration. Notably, there is no obvious correlation between the levels of
the two analytes per patient, as shown in Figure 6.S2 in supplemental.
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Figure 6.7 shows the reference spectra of urea and glucose used for EMSC correction of the
raw spectral data. The signature peak of urea is a relatively sharp band seen at 1006 cm-1, as
seen in Figure 6.7A, which can be attributed to the symmetric stretching of C-N (88). Figure
6.7B shows Raman peaks of glucose at 1060 cm-1, due to ν(C1-OH) stretching, and a sharp
peak at 1125 cm-1, which can be assigned to the δ(C-O-C) angle-bending mode (89).
In the case of glucose, Figure 6.S7, 6.S8 and 6.S9 in the supplemental display the previously
reported prediction models built from varying concentrations of glucose in distilled water,
spiked in commercial serum, and patient serum, respectively (64). The RMSECV value
calculated for the model built from varying concentrations in distilled water (100-1000
mg/dL) was 10.93 mg/dL and R2 was calculated as 0.9705. Notably, in the patient samples,
the overlap of the strong spectral features of urea and glucose can interfere with the PLSR
prediction of glucose using the full spectral range, as shown in Figure 6.S9. In order to
facilitate efficient prediction of glucose from the filtrate, the spectral region from 1030 cm -1
to 1400 cm-1 was chosen to build a PLSR prediction model of glucose from patient samples
(Figure 6.S8), (52.25-440 mg/dL) resulting in an RMSECV value of 1.84 mg/dL and R2 value
of 0.84, comparable with the values obtained for the pure aqueous solutions (64). The results
suggest that this method could detect the concentration of glucose in the ranges of hyper
(>130 mg/dL) or hypoglycaemia (<70 mg/dL) (51).
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A

B

Figure 6.7. (A) Reference spectrum of urea (1000 mg/dL) and (B) Reference spectrum of
glucose (45000 mg/dL). The reduced spectral regions selected for PLSR analysis are
indicated by dotted lines in each spectrum.

Prior to the analysis of urea in patient samples, aqueous solutions of varying concentrations
of urea were made up and Raman analysis with the optimised protocol was performed. The
recorded spectra were pre-processed and PLSR analysis was performed. EMSC efficiently
subtracts the water spectrum, which has an OH bending vibration at ~1640 cm-1 (64) and
obscures the protein signals at low concentrations. Figure 6.S11 shows the spectra corrected
with the EMSC algorithm, showing strong features of urea increasing as the concentration is
increased from 1 mg/dL to 1000 mg/dL. The PLSR algorithm, using 6 latent variables, was
applied to the smoothed and background-subtracted spectra and a linear predictive model
was built, yielding a lowest value of RMSECV of 70.4 mg/dL and an R2 value of 0.9048. The
overall standard deviation was calculated to be 1.0975 mg/dL.
Having verified the protocol for analysis of urea in water, it was applied to the filtrate
obtained after filtration from patient serum. Higher (<20 mg/dL) or lower levels (>5 mg/dL)
of urea in the patient serum could indicate various pathologies such as kidney or liver
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malfunction (46–49). Figure 6.8A shows the EMSC-corrected data of the fingerprint region
and Figure 6.8B indicates 12 latent variables should be used to build the model. The PLSR
coefficient shows the features of urea, as displayed in 6.8C and Figure 6.8D shows the linear
model built from this dataset. The linearity is indicated by R2 = 0.9232 and the RMSECV
was calculated as 1.736 mg/dL. The overall standard deviation was calculated to be 2.89
mg/dL.

Figure 6.8. (A): EMSC corrected Raman spectra of filtrate obtained after filtration with 10
kDa filters of patient samples (2.5 mg/dL, 10.64 mg/dL, 19.04 mg/dL and 78.99 mg/dL). The
spectra have been offset for clarity (B): Evolution of RMSECV of the data set regressed
against urea concentrations (C): plot of PLSR coefficient with strong features of urea, (D):
Linear predictive model built from the PLSR analysis. The RMSECV, R 2, and standard
deviation values were calculated as 1.736 mg/dL, 0.9232 and 2.89 mg/dL.
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Notably, the typical serum concentrations of urea are considerably higher than those of
glucose, as shown in Table 6.1, and therefore the characteristic features of urea dominate
over those of glucose. Nevertheless, having observed the improvement of the sensitivity of
the model for the case of glucose, a reduced spectral region, from 800 cm-1 to 1030 cm-1, was
also tested for the urea regression.

Figure 6.9. (A): EMSC corrected Raman spectra of filtrate obtained after filtration with
10kDa filters of patient samples (2.5 mg/dL, 10.64 mg/dL, 19.04 mg/dL and 78.99 mg/dL).
Spectra have been offset for clarity, (B): Evolution of RMSECV of the data set regressed
against urea concentration (C): plot of PLSR coefficient with strong features of urea, (D):
Linear predictive model for urea concentration built from the PLSR analysis. The RMSECV,
R2 and standard deviation values were calculated as 2.52 mg/dL, 0.9722 and 1.1418 mg/dL.
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Figure 6.9A shows the EMSC corrected spectra of urea over the reduced spectral range, and
Figure 6.9C displays the PLSR coefficient, which is dominated by the 1006 cm-1 peak of
urea. 12 latent variables were used to build the model after calculating the lowest value of
RMSECV, as seen in Figure 6.9B. Figure 6.9D confirms that the linear predictive model is
based on systematic variations of the features of urea. The value of RMSECV, R2 and overall
standard deviation calculated are 1.1418 mg/dL, 0.9722 and 2.52 mg/dL. Better R2 and
RMSECV values were obtained when the PLSR analysis was performed over the reduced
spectral range of urea as compared to the full fingerprint region, suggesting that the
sensitivity and the accuracy of the model could be considerably improved. The proposed
method also has a better prediction accuracy than the previously reported methods on Raman
by Berger et al. (3.8mg/dL) (57) and mid IR spectroscopy by Shaw et al. (3.08mg/dL) (90),
Petrich et al. (16mg/dL) (58) and Rohleder et al. (2.1mg/dL) (83).
Table 6.2. Summary of the results obtained from the patient samples
Analyte

Analysis range

Total protein
(whole serum)
γ-globulin
(whole serum)
Albumin
(HMWF)
Glucose
(LMWF)
Urea (LMWF)

400-1800 cm-1

Urea (LMWF)

800-1030 cm-1

1150-1600 cm-1
400-1800 cm-1
1030-1400 cm-1
400-1800 cm-1

Concentration
range
4200-7900
mg/dL
329-1404
mg/dL
2600-4780
mg/dL
52.5-434.2
mg/dL
2.52-78.99
mg/dL
2.52-78.99
mg/dL
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R2

RMSECV

0.82

115 mg/dL

Standard
deviation
5.7 mg/dL

0.88

126 mg/dL

4.6 mg/dL

0.90

90 mg/dL

1.2 mg/dL

0.84

1.8 mg/dL

3.5 mg/dL

0.92

1.7 mg/dL

2.9 mg/dL

0.97

1.1 mg/dL

2.5 mg/dL

6.5 Discussion

The study demonstrates that Raman spectroscopy, coupled with ultra-filtration and PLSR
analysis, can be employed to detect variations in multiple analytes from the same serum
samples with a high degree of higher accuracy. The routine serum analysis techniques used
for the measurement of total protein (biuret method) and γ-globulin (RID and Turbidometric
Immuno assay (TIA)) are expensive, require technically competent laboratory personnel and
cannot measure multiple analytes from the same serum samples (91). The strategy
demonstrated in this study enables the simultaneous estimation of total protein level and
detection of imbalance in γ-globulin concentration accurately from whole serum, without the
use of any reagents and without destroying the sample being studied. The proposed method
has many advantageous over the biuret method, as the required sample volume can be as low
as 10μL, it is rapid and non-destructive to the medium being studied, whereas the biuret
method is considered impractical due to the requirement of large sample volume and
laborious sample processing steps (1,92). Current methods used for determination of γglobulins are time and temperature dependent and are time consuming, which is a major
impediment for early diagnosis (93–96). Moreover, the linearity reported for a comparative
study of RID and TIA is 0.59 (1), lower than the R2 calculated in the present study. The gold
standard methods used for albumin measurements, such as BCG and Bromocresol purple
assays have been reported to be susceptible to overestimation of albumin content, especially
at lower albumin concentrations (97,98). In this study, it has been demonstrated that PLSR
can be used to extract concentration predictions in order to build a prediction model from
blood serum. With the use of filtration, the albumin was isolated from patient serum and the
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prediction model had a prediction accuracy significantly superior to that of the BCG method
(2.2 g/dL) used to determine albumin concentrations from cirrhotic patients (99).
Serum fractionation considerably enhanced the capability to detect and quantify LMWF
analytes (9) and it has been shown that reducing the spectral region helped to avoid the
spectral interference from other analytes and yielded improved accuracy (64). It has
previously been reported that selecting the spectral region from 1030 cm-1 to 1400 cm-1
improved the sensitivity and specificity for the prediction model of glucose from patient
samples over the concentration range 52.5-434.2 mg/dL, and the technique was demonstrated
to be at least as accurate as ATR-FTIR of similar patient samples (9), measured in the dried
state and closer to the accuracy of colorimetric methods, 1.4 mg/dL urea (100) and 2 mg/dL
glucose (101). As anticipated, similarly higher prediction accuracy (RMSECV=1.14 mg/dL)
was attained when PLSR analysis was performed on a reduced range for urea from patient
samples over the concentration range 2.52-78.99 mg/dL, compared to the full range
(RMSECV=1.73 mg/dL).
The strategy illustrated in this and previous studies enables simultaneous detection of various
analytes from human serum using Raman spectroscopy with minimal sample preparation, no
labelling and no additional sample drying steps. Depletion of the HMWF is a non-optional
step in the investigation of protein imbalances or disease related biomarkers in the LMWF
of serum. Mass spectroscopy, the most commonly used technique for LMWF analysis also
makes use of the HMWF depletion in order to potentially target small circulating biomarkers
(102). While most of these methods found in the literature are based on chemical
extraction/precipitation, the impacts of these solvents are unknown and cross contamination
from these solvents is highly probable (102–104). Therefore, ultra-filtration coupled with
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chemometrics is a viable option to investigate the less studied LMWF and to interpret the
results by overcoming the intricacies of the multidimensional dataset.
Several methods have been previously described in literature for the quantification of
multiple analytes in serum samples. Perez-Guaita et al., established models for the
determination, in serum samples, of albumin, -globulin, total globulin, and
albumin/globulin coefficients, using ATR-FTIR. Values of RMSECV determined for
albumin (126 mg/dL) and -globulin (138 mg/dL) are comparable, or larger than the
RMSECV determined in the current study (albumin 90 mg/dL, -globulin 126 mg/dL).
Although the spectral co-efficient of prediction of Figure 7.5C is somewhat unsatisfactory,
in that the specific distinctive features of -globulin are not prominent, the -globulin levels
are not correlated with albumin levels, and the predictive model shows a relatively high
degree of linearity and low standard deviation, giving some assurance that it is indeed
predicting -globulin levels. In the study reported by Roy et al., ATR-FTIR spectroscopy
enabled the simultaneous quantification of glucose and urea analytes along with malaria
parasitemia quantification from a spectrum obtained from a dried drop of blood on a glass
slide. The specificity for the PLS-DA was found to be 98% for parasitemia levels but low
sensitivity of 70% was achieved because of the negative samples in the model. The RMSECV
for parasite concentration (0-5%), glucose (0-400 mg/dL) and urea (0-250 mg/dL) spiked
samples were 0.58%, 16% and 17%, respectively (56), whereas the present study showed a
considerably lower RMSECV value of 1.84 mg/dL (52-440 mg/dL) and 1.69 mg/dL (2-79
mg/dL) for glucose and urea from patient samples. Another study conducted by Shaw et al.,
based upon the infrared spectra for 8 serum analytes, reported standard errors of 2.8 g/L (total
protein), 22 mg/dL (albumin), 0.23 mmol/L (triglycerides), 0.28 mmol/L (cholesterol), 7.4
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mg/dL (glucose) and 6.6 mg/dL for urea, with correlation coefficients of 0.95 (55). In an
investigation conducted on 247 serum donors by Rohleder et al. using Raman spectroscopy
of λex-785nm, the standard errors for 7 analytes were reported as 176mg/dL (total protein),
20.7mg/dL (triglycerides) , 11.0mg/dL (high density lipoprotein), 15.7mg/dL (low density
lipoprotein), 0.81mg/dL (uric acid), 2.1mg/dL (urea) and 6.8mg/dL (glucose) and the
efficiency of ultra-filtration technique in improving the prediction accuracy of glucose and
urea was demonstrated (83). Although the samples were dried in all these, superior prediction
accuracy was afforded by Raman analysis of liquid samples. Berger et al. demonstrated the
use of Raman spectroscopy to measure concentrations of serum and whole blood components
to simultaneously predict the content of 6 analytes in serum from a 66 patient data set. The
quoted prediction errors for albumin, urea and glucose were 120 mg/dL, 3.8 mg/dL and 26
mg/dL, respectively (57), and therefore the combination of improved measurement protocols,
serum fractionation, and sectioning the spectral region for regression results in considerable
improvement in the prediction accuracy.
It should be noted that direct comparisons of the two techniques of ATR-FTIR and Raman,
and even different studies using the same technique, can only be tenuous at best, given the
number of potential variables in samples, measurement protocols and data analysis
techniques. Notably, a systematic study of the PLSR model construction, validation and
testing protocols has not as yet been carried out. The previous study of Parachalil et al., (11)
tried to minimise these variabilities by utilising the same sample preparation/processing as
well as data analysis techniques in the direct comparison of ATR-FTIR of dried serum with
Raman of the liquid state, for the quantification of glucose in serum. The present study has
further demonstrated the capacity for prediction of serum content for total protein, γ-globulin,
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albumin, urea and glucose from the same patient samples, with a high degree of accuracy,
consolidating the prospect of establishing Raman spectroscopy as a biomedical tool to rival
and/or augment conventional approaches such as Mass spectroscopy or chromatography,
currently used to deliver crucial information relevant for diagnosis. Further improvements in
the sensitivities and variabilities of the techniques ultimately rely on the reproducibility of
the measurement, and the signal to noise ratio. The former could potentially be improved by
an automated focussing and sampling methodology, while the latter is largely an instrumental
consideration. As longer accumulation times to reduce the noise are not recommended,
because of sample evaporation and also speed of measurement throughput, optimisation of
instrumentation for higher signal throughput could be explored, for example by sacrificing
spectral resolution.

6.6 Conclusion

In summary, the potential of Raman spectroscopy combined with filtration and chemometrics
to detect variations in total serum protein, γ-globulin, HMWF and LWMF analytes from the
same patient serum is successfully demonstrated. Firstly, the prediction model was built in
the spiked samples of the analytes in water and was then translated to the patient serum.
Although Raman spectroscopy can build quantitative models with higher accuracy in spiked
samples, the analysis of patient samples can be affected by numerous factors such as multiparametrical variability, normally observed in clinical application. Nevertheless, the
proposed approach successfully built the prediction model from the whole serum (total
protein, γ-globulin), concentrate (albumin) by removing β-carotene and filtrate (urea and
glucose) of patient samples at higher accuracy and sensitivity. Given its low cost, easy
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implementation, rapid results and higher sensitivity and specificity, the technique may
become an alternative for the existing laboratory screening methods. Furthermore, the
methodology presented in this work can be applied to a wider range of bodily fluids and can
be implemented as a next generation point of care biochemical diagnostic tool in a clinical
setting.
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6.8 Electronic Supplementary information:

1. No correlation was found between the concentrations of globulin and albumin in
patient samples

Figure 6.S1. Plot of the concentrations of albumin and immunoglobulin for each patient

2. No correlation was found between the concentrations of urea and glucose in patient
samples
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Figure 6.S2. Plot of the concentrations of urea and glucose for each patient
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3. Reference spectrum of β-carotene

Figure 6.S3. Raman spectrum of β-carotene used for EMSC correction of human serum
from patient samples

4. Reference spectrum of human serum

Figure 6.S4. Raman spectrum of human serum used for EMSC correction of total protein
and globulin from patient samples
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5. PLSR was performed on shorter spectral region of γ globulin from patient serum samples

B

A

C

D

Figure 5.S5. (A) EMSC corrected Raman spectra of γ globulin of patient serum samples
from 800cm-1 to 980cm-1 (329 mg/dL, 690 mg/dL, 836 mg/dL and 1404 mg/dL), the spectra
has been offset for clarity. (B): Evolution of RMSECV of the data set (C): plot of PLSR
coefficient for regression against γ globulin concentration shows the peaks of γ globulin, (D):
Linear predictive model for γ globulin concentration built from the PLSR analysis.
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6. PLSR was performed on varying cocnentration of albumin in water (5-50mg/dL)
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Figure 6.S6. (A): Rubberband corrected Raman spectra of varying concentrations of
Albumin from 5mg/mL to 50mg/mL (500mg/dL to 5000mg/dL) in distilled water, (B):
Evolution of RMSECV on the validation model, (C): plot of PLSR coefficient with Albumin
features, (D): Linear predictive model built from the PLSR analysis. The RMSECV is
calculated as 1.58mg/mL (158mg/dL)
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7. PLSR result of varying concentrations of glucose in distilled water (1001000mg/dL) (2)
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Figure 6.S7. (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of varying concentrations of glucose (5 x100mg/dL, 5 x
450mg/dL and 5 x 1000mg/dL, spectra offset for clarity), in distilled water and signature
peaks of glucose are highlighted with asterisks, (B): Evolution of the RMSECV on the
validation model, (C): plot of PLSR coefficient with glucose features, (D): Predictive model
built from the PLSR analysis. The value displayed in the PLSR model is an average of the
concentration predicted with the corresponding standard deviation calculated from the 20
iterations of the cross validation. The RMSECV and R2 values were calculated as
10.93mg/dL and 0.9705 respectively.
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8. PLSR analysis performed on the filtrate collected after centrifugal filtration of
glucose spiked in serum samples using 10kDa filters (2)
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Figure 6.S8. (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of glucose spiked in serum (spiked concentrations 5 x 0mg/dL,
5 x 120mg/dL and 5 x 220mg/dL, offset for clarity) and the signature peaks of glucose are
highlighted by asterisks, (B): Evolution of RMSECV of the data set (C): plot of PLSR
coefficient with glucose features, (D): Predictive model built from the PLSR analysis. The
value displayed in the PLSR model is an average of the concentration predicted with the
corresponding standard deviation calculated from the 20 iterations of the cross validation.
The RMSECV and R2 values were calculated as 1.66mg/dL and 0.9914
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9. PLSR analysis performed on the filtrate collected after centrifugal filtration of
patient samples using 10kDa filters (2)
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Figure 6.S9. (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of patient samples (5 x 52.25mg/dL, 5 x 75.67mg/dL, 5 x
93.69mg/dL, 5 x 210.81mg/dL and 5 x 434.35mg, offset for clarity) and the signature peaks
are marked by asterisks, (B): Evolution of RMSECV of the data set, (C): plot of PLSR
coefficient with glucose features, (D): Predictive model built from the PLSR analysis. The
value displayed in the PLSR model is an average of the concentration predicted with the
corresponding standard deviation calculated from the 20 iterations of the cross validation The
RMSECV and R2 values were calculated as 1.84mg/dL and 0.84 respectively.

242

10. PLSR performed on varying concentrations of urea in water
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Figure 6.S10 (A): EMSC corrected Raman spectra of filtrate obtained after centrifugal
filtration with 10kDa filters of urea spiked in water (1mg/dL to 1000mg/dL), (B): Evolution
of RMSECV of the data set (C): plot of PLSR coefficient with urea features, (D): Linear
predictive model built from the PLSR analysis. The RMSECV, R2 and overall standard
deviation values values were calculated as 70.4044mg/dL, 0.9048 and 1.0975mg/dL.
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7.1 Abstract

A methodology is proposed, based on Raman spectroscopy coupled with multivariate
analysis, to determine the Limit of Detection (LOD) and Limit of Quantification (LOQ) for
therapeutic drug monitoring in human serum, using the examples of Busulfan, a cell cycle
non-specific alkylating antineoplastic agent, and, Methotrexate, a chemotherapeutic agent
and immune system suppressant. In this study, ultra-filtration is employed to fractionate
spiked human pooled serum to efficiently recover the drug in the filtrate prior to performing
Raman analysis. The drug concentration ranges were chosen to encompass the recommended
therapeutic ranges and toxic levels in patients. Raman spectra were collected from the
filtrates in the liquid form, using an inverted backscattering microscopic geometry, using
532nm as source. Finally, prediction models were built by using Partial Least Squares
Regression (PLSR) and LOD and LOQ were calculated directly from the linear prediction
models. The LOD calculated for Busulfan is 0.0002 ± 0.0001 mg/mL, 30-40 times lower than
the level of toxicity, enabling the application of this method in target dose adjustment of
Busulfan for patients undergoing, for example, bone marrow transplantation. The LOD and
LOQ calculated for Methotrexate are 7.8 ± 5 µM and 26 ±5 µM, respectively, potentially
enabling high dose monitoring. The promising results obtained from this study suggest the
potential of Raman spectroscopy for therapeutic drug monitoring of drugs in bodily fluids.

7.2 Introduction

Therapeutic drug monitoring (TDM) refers to the clinical practice of management of a
patient's drug dosage within a targeted therapeutic window, based on measurement of
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concentration of the drug in the bloodstream at timed intervals. For drugs with a narrow
therapeutic range, such monitoring is essential to provide individualised patient treatment,
while maintaining the efficacy of drugs and minimising drug toxicity and related adverse
effects (1,2).
TDM has also been increasingly advocated to improve the standard of chemotherapy, in
which side effects can be substantial and life threatening (3–6). The currently available
technique of chemotherapeutic-dosage calculation based on dose intensity and body surface
area has been reported to be inaccurate for patients undergoing sustained chemotherapeutic
treatment (7,8). In the era of rising cost of healthcare, it is necessary to develop a rapid,
sensitive, and cost-effective, point-of-care technique for TDM, which can quantitatively
measure the serum concentration of drugs, such that the dosing strategy can be tailored to the
metabolism of an individual patient for a personalised therapeutic regime.
Busulfan (Bu) is a bi-functional alkylating agent (see chemical structure in inset of Figure
2A) used in the chemotherapy-based conditioning regimen for hematopoietic stem cell
transplantation (HSCT) (9–17). Bu has a very narrow therapeutic index, and higher systemic
exposure to Bu is related to hepatic sinusoidal obstruction syndrome, neurotoxicity or
insterstitial pneumonia, while low levels have been shown to be associated with increased
incidence of graft rejection (18–21). Measurement of individual serum Bu levels during oral
or intravenous dosing is likely to provide the necessary elements to monitor the drug
disposition, ensuring efficacy, reduced incidences of toxicity and graft rejection (18–22).
Several analytical methods, including chromatographic techniques coupled with a number of
detection methods, have been described for analysing Bu in biological fluids; Gas
chromatography (GC) with electron capture detection, high performance liquid
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chromatography (HPLC) with UV detection, GC-Mass spectroscopy (MS) with selected ion
monitoring, and Enzyme linked immunosorbent assays (ELISA) have been reported to have
high sensitivity for monitoring Bu in biological fluids (10,11,23–26). However, the
translation of these techniques to a routine analytical tool in a clinical setting for TDM is
impractical, owing to their complexity and cost.
Methotrexate (MTX) is a folate antagonist (see chemical structure in the inset of Figure 2B)
widely used as an anti-cancer agent to treat various malignancies, such as leukemia, breast
cancer, lymphomas and autoimmune diseases (27). MTX is administered in both low and
high dosage (LDMTX and HDMTX), and monitoring serum MTX concentrations is essential
to avoid high dosage related side effects (28). Serum MTX concentrations can vary from 10
nM to 1 mM for different patients, due to pharmacokinetic variability (28). The serum MTX
concentration should reach between 10µM (0.001mM) and 100µM (0.01mM) after 12-36
hours of HDMTX infusion and should reduce to 0.2µM after 72 hours. From the clinical
point of view, it is essential to be able to detect the serum concentrations of MTX between
0.1µM and 10µM, as high toxicity related adverse effects are associated with concentrations
>10µM (28,29). Various sophisticated analytical tools such as Enzyme multiplied
immunoassay technique (30), radioimmunoassay (31), enzyme exhibition assays (32),
capillary zone electrophoresis (33) and liquid chromatography coupled with tandem mass
chromatography (HPLC-MS/MS)(6,34–39) have been reported for TDM of MTX from
biological fluids. Although immunoassays (40) and separation techniques (38) are routinely
employed due to, they suffer from major limitations such as interferences from other
compounds and lack of availability for all the drugs currently monitored (4). HPLC-MS/MS

247

is considered the gold standard method for MTX (35-39) analysis due to its high sensitivity
and robustness; however, it is time consuming, expensive and requires skilled personnel.
In recent years, Surface enhanced Raman spectroscopy (SERS) has been reported to be a
good candidate for TDM of MTX (28,29,41), doxorubicin (42), paclitaxel and
cyclophosphamide (3) in biological fluids, since quantitative analysis of drugs can be
performed rapidly and higher sensitivity. By comparison, quantification of Bu in biological
fluids using spectroscopic techniques has not been explored. Critical issues of using SERS
for TDM include development of standardised substrates, intense surface enhanced
resonance SERS responses from other biological molecules such as carotenoids and also the
spectral interference from the fluorescence that could interfere with the drug detection
(28,43). Therefore, new techniques that are inexpensive, less complex and faster are essential
to quantitatively determine the concentration of drugs in a clinical setting. Herein, a rapid
drug screening strategy using Raman spectroscopy coupled with ultra-filtration and
multivariate analysis technique for Bu and MTX from liquid serum that yields a significant
improvement in detection capabilities and minimises error is explored.

7.3 Materials and Methods

7.3.1 Materials

Methotrexate (A6770), Busulfan (B058) and human pooled serum (H6914) were purchased
from Sigma Aldrich, Ireland. Stock solutions of 0.1mg/mL Bu in methanol and 1mM MTX
in 0.1M NaOH were prepared. The spiked concentrations of Bu in serum are expressed in
mg/mL and MTX in µM to be consistent with previous studies (4,29). The commercial
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human serum was spiked with Bu and MTX over the therapeutically relevant concentration
ranges, to achieve the final concentrations of (0 - 0.05 mg/mL) for Bu and (0 – 100 µM) for
MTX. The normal therapeutic range for Bu is 0.0005mg/mL to 0.005mg/mL and any
concentration below 0.0005mg/mL can cause transplant failure, or higher than 0.005mg/mL,
transplant related mortality (11), whereas for MTX, 1µM to 10µM and <10µM is considered
toxic (29). Raman spectra of highly concentrated Bu and MTX drug solutions prepared with
a minimal amount of water (~1mg/mL) are used as the reference for the Extended
Multiplicative Signal Correction algorithm (see Data pre-processing and analysis ).
Amicon Ultra 0.5mL centrifugal filter devices (Millipore- Merck, Germany), with a cut off
point of 10kDa, were employed to fractionate the serum samples. The centrifugation
procedure previously reported by Bonnier et al. was followed (44). The optimised washing
and rinsing procedure includes spinning 0.5mL 0.1M NaOH at 14000×g for 30 minutes,
followed by three rinses with distilled water by spinning 0.5mL distilled water for 30 minutes
at 14000×g. Every 30 minute wash and rinse must be followed by spinning the device in the
inverted position at 1000×g for 2 minutes, to remove the residual solution contained in the
filter. After washing, 0.5mL of spiked serum solution is transferred to the 10kDa filter and
centrifuged at 14000×g for 30 minutes. The filtrate that passes through the 10kDa filter
contains mostly water and molecules smaller than 10kDa. All the filtrate solutions were
analysed using Raman spectroscopy and five replicate measurements from different positions
have been recorded. In subsequent analysis, each dosed serum sample is represented by all
the spectra recorded from that sample, rather than the mean.
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7.3.2 Raman spectroscopy

The measurement conditions used for screening analytes in human serum in the liquid form
have recently been detailed (45,46). Raman spectra of all the liquid serum filtrate samples
and references were recorded at stabilised room temperature (18ºC) using a Horiba JobinYvon LabRam HR800 spectrometer with a 16-bit dynamic range Peltier cooled CCD
detector. A 532nm laser was used, which had a power of ~30 mW at the sample, with a 600
lines/mm grating and the backscattered Raman signal was integrated for 3×80 seconds over
the spectral range from 400-1800 cm-1. The spectrometer was coupled to an Olympus 1X71
inverted microscope and a x60 water immersion objective (LUMPlanF1, Olympus) was
employed. The substrate used was a Lab-Tek plate (154534) with a 0.16-0.19mm thick, 1.0
borosilicate glass bottom, and was purchased from Thermo Fischer Scientific, Ireland.

7.3.3 Data pre-processing and analysis

The raw spectra were subjected to pre-processing techniques in Matlab before further
analysis, to remove the background signal and reduce the noise. Smoothing of the raw data
was done using the Savitzky–Golay method (polynomial order of 5 and window 13) and the
rubberband method (45) was found to be appropriate to baseline correct the smoothed
reference spectra of both the drugs. The ‘rubberband’ correction was carried out by wrapping
a ‘rubberband’ of defined length around the ends of the spectrum to be corrected and fitting
against the curved profile of the spectrum. An adapted Extended Multiplicative Signal
Correction (EMSC) algorithm (47), with a 3rd order polynomial, was applied to remove the
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underlying water spectrum from all the dataset, whose OH bending feature at 1640 cm-1 can
interfere with the analyte spectra, and also scales the analyte spectra, assuming a constant
water contribution to all sample spectra (47).

7.3.4 Partial Least Squares Regression

Partial Least Squares Regression (PLSR) was employed to establish a model that relates the
variations of the spectral data to a series of concentrations. This regression model can be used
to establish the limit of detection and quantitation of Raman bio-sensing of drugs (48,49).
Constructed based on the spectra of samples of known drug content, over a range of varying
concentrations of drug (in commercial serum), the model is then validated using a rigorous
cross validation procedure which evaluates its performance in accurately predicting drug
concentrations. For consistency with previous studies (45,46), a 20 fold cross validation
approach has been employed to validate the robustness of the method. This approach involves
randomly dividing the set of observations into approximately equal size, 50% of the spectral
data were randomly selected as test set, while the remaining 50% is used as the training set
(50). The cross-validation process is then repeated 20 times (the folds), whereby all
observations are used for both training and testing, and each observation is used for testing
exactly once. The results from the folds can then be averaged to produce a single estimation.
The Root Mean Square Error of Cross Validation (RMSECV) is calculated from the 20
iterations to measure the performance of the model for the unknown cases within the
calibration set. The correlation between the true and predicted concentrations is given by the
R2 value. The standard deviation was calculated to quantify the amount of variation in the
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dataset. The number of latent variables used for building the PLSR model is optimised by
finding the value that is equivalent to the minimum of the RMSECV. The Limit of Detection
(LOD) and Limit of Quantification (LOQ) of these two drugs for this method were calculated
from the PLSR prediction plot, using a IUPAC-consistent approach previously reported for
multivariate regression analysis by Ostra et al. (48).
LOD = 3 x Sblank x b

(1)

LOQ = 10 x Sblank x b

(2)

where, Sblank is the standard deviation of a blank (zero concentration sample) and b is the
slope of the regression (inverse calibration) model, in the region of linearity. The slope was
calculated for the linear region of the prediction plot, including the standard deviation of each
point, by initially regressing over the higher concentrations, and progressively adding smaller
concentrations to the regression range, until the calculated slopes were seen to begin to
reduce.

7.4 Results and Discussion

Figure 7.1 shows the schematic diagram of the strategy used to collect the Bu and MTX data
from the serum samples to build the prediction models.
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Figure 7.1. Schematic representation of the ultra-filtration, Raman analysis, data preprocessing and PLSR analysis of the Bu/MTX serum samples. LOD and LOQ is calculated
from the prediction plot
The advantages of employing an inverted geometry to record Raman spectra have been
detailed by Bonnier et al (51). The feasibility of using a Lab-Tek plate as substrate (45) and
impact of ultra-filtration coupled with multivariate analysis techniques in detecting low
molecular weight fraction analytes have also previously been reported (46,52,53). The
Raman spectra recorded from the 10kDa filtrate of Bu and MTX spiked serum samples were
subjected to pre-processing steps followed by PLSR analysis. The whole finger print region
(400-1800cm-1) was chosen to build PLSR prediction for Bu, whereas a shorter region, in
which there are strong bands of MTX (1200-1800cm-1), was chosen to facilitate efficient
prediction of MTX by increasing the sensitivity. The improvement of the sensitivity of the
prediction model for the case of glucose and urea when regressed over a reduced spectral
region was previously reported (46,54). The normal and toxic ranges of the Bu and MTX
were encompassed by the range of spiked serum samples.
Figure 7.2A shows the reference spectrum of Bu, and the signature peaks of Bu at 1097cm-1
and 1453cm-1, which can be ascribed to a CH2 scissoring mode and C-C stretching,
respectively (55). In the case of MTX, the signature peaks are a strong band at 1593cm-1,
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which can be ascribed to the scissoring of the NH2 group, while the sharp band at 1351cm-1
can be ascribed to CH2 scissoring vibrations (Figure 7.2B) (4,29,41). The pre-processed data
set of systematically varied concentration of spiked, filtered serum (Figure 7.S1A and B) is
fed into the PLSR algorithm to build a prediction model that correlates the known
concentration and the predicted concentration, based on the variation in spectral intensity, for
each drug. On the basis of the percent variance explained by the latent variables and the
lowest value of RMSECV, the total number of latent variables used to reach the best
performance is calculated to be 3 for both Bu and MTX (Figure 7.S2A and B). The RMSECV
values are calculated to be 0.0003mg/mL for Bu and 4.02µM for MTX. The PLSR coefficient
plots (Figure 7.2C and D) of Bu and MTX display Raman bands in good accordance with the
reference ones, namely, the presence of peaks at 1097cm-1 and 1453cm-1 for Bu, and 1593cm1,

and 1351cm-1 for MTX, respectively.
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A
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Figure 7. 2. Reference spectrum of Bu used for EMSC correction. The chemical structure of
Bu is shown in the inset. B: Reference spectrum of MTX used for EMSC correction. The
chemical structure of MTX is shown in the inset. C: PLSR coefficient plot of Bu (4001800cm-1) from serum filtrate concentrations showing spectral features similar to the Bu
reference at 1097cm-1 and 1453cm-1. D: PLSR coefficient plot of regression against MTX
from 1200-1800cm-1 showing spectral features similar to the MTX reference at 1351cm-1,
and 1593cm-1. RMSECV were calculated to be 0.0003mg/mL for Bu and 4.02 µM for MTX,
respectively
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Y=0.96*x-2.5e-06

A

Y=0.94*x +1.4

B

B

Figure 7.3. Linear predictive model for (A) Bu and (B) MTX built from the PLSR analysis.
The LOD and LOQ for Bu were calculated to be 0.0002±0.0001mg/mL and
0.00073±0.00010mg/mL, whereas the LOD and LOQ of MTX were calculated to be 7.8 ±5.0
µM and 26 ±5µM.

Figure 7.3A and B indicate that the concentration dependence of the sample set is conserved
by centrifugal filtration and a satisfactory linear model could be obtained for Bu and MTX
from the filtrate of the serum samples. A linear prediction plot with a correlation accuracy
(R2) of 0.97 was obtained for Bu, with an LOD of 0.0002 ±0.0001mg/mL and LOQ of
0.00073 ±0.0001mg/mL (b=0.96 and Sblank= 0.00008mg/mL), both in the acceptable range of
clinical use. Samples with Bu concentrations higher than 0.002mg/mL are frequently
observed in many hospitals, but, Bu concentrations less than 0.0005mg/mL are rarely seen
(11). This Raman spectral response was validated to be linear over the entire range of
0.0003mg/mL to 0.0125mg/mL, which has not been fully validated in previous studies. In
comparison to the earlier studies based on LC-MS, the present method shows similar
performances in precision and recovery (13,16,24,56). However, considering the time needed
for sample preparation for the chromatography based methods, the present method has an
added advantage that it does not require complex sample preparation steps. Besides, the
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amount of sample required for this method (1-50 μL) is slightly less than that for other
commonly employed methods (50 to 200 μL)(11). Thus, this proposed approach can be
expeditiously implemented in laboratories in clinical settings for introduction of TDM of Bu
to achieve safe and proper dosing.
Similarly, the correlation accuracy (R2) is as high as 0.96 for MTX. The LOD was calculated
to be 7.8 ±5.0µM and the LOQ to be 26 ±5 µM (b=0.94 and Sblank = 2.8 µM). High risk of
toxicity related adverse effects are associated with serum MTX concentrations of >10µM
(4,29). The concentrations outside of safety values of MTX are >10 µM at 24 hours or >1
µM at 48 hours, and the serum MTX concentration should drop down to 0.2µM after 72
hours to reach the safety value (4,29,57,58). For most drugs, the process of drug elimination
is a first-order rate process, and so, in a given patient, can be characterised by a rate constant
(59). Therefore, from the clinical point of view, regular monitoring of MTX levels in patient
serum can be used to determine a rate of drug elimination and help establish a personalised
dosing regime for each patient. In previous studies, many researchers have reported the use
of SERS substrates to detect MTX in plasma/serum with a LOD as low as 0.17µM (29).
Preparation of these substrates are time consuming and expensive and are prone to
experimental errors, however (43). In contrast, the proposed method with inverted Raman
spectroscopy is cost-effective and easy to use, that can be translated as a point-of-care
diagnostic tool for high-dosage MTX in bodily fluids. Notably, in determining the LOD and
LOQ, while the slope of the concentration dependent response is dependent on the Raman
scattering cross section of the analyte, the standard deviation of the blank is a measurement
parameter, and instrument specific, and could potentially be improved by reduced noise
and/or signal variability.
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7.5 Conclusion

In summary, a rapid, sensitive, cost effective and reproducible method to determine the Bu
and MTX levels in human serum has been demonstrated. In clinical practice, identification
of individual therapeutic concentration of drugs is crucial for specific drugs with narrow
therapeutic window by measuring the levels of these drugs at designated intervals in the
serum/plasma, as the drug concentration in serum/plasma largely varies with time for
different individuals based on their age, body weight, pregnancies, temporary illnesses,
infections, emotional and physical stresses, accidents, and surgeries (12,58,60–62). TDM
takes these factors into consideration and accommodates them while establishing an
individual therapeutic concentration to fit the specific needs of a patient. This simple
approach of Raman spectroscopy coupled with ultra-filtration and multivariate analysis
technique allows to effectively preserve the information in the filtrate while enabling easy
detection of the drug concentration with higher accuracy. This strategy could be widely
adopted for monitoring a variety of other drugs and small molecules. The present method
accurately determines MTX concentrations at 7.8±5.0µM, suggesting that this method can
be applied for high dose monitoring of MTX. On the other hand, this method determined the
concentration of Bu as low as 0.0002±0.0001mg/mL, which is 30-40 fold below the lowest
Bu level that may present a risk for toxicity (19), thus ensuring effective and safe therapy for
patients undergoing bone marrow transplant. Therefore, this can be a useful protocol for
TDM of Bu to achieve safe and appropriate dosing. Further studies are needed to investigate
the determination of these drugs in patient serum to ensure successful implementation of this
method as a diagnostic tool. Thus far, this study is a proof of concept that simple Raman
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spectroscopy combined with multivariate analysis technique and ultra-filtration has the
potential to be used as a diagnostic tool for therapeutic drug monitoring from human serum.
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7.7 Electronic Supplemental information
1. EMSC corrected dataset of Busulfan and Methotrexate

B

A

Figure 7.S1. EMSC corrected and smoothed dataset of A Busulfan from 0mg/mL to
0.05mg/mL in the fingerprint region. B: Methotrexate from 0µM to 500µM from 1200cm-1
to 1800cm-1. The spectra are offset for clarity.
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2. Root Mean Square Error Cross Validation (RMSECV) plots for Busulfan and
Methotrexate

A

B

Figure 7.S2. Evolution of RMSECV for (A) Busulfan and (B) Methotrexate. The RMSECV
values are calculated to be 0.0003mg/mL for Bu and 4.02µM for MTX
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8.1 Abstract

There is compelling evidence in the literature to support the application of Raman
spectroscopy for analysis of bodily fluids in their native liquid state. Naturally, the strategies
described in the literature for Raman spectroscopic analysis of liquid samples have
advantages and disadvantages. Herein, recent advances in the analysis of plasma/serum in
the liquid state are reviewed. The potential advantages of Raman analysis in the liquid form
over the commonly employed infrared absorption analysis in the dried droplet form are
initially highlighted. Improvements in measurement protocols based on inverted microscopic

269

geometries, clinically adaptable substrates, data preprocessing and analysis, and applications
for routine monitoring of patient health as well as therapeutic administration are reviewed.
These advances suggest that clinical translation of Raman spectroscopy for rapid biochemical
analysis can be a reality. In the future, this method will prove to be highly beneficial to
clinicians for rapid screening and monitoring of analytes and drugs in the biological fluids,
and to the patients themselves, enabling early treatment, before the disease becomes
symptomatic, allowing early recovery.
8.2 Introduction
Vibrational spectroscopic techniques, both Raman and Infrared (IR) absorption, have been
extensively explored over the last two decades for obtaining the biochemical composition of
bodily fluids in the field of biomedical analysis [1–10]. The sensitivity to detect subtle
changes in the biochemical composition and ability to detect the presence of specific
biomarkers or drugs makes vibrational spectroscopy an ideal tool for the early diagnosis of
various pathologies [11–14] and therapeutic drug monitoring [15–17]. Both techniques are
truly label free, rapid, cost-effective, easy to operate, non-destructive and provide the unique
molecular fingerprint of the sample with minimal sample preparation steps. Such techniques
are particularly attractive for routine analysis of biofluids, as they are easy to apply, require
minimal sample preparation and are readily adaptable to analysis of various bodily fluids [15], potentially reducing clinical analysis time, and alleviating patient angst (figure 1).
Over the past decades, there have been numerous studies of analytes in biofluids using
vibrational spectroscopy, and, in recent years, attenuated total reflection (Fourier Transform)
IR (ATR-FTIR) has become popular for rapid screening of biofluids, particularly blood
plasma and serum [13]. Notably, however, ATR-FTIR is predominantly conducted on dried
270

droplets of bodily fluids, adding to the complexity of the measurement and the clinical
workflow [18,19]. In comparison, the prospect of using Raman spectroscopy for the labelfree extraction of biochemical information from biological fluids is attractive from various
perspectives; liquid sample analysis, no requirement for additional reagents, ease of use,
speed, cost-effectiveness and low sample volume requirement. The application of Raman
spectroscopy to biomolecules and even tissues was first demonstrated as early as the 1960s,
and by the mid 1970s biomedical applications were explored [20–22]. Whole cell and tissue
studies have been carried out on a range of pathologies [23–25] and in vivo studies [26,27]
have demonstrated the prospective for diagnostic applications. Raman microspectroscopy
potentially lends itself naturally to the analysis of liquid biofluids and such applications have
attracted considerable attention in recent years. There have been, however, multiple strategies
that are used to perform such real-time analysis and these options must be carefully
considered to achieve optimum Raman spectra from liquid samples [28,29]. Several studies
have reported the proof-of-concept of liquid sample analysis using Raman spectroscopy [30–
37]. However, no systematic validation and testing of protocols has yet been carried out to
consider this technique for real-time clinical applications. This review will summarise the
recent advances in the standardisation of measurement protocol for biological fluid analysis
in the liquid state using Raman spectroscopy, in terms of the optimal wavelength and
substrate, serum fractionation methods, data collection, pre-processing and post processing
steps to obtain results with higher accuracy and sensitivity. Applications for both analysis of
imbalances of high and low molecular weight serum constituent components of pathological
and clinical significance, as well as therapeutic drug monitoring will be considered. Note,
that the studies considered do not require signal enhancement techniques such as surface
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enhanced Raman spectroscopy, and therefore such techniques are not considered within the
scope of the review. However, as they has been extensively explored in recent times, a brief
comparison of the techniques to infrared absorption based techniques is provided.

Real time analysis

Patient serum

60x
LUMPlan F1

Early disease diagnostics
Figure 8.1. Early disease diagnosis, prognosis and treatment is possible with real-time
analysis of patient serum using the inverted Raman spectral analysis.

8.3 Raman vs Infrared absorption spectroscopy
Although Raman and IR spectroscopy are considered complementary techniques, the
fundamental physical phenomena governing them are very different, and thus result in
distinct technical challenges to their clinical implementation [6,38]. As IR spectroscopy is
based on absorption due to electric dipole transitions associated with molecular vibrations,
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water cannot be used as a solvent, due to its intense absorption in the IR region due to the
highly polar OH groups [39,40]. IR analysis of bodily fluids has therefore been
predominantly performed on air-dried samples, which leads to chemical and physical
inhomogeneity due to the so – called “coffee ring” effect and thereby inconsistencies in the
results obtained [18,19,39]. Raman spectroscopy is an inelastic scattering technique based on
the Raman effect, i.e., the coupling of the oscillating electronic polarisabilities of the
molecular bond with the source electromagnetic field [41,42]. The distinct advantage of this
technique is that it is compatible with water-rich samples such as serum/plasma, as water
molecules have a relatively low scattering cross section and do not mask the scattering from
the solutes in the aqueous solutions [43–45]. Zhao et al., developed a fast and reliable
approach to identify and quantify liquid injectables in the liquid state for spurious/falselylabelled/falsified/counterfeit medical products (SFFCs) using Raman spectrophotometer of
785nm excitation source [46]. Principle Component Analysis (PCA) combined with
Classical Least Squares (CLS) chemometric methods were used to overcome the problems
of the interference signals of glass containers and solutions, and weak signals from active
pharmaceutical ingredients were finally extracted. Water was used as an internal standard for
normalisation and CLS quantitation models were established. When Raman predicted values
were compared with HPLC reference results, the relative error of eight doxofylline liquid
injectable samples were within 5% and three low-concentration Levofloxacin in
Levofloxacin Lactate and Sodium Chloride Injection samples were within 10%,
demonstrating this approach to be a reliable and rapid screening method to detect SFFCs in
liquid dosage forms. In order to extend this Raman spectroscopic set up for the study of
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biological fluids, further studies should be conducted on biological fluids to extract clinically
relevant information.
Multianalyte, dried serum analysis has previously been reported using mid-infrared
spectroscopy, for the simultaneous quantitation of eight serum analytes: total protein content,
albumin, triglycerides, cholesterol, glucose, urea, creatinine and uric acid [47] and for
simultaneous quantification of glucose and urea analytes along with malaria parasitemia
quantification using ATR-FTIR [11]. As a direct comparison of the techniques of mid-IR and
Raman spectroscopy, together with multivariate data analysis, for the quantitative analysis
of serum, Rohleder et al. analysed the serum of 247 blood donors [36]. The IR analysis was
undertaken on dried droplets, whereas the Raman analysis was of the liquid serum and/or
serum filtrates. Under their investigation for the quantification of glucose, urea, uric acid,
LDL cholesterol, HDL cholesterol, total protein, cholesterol and triglycerides, Raman and
mid-infrared spectroscopy delivered similar accuracies for the prediction of physiologically
relevant analyte levels [36]. More recently, Parachalil et al., undertook a similar comparison
of Raman compared to ATR-FTIR, using identical sample preparation and analysis
protocols, to quantitatively monitor diagnostically relevant changes of glucose [44],
indicating that Raman spectroscopy in the liquid state can perform at least as well as ATRFTIR, without the need for the drying step.
Notably, whereas many of the previous studies of liquid serum samples employed an upright
microscopic geometry, that of Parachalil et al., employed an inverted geometry, as previously
demonstrated by Bonnier et al. [62]. Improved analysis of serum using Raman spectroscopy
was reported when the sample was analysed in the inverted geometry using a water
immersion objective with a 785nm laser and CaF2 substrate. A drop of water is used to
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minimise the differences in the refractive indices between sample, objective and the
substrate, and thus improve the optical coupling. However, the water drop does not contribute
to the data collected, as it is outside the focus of the beam. As a much better cost-effective,
clinically adaptable option, Parachalil et al. introduced a commercial, cover slip (of 0.160.19 mm thickness) bottomed vesicle (Lab-tek plate) as the substrate. The use of glass
precludes the use of a 785nm source [48,49], and thus a 532nm laser was chosen as the
source, which provides a strong Raman signal of water with minimal background interference
(Figure 2). This set-up also has the added advantage of providing high quality, consistent
Raman spectra from a sample volumes as low as 1μL. Medipally et al. also reported the
benefits of using inverted Raman geometry to analyse plasma samples of small volume
(20µL) from prostate cancer patients [50]. Note, enhanced methods such as Surface
Enhanced Raman Spectroscopy (SERS) are not considered in this review.

60x
LUMPlan F1

The volume of the
sample measured can
be as low as 1μL. The
spectral features are
found to be stable at
the highest and the
lowest volume

Figure 8.2. Thin glass bottomed Lab-Tek plate combined with inverted Raman analysis can
collect spectral data from very low amount of samples (1µL) making it an ideal tool for
clinical laboratory analysis. Spectra can be recorded in less than 1 minute.

8.4 Measurement of Plasma vs Serum
Human blood plasma or serum are the most commonly studied bodily fluids for disease
diagnosis, biomarker discovery and therapeutic drug monitoring [51–57]. While plasma and
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serum are both cell-free fluids obtained from blood samples by centrifugation, they differ on
the basis of whether clotting has been allowed or not. One question which inevitably arises
in performing biochemical estimation of blood, therefore, is what is the right choice of
medium to be used, plasma or serum? Plasma is commonly obtained as the supernatant layer
after refrigerated centrifugation of blood collected with anticoagulants (such as potassiumEthylenediaminetetraacetic acid, sodium-citrated and lithium-heparin) for 10 minutes at
2,000 x g to concentrate unwanted cells and platelets [58]. For serum preparation, whole
blood is allowed to clot at room temperature for about 15–30 minutes, whereupon the clot is
removed by refrigerated centrifugation at 1,000–2,000 x g for 10 minutes, often separated by
a gel component to avoid contamination [58]. It is important to immediately transfer the
supernatant (plasma or serum) into a clean polypropylene tube and maintain samples at 2–
8°C while handling. If the samples are not analysed immediately, they should be stored at –
20°C or preferably lower [59]. The time delay between centrifugation and separation of the
globular fraction and the improper storage conditions could negatively impact on the protein
profile obtained [59]. Therefore, standardisation of sample collection, processing and storage
protocols is crucial to ensure reproducibility and consistency in the results obtained. It is also
recommended to avoid freeze-thaw cycles, because this may have detrimental effects on
many serum components [60].
Blood serum and plasma are predominantly composed of water (~90%), minerals, organic
substances and gas (oxygen, carbon dioxide) [60]. Proteins are the predominant molecular
components of blood plasma, the remaining constituents being carbohydrates, lipids and
amino acids. Serum albumin, globulins, fibrinogen and a handful of other abundant proteins
account for 99% of total plasma/serum proteins, while the remaining 1% is composed of low
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abundance circulatory proteins [54]. Additionally, plasma or serum contain more than
114,000 known metabolites at varying concentration level (<1 nmol/L to mmol/L) (60)’
Since most of the clinical analytical instruments are accurate for both serum and plasma,
these two terms are used erroneously interchangeably in most clinical tests [7]. Notably,
many studies that have been reported to be carried out in serum were in fact carried out in
plasma [61–66].
Medipally et al. investigated the effect of different instrumental and sample preparation
parameters to identify a combination that would reduce the overall acquisition time for
recording spectra from blood plasma with minimal of sample preparation steps [50]. Out of
the four different laser lines (785 nm, 660 nm, 532 nm and 473 nm) tested, only the 785 nm
laser line gave a reliable biochemical signature of liquid plasma samples. Fluorescence was
observed when the 660 nm laser line was used and a resonance Raman effect due to the
presence of β carotene was observed when 532 and 473 nm laser lines were used. Plasma
samples from 10 prostate cancer patients and 10 healthy volunteers were used in this study.
A 96 well plate (cover glass bottomed) was used to hold samples of 20 µL and the Raman
spectra were recorded in the inverted geometry. Spectral preprocessing steps and principal
component analysis – linear discriminant analysis (PCA-LDA) was performed in the R
environment. The classification resulted in a sensitivity and specificity of 96.5% and 95%
respectively. Although a cost effective approach to perform rapid analysis of liquid plasma
is demonstrated in this study, no attempts have been made to reduce the effect of spectral
interferents while using the 532 nm laserline.
In validating the protocols for analysis of bodily fluids using inverted Raman microscopic
analysis using 532nm, Parachalil et al. utilised a simulated blood plasma mixture of albumin,
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fibrinogen, cytochrome C, and vitamin B12 [44]. The findings from this study with simulated
plasma protein mixture show that the poorly soluble fibrinogen component obscured the
systematic variations of the protein concentrations due to high degree of scattering. Mild
sonication of the aqueous solution helped to improve the solubility of fibrinogen and
significantly improved the Raman spectral intensity by minimising scattering effects. Since
centrifugal filtration failed to separate fibrinogen from rest of the proteins, ion exchange
chromatography had to be applied to separate the fibrinogen by altering its net surface charge.
Although ion exchange chromatography is a quick method to separate proteins, this method
has to be tailored for a specific protein depending on its charge and cannot be used as a ’onefor-all’ separation kit for all the proteins. In terms of the applications of Raman Spectroscopy
for analysis of blood content, it is therefore recommended that fibrinogen content should be
extracted from plasma, and mildly sonicated for quantitation, whereas blood serum can be
readily further analysed for High Molecular Weight Fraction (HMWF) and Low Molecular
Weight Fraction (LMWF) quantification.
8.5 Serum Fractionation
As long ago as 1999, Berger et al. used near IR light at 830nm to perform Raman microscopic
analysis of liquid whole human blood and serum samples to quantify the content of six
analytes, namely glucose, cholesterol, triglyceride, urea, total protein and albumin [28]. The
total acquisition time per sample was 5 min and the samples were continuously stirred in a
quartz cuvette to minimise heating artefacts from high intensity laser. However, no attempts
were made to fractionate the serum to deplete the HMWF analytes.
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Centrifugal filtration devices have been utilised to improve the sensitivity of quantitative
analysis by both Raman and IR spectroscopy, by separating the molecules according to their
molecular weight [68]. The proteins that are highly abundant in serum dominate the spectral
profile, and by the removal of these proteins (albumin and globulins,) the ability to monitor
changes in the lower molecular weight fraction (LMWF) is enhanced. Pre-rinsing of the filter
devices with 0.1M NaOH prior to plasma analysis is essential to avoid glycerine interference
in the analysis [67]. The optimised washing and rinsing procedure includes spinning 0.5mL
0.1M NaOH at 14000×g for 30 minutes, followed by three rinses with distilled water by
spinning 0.5mL distilled water for 30 minutes at 14000×g. Every 30 minute wash and rinse
must be followed by spinning the device in the inverted position at 1000×g for 2 minutes, to
remove the residual solution contained in the filter. After washing, 0.5mL sample is
transferred to the filter and centrifuged at 14000×g for 30 minutes. The solution that flows
out from the filter is the filtrate, which contains mostly water and molecules smaller than the
pore size of the chosen filter. The remainder of the sample, known as the concentrate, is
collected by placing the filter device upside down and spinning for 1000×g for 2 minutes.
The resultant concentrate, ~50µL, contains molecules with molecular weight larger than
chosen pore size, and is concentrated by a factor of ~10. This indicates the potential for the
prediction of other biomolecules that exist within the LMWF with this method, and with
further research, such techniques could be translated into the clinical environment as a rapid
tool for screening and monitoring.
In the study conducted using 247 blood donors by Rohleder et al. [37], a key was that the
prediction accuracy of glucose and urea were improved by up to a factor of 2 by depletion of
the HMWF using centrifugal filtration techniques. The processing protocol has been
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extensively explored for both ATR-FTIR and Raman analysis [39,68] whereby the HMWF
can be isolated in the unfiltered concentrate, while the LMWF filtrate can be further
fractionated and/or concentrated. Notably, Bonnier et al. have highlighted the importance of
appropriate rinsing of the filters to avoid contamination of the filtrate [67]. In the study of
Rohleder et al. [37], Raman spectroscopy was used for quantitative analysis of serum and
serum ultrafiltrate with an accuracy, within the range of clinical interest [37], by using 785nm
laser as the excitation wavelength and a quartz cuvette to hold the sample. In this
measurement setup, a minimum of 200 µL sample was required. 10kDa centrifugal filters
were used to deplete the HMWF from the serum and the spectra of glucose, urea and uric
acid were recorded from the serum as well as the ultrafiltrate.
Parachalil et al. further demonstrated the suitability of Raman spectroscopy as a bioanalytical
tool, when coupled with ultra-filtration and multivariate analysis, to detect imbalances in
both HMWF (total protein content, γ globulins and albumin) and LMWF (urea and glucose)
of the same samples of human patient serum, in the native liquid form [69]. Using a validated
Partial Least Squares Regression (PLSR) method, the γ globulin and total protein analysis
models, based on unfiltered patient serum, produced R2 values of 0.88 and 0.82, and Root
Mean Square Error of Crossvalidation (RMSECV) of 126 mg/dL and 115 mg/dL,
respectively. Post fractionation of the patient serum samples by ultra-filtration using 100 kDa
and 50 kDa filters, a similar analysis produced an R2 value of 0.91 and RMSECV of 90
mg/dL for albumin, which is comparable to the values previously reported for a model of
aqueous solutions of albumin over a similar concentration range. In the case of urea, R 2 and
RMSECV values of 0.90 and 70.40 mg/dL for the range of aqueous solutions of varying
concentrations were achieved, and 0.92 and 1.73 mg/dL, for the low molecular weight (<10
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kDa) filtrate of patient samples, when the full spectral range of 400-1800 cm-1 was employed.
Reducing the spectral range of the analysis to 800 cm-1 to 1030 cm-1 considerably improved
the prediction accuracy and sensitivity, resulting in an R2 value of 0.97 and RMSECV of 1.14
mg/dL. In the case of glucose, a reduced spectral range from 1030 cm-1 to 1400 cm-1 was
chosen to avoid interference from urea, resulting in an R2 value of 0.84 and RMSECV value
of 1.84 mg/dL in the filtrate from the same patient samples. Although both the proof-ofconcept studies have been carried out on rather small populations (25 patient samples), they
demonstrate that the method has potential for clinical implementation for early disease
diagnostics from bodily fluids. In this work, ultrafiltration in conjunction with chemometric
methods were used to overcome three problems: first, eliminating the interference from water
and β-carotene; second, extracting the Raman signals from LMWF analytes; and third,
solving the problems associated with multiple analyte variations in the serum. The sample
preprocessing enables a fractionation and concentration of the different molecular weight
fractions of the serum, enabling their analysis and quantification without the need for
additional enhancement techniques. It has been demonstrated that, using Ag or Au colloids,
intense and repeatable spectra are only obtained if the high molecular weight protein fraction
is filtered out from the serum [70]. Enhanced signals of the low molecular weight fraction
can then be obtained, although the process of addition of colloids would add to the workflow
in terms of time and cost.

281

8.6 Data preprocessing
Data preprocessing, such as spikes removal, baseline correction, smoothing etc., aims to
remove any perturbations to the spectra due to any distortions to the spectra which might
arise during the measurement process (scattering, electronic noise). This pretreatment of data
is critical to accessing the desired information without losing crucial information. The
fundamental concepts and basic theory of most used chemometric tools in the pharmaceutical
industry for pre-processing, processing and post-processing of the generated data have been
detailed in the review article by Sacre et. al [71]. The majority of the commercial software,
e.g. Labspec, includes real-time spikes correction, enabling visual inspection of the spectra,
and/or manual spike removal when very few spikes are present. Some algorithms have been
developed to perform automated spike removal in the case of a large dataset, for which
manual correction is not possible [72–76]. The most commonly used smoothing algorithm
for de-noising the spectra without losing much information is that of Savitzky-Golay [77].
Drifts in the baseline occurring due to scattering or fluorescence may be corrected using
different approaches such as asymmetric least squares [78], mixture models [79], polynomial
filter [80,81] and the rubber band method [82]. In the study conducted by Medippally et. al.,
rubber band baseline correction, Savitzky–Golay smoothing algorithm

and vector-

normalisation was performed on the raw Raman spectra of liquid plasma prior to post
processing, in R based statistical software [50]. In studies aimed at early diagnosis of oral
cancer using Raman spectroscopy by Sahu et. al.[83] and differentiation Meningioma by
Mehta et. al.,[84], raw liquid serum spectra were baseline corrected using a fifth order
polynomial function, smoothed using Savitzky-Golay algorithm and vector normalised in
Matlab based statistical software. Fifth order polynomial background subtraction from the
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raw serum spectra and normalisation was also implemented in Matlab by Rohdeler et. al.
[36] in their study to compare mid-IR and Raman spectroscopy in quantitative analysis of
serum. Two different algorithms were used by the same group to perform pre-processing of
spectra of serum spectra of ultrafiltrate [37]. Spectra originating from ultrafiltrate were scaled
to the area under the water Raman band at 1640 cm2 after determining the area by a Gaussian
fit with linearly decreasing background from 1550 to 1770 cm2. In the case of serum, spectra
were scaled to the maximum intensity and a fifth order polynomial background was
subtracted. In their study to detect alterations in glucose and lipid components in the serum
using near-IR Raman spectroscopy, Borges et. al.[85] fitted a seventh-order polynomial
function over the 400-1800 cm–1 region and subtracted from the raw serum spectrum to
remove the unwanted background, providing an effective baseline correction, and spectra
were normalised by the area under the curve prior to data analysis. Least squares fitting was
used by Berger et al. to remove the background mathematically by subtraction of a sloped
straight line from each serum spectrum without affecting the shape of the Raman peaks [28].
Jenkins et. al. subjected the raw Raman spectra of serum to wavenumber standardisation,
background subtraction using a rolling circle filter algorithm and normalisation to the peak
at 1004 cm−1 [29]. The phenyl alanine peak was chosen for normalisation as it is the sharpest
and most intense peak within the serum spectra and it is observed that normalisation to this
peak produced better diagnostic discriminatory results when compared to other normalisation
methods such as vector normalisation.
Although the accepted dogma is that the contribution of water to Raman spectra is
significantly less than to mid-IR spectra, water still has a significant contribution to the
Raman signatures in the fingerprint region of bodily fluids, due to the OH stretching vibration
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at 1640cm-1. Analysis of the ultracentrifugation concentrate reduced the relative contribution
of the water signal [68] but further efforts to remove it by data preprocessing have been
explored, to increase the relative contribution of the analyte. Kerr et al., [86] have compared
a number of commonly employed data pre-processing techniques, and, especially in the case
where the background contains a known interferent, such as substrate or background,
demonstrate the benefits of the adapted EMSC model, which also contains a polynomial with
linear and higher order components. Parachalil et al. adopted an adapted method of Extended
Multiplicative Signal Correction (EMSC) [86] to subtract the known spectrum of water from
their spectra, initially for the analysis of the HMWF in simulated plasma mixtures [44], and
subsequently the measurement protocol was used to quantitatively monitor diagnostically
relevant changes of glucose in liquid serum samples (spiked serum samples and patient
samples), and the results were compared with similar analysis protocols using infrared
spectroscopy of dried samples [43]. The analysis protocols to detect the imbalances in
glucose using Raman spectroscopy were first demonstrated for aqueous solutions and spiked
serum samples. As in the case of infrared absorption studies [87], centrifugal filtration was
utilised to deplete abundant analytes and to reveal the spectral features of LMWF analytes,
in order to improve spectral sensitivity and detection limits. After the depletion of the
abundant proteins, the dominant water peak from the filtrate collected after centrifugal
filtration using 10kDa can be removed by using the EMSC algorithm, and PLSR analysis
applied to obtain a prediction model relating the glucose concentrations and the intensity of
glucose features. Note, that the study introduced a water normalisation factor into the EMSC
protocol, using the fitted co-efficient of the water scaling factor, which has the effect of
scaling the analyte spectra, assuming a constant water contribution to all sample spectra. This
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step helps to considerably reduce the spectral variability of the Raman spectra of glucose
recorded from 25 patient samples (Figure 3) [44].
The principle of EMSC for subtraction of a specific measureable background spectrum and
the associated Matlab codes have previously been published by Kerr and Hennelly, 2016
[86], and their description is adapted in the following. The raw spectrum, S, consists of
Raman spectrum of interest, R, a baseline signal, B, and the water signal, W.
S = R + B + W [86]

(1)

The Raman spectrum of interest can be represented by a reference spectrum of the material
of interest, r, and it can be assumed that R is the product of this reference spectrum and a
certain scalar weight, Cr, which describes the concentration dependence [88,89]
R ~ Cr x r

[86]

(2)

Similarly, a spectrum, w, is recorded from water directly in order to represent the spectral
contribution of water in W, as the product of pure water spectrum and a certain scalar weight.
W = Cw x w

[86]

(3)

The baseline, B, is now represented by an appropriate order of polynomial (N) as:
BN = C0 + C1X + C2X2 +……+ CNXN

[86]

(4)

where N is the order of polynomial and Cm for m = 0  N represents various coefficients of
polynomial. The EMSC algorithm is used to obtain estimates of the scalar values Cr, Cm and
Cw. These estimates are obtained from an optimal fit of the various vectors in Equation 5.
𝑚
S~ [𝐶𝑟 × 𝑟] + [𝐶𝑤 × 𝑤] + [∑𝑁
𝑚=0 𝐶𝑚 𝑋 ]

[86]
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(5)

The background corrected, concentration dependent analyte spectra, T, can be represented
as:
S−[𝐶𝑤 ×𝑤]−[∑𝑁
𝑚=0 𝐶𝑚𝑋𝑚 ]

T=

𝐶𝑤

[86]

(6)

Note, that division by Cw has the effect of scaling the analyte spectra, assuming a constant
water contribution to all sample spectra.

A

B

Figure 8.3. (A) PCA scatter plot of Raman data of the filtrate obtained after ultrafiltration of
patient serum without scaling the analyte (glucose) spectra from the previously published
study by Parachalil et. al [44] and (B) after scaling the analyte spectra to the water content.
Figure 3B displays less scatter when compared to Figure 3A, indicating less variability
among the spectra

However, although the EMSC algorithm removed the underlying water spectra effectively,
interference from other LMWF analytes, namely, urea was noticed. Hence, a shorter spectral
range from 1030cm-1 to 1400cm-1 was chosen for data analysis, as this region does not contain
signature peaks of urea. Improved Root RMSECV was observed for Raman prediction
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models, whereas slightly higher R2 values were reported for infrared absorption prediction
models.
The adapted EMSC algorithm can also be employed to remove known spectral interferents.
In several studies of human serum, β-carotene has been observed as a string contributor to
the spectrum, particularly when using 532nm or lower as source, as the scattering from the
conjugated antioxidant species are resonantly enhanced [29,50,83]. The LMWF species are
not easily removed by centrifugal separation [69], but their contributions can be effectively
“digitally” removed using the adapted EMSC protocol.
8.7 Data Analysis
Data analysis protocols can be differentiated into classification protocols, largely employed
for diagnostic purposes, and regression protocols, predominantly used for quantitation of
identified analytes. The latter have been explored for both imbalances in intrinsic blood
constituents, as well as for therapeutic drug monitoring.
Depciuch et al. collected Raman and FTIR spectra from dried and liquid serum from
depressed patients and their analysis indicated that both methods provided equally valid
results to discriminate the patients with similar accuracies [33]. The light source wavelength
was 780 nm and the sample volume used was 1.5ml, which could be an impediment for
clinical translation. Other similar studies conducted by the same group using the same set up
on phospholipid-protein balance in human serum and qualitative, quantitative changes in
phospholipids and proteins in animal depression models. The role of zinc deficiency induced
phospholipid-protein imbalance in serum of the animal models suggest that both IR and
Raman spectroscopic techniques could be used as effective tools to identify the changes in
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the blood serum [30–32]. To investigate similarities and differences between the serum
samples of different types of depression in humans, Principal Components Analysis-Linear
Discriminant Classification (PCA-LDC) was employed in their analysis of Raman and FTIR
spectra from dried and liquid serum from depressed patients [33]. The results from both FTIR
and Raman spectra unambiguously demonstrated that the levels of proteins and
phospholipids are higher in healthy controls than in depressed subjects and that phospholipids
affect the structure of proteins. Two measurement strategies were compared in order to
determine the influence of water on the measured spectra; the first method entailed recording
the water spectrum as back-ground, and subsequently automatically subtracting it from each
serum spectrum, while the second method entailed recording a spectrum of the air prior to
the spectrum of blood serum and subsequently the water spectrum was subtracted from the
blood serum without air background. Both the methods provided identical serum spectra,
suggesting that appropriate measurement of the background and the subtraction of water
signal had the greatest impact on the reliability of the results.
Jenkins et al. developed a high-throughput (HT) serum Raman spectroscopy platform and
compared dry and liquid data acquisition of serum samples for liquid biopsy of 30 colorectal
cancer patients and 30 matched control patients [29]. Using a stainless steel high throughput
substrate that allows up to 40 samples to be loaded at once, and 785 nm laser as the excitation
wavelength, the maximum sensitivity and specificity obtained for discrimination of
colorectal cancer patients were 77% and 81% respectively. In this study, Raman spectra were
subjected to routine preprocessing such as wavenumber standardisation, background
subtraction using a rolling circle filter algorithm and normalisation to the peak at 1004 cm−1.
Partial least squares discriminant analysis (PLS-DA) was used to investigate causes of
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differences and variances within datasets. PLS-DA models were cross validated using k-fold
cross validation with 5 folds. The sample volume required was 200 µL and the total time for
the data collection was 12.5min. In a clinical setting, it would be advantageous to reduce the
data collection time in order to avoid delay in analysis. When excitation wavelength of
532nm was used on the liquid platform, the specificity was found to be low, due to the
prominence of carotenoids in the serum spectra. No measures were taken to remove the
interference of carotenoids from the spectral data. The prominence of carotenoids due to
resonance Raman was also reported by Sahu et al., in an exploratory study for detection of
oral cancers [83] and by Mehta et al., in their study conducted to differentiate meningioma.
Sahu et. al. used 532nm as excitation source and Raman spectra were collected by placing
30µL serum samples on a glass slide and the laser was focused through a 50X Nikon
objective. The spectra were vector normalised, baseline corrected, smoothed and subjected
to PCA-LDA followed by cross-validation using leave-one-out cross-validation (LOOCV).
Although this study reported spectral differences between DNA, changes in the plasma amino
acid profiles and β-carotene levels across the analysed groups, the strong bands of β-carotene
could interfere with the detection of other analytes increasing the ambiguity in the results
obtained. In the study conducted by Mehta et al., 25 patient samples from healthy and
meningioma groups were subjected to PC and PC-LDA followed by LOOCV cross
validation, yielding classification efficiency of 92% and 80% for healthy and meningioma
respectively. Passively thawed 30µL serum samples, on a calcium fluoride (CaF2) slides were
subjected to Raman analysis using 785nm laser excitation source. Borges et al.[85], collected
blood serum from 44 volunteers to discriminate between altered and normal concentrations
of glucose, total cholesterol, triglycerides, low density (HDL) and high density lipoproteins
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(LDL). Raman analysis was performed using 830nm excitation source for a sample volume
of 100µL. The data collected was subjected to PCA yielding a classification efficiency of
77% for total cholesterol, 81% for triglycerides, 59% for HDL and 60% for LDL.
In terms of quantification of systematically variable analyte concentrations, multivariate
PLSR analysis is often the method of choice. PLSR is most commonly employed to construct
a model that can relate variations of the measured spectral responses to a systematic variation
of concentrations of the target analyte [90–92]. The constructed model can them be employed
to identify spectral factors which account for the maximum variation in predictors ‘X’
(spectral data) versus associated responses ‘Y’ (target values of protein concentration) [91].
The spectral data (X matrix) can thus be related to the target concentrations (Y matrix)
according to the linear relationship Y = XB +E, in which B and E are matrices of regression
coefficients and residuals, respectively. The PLSR model can be used to predict the outcome
of varying concentration of analytes based on the spectral dataThe model is validated using
a rigorous cross validation procedure which evaluates its performance in accurately
predicting analyte concentrations [44]. In the study of Berger et al., PLSR prediction models
were built, using leave one out cross validation (LOOCV), for each the six analytes after
spectral background removal, providing an root mean square error of 26mg/dL, 12mg/dL,
29mg/dL, 3.8mg/dL, 0.19mg/dL and 0.12mg/dL for glucose, cholesterol, triglyceride, urea,
total protein and albumin, respectively [28]. A similar approach was employed by Parachalil
et al. [43] to compare the predictive capacity of Raman microscopy for quantitation of
glucose in human serum, compared to the similar ATR-FTIR analysis of Bonnier et al. [87]
indicating that the RMSECV for Raman of 1.84mg/dL is comparable or better than that of
3.1mg/dL for ATR- FTIR.
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Having removed the spectral interferents using EMSC, PLSR can independently identify
spectral correlation associated with target analyte range. Cross-validation of the PLSR model
is required to evaluate the accuracy, often cited in terms of the Root Mean Square Error of
Cross Validation (RMSECV) [93]. The number of latent variables used for construction of
the PLSR model is optimised by establishing the value that is equivalent to the minimum of
the RMSECV. The R2 value provides an indication of the correlation between the analyte
concentration and spectral intensity, while the standard deviation (STD) provides an
indication of the variation between each spectrum calculated from the same sample.
Commonly, a multiple fold cross validation approach is employed to validate the robustness
of the method. Typically, the set of observations is randomly divided into approximately
equal size, e.g. 50% of the spectral data randomly selected as test set, while the remaining
50% is used as the training set [101]. The cross-validation process is then repeated multiple
times (the folds), such that all observations are used for both training and testing, and each
observation is used for testing exactly once. The results from the folds can then be averaged
to produce a single estimation. The Root Mean Square Error of Cross Validation (RMSECV)
is calculated from the multiple iterations to measure the performance of the model for the
unknown cases within the calibration set.
In order to advance the studies of Berger et al., [28] and Rohleder et al.,[36,37] using the
improved inverted microscopy modality, Parachalil et al.[69] also used the EMSC correction,
ultrafiltration protocols and PLSR analysis to construct models for the quantitation of the
whole serum (total protein, γ globulin), serum concentrate (albumin) and serum filtrate (urea
and glucose) of patient samples, resulting in higher accuracy and sensitivity of analysis. The
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strategy demonstrated in this study enables the simultaneous estimation of total protein level
and detection of imbalance in γ globulin concentration accurately from whole serum, without
the use of any reagents and without destroying the sample being studied. The proposed
method has many advantageous over the routinely used biuret method, Turbidimetric
Immunoassay (TIA) and Radial Immunodiffusion (RID), as the required sample volume can
be as low as 10μL, it is rapid and non-destructive to the medium being studied, whereas the
conventional methods are considered impractical due to the requirement of large sample
volume and laborious sample processing steps [94–96]. Moreover, the linearity reported for
a comparative study of RID and TIA is 0.59 [97], substantially lower than the R2 calculated
by Parachalil et al. [44]. Using filtration, the albumin was isolated from patient serum and
the prediction model had a prediction accuracy significantly superior to that reported for the
Bromoscerol Green method (2.2 g/dL), used to determine albumin concentrations from
cirrhotic patients [98]. It has previously been reported that selecting the spectral region from
1030 cm-1 to 1400 cm-1 improved the sensitivity and specificity for the prediction model of
glucose from patient samples over the concentration range 52.5-434.2 mg/dL, and the
technique was demonstrated to be at least as accurate as ATR-FTIR of similar patient samples
[69], measured in the dried state and closer to the accuracy of colorimetric methods, 1.4
mg/dL urea [99] and 2 mg/dL glucose [100]. Similarly, higher prediction accuracy
(RMSECV=1.14 mg/dL) was attained when PLSR analysis was performed on a reduced
range for urea from patient samples over the concentration range 2.52-78.99 mg/dL,
compared to the full range (RMSECV=1.73 mg/dL).
This standardised, optimised methodology was also applied to determine the Limit of
Detection (LOD) and Limit of Quantification (LOQ) for therapeutic drug monitoring (TDM)
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in human serum, using the examples of Busulfan, a cell cycle non-specific alkylating
antineoplastic agent, and, Methotrexate, a chemotherapeutic agent and immune system
suppressant [101]. Ultrafiltration of the spiked human pooled serum with 10kDa centrifugal
filter efficiently recovered the drug in the filtrate prior to performing Raman analysis. The
drug concentration ranges were chosen to encompass the recommended therapeutic ranges
and toxic levels in patients. Finally, prediction models were built by using PLSR and LOD
and LOQ were calculated directly from the linear prediction models. The LOD calculated for
Busulfan is 0.0002 ± 0.0001 mg/mL, 30-40 times lower than the level of toxicity, enabling
the application of this method in target dose adjustment of Busulfan for patients undergoing,
for example, bone marrow transplantation. The LOD and LOQ calculated for Methotrexate
are 7.8 ± 5 µM and 26 ±5 µM, respectively, potentially enabling high dose monitoring.
Although SERS gives promising results in detecting drugs at low concentrations in biological
matrices [16,102], qualitative variations within the SERS substrate, and the interference of
other biomolecules with the SERS spectra, makes quantification in real samples a challenging
task [103]. The simpler approach, adopted here, of Raman spectroscopy coupled with
concentration of the high and low molecular weight serum fractions using commercially
available centrifugal filter devices and multivariate analysis technique ensures that the
information in the fractions is effectively preserved, while enabling easy detection of the
analyte concentration with higher accuracy that in the unprocessed sample. Better analysis
of serum using Raman spectroscopy was observed when the sample was analysed in the
inverted geometry using the water immersion objective with a 532nm laser as source with
Lab-Tek plate as substrate [44]. A drop of water is used to minimise the differences in the
refractive indexes between sample, objective and the substrate. However, the water drop does
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not contribute to the data collected, as it is outside the focus of the beam. The promising
results from the systematic studies conducted by Parachalil et al.[69] using this analytical set
up combined with chemometric techniques such as EMSC to measure concentrations of
HMWF, LMWF and drugs in human serum strongly indicates a highly significant correlation
between predicted and reference concentrations. These results suggest that Raman can on its
own can detect and quantify concentrations close to 1% without the aid of any enhancement
method [37].
Considering the more general applications of the technique to a broader range of drugs or
analytes, it is notable that both the LOD and LOQ for a given set up are determined by the
STD of the measurement of the control (serum or filtered serum), and the Raman scattering
efficiency of the analyte. To further illustrate this point, the LOD of vitamin B12, cholesterol,
urea and glucose from liquid samples for this measurement protocol were also determined
using the method previously reported by Parachalil et al. [101] (Table 1). Figure 4 displays
a plot of LOD versus the maximum intensity per unit acquisition time, per unit concentration.
An approximately linear, inverse relationship can be seen, which simply emphasises the
maxim that the stronger the Raman signal of the analyte, the easier it is to detect. The
correlation also implies, however, that a simple measurement of the analyte in aqueous
solution could be employed to predict the LOD, and therefore the suitability of the technique
for the therapeutic monitoring application.
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Table 8.1: LOD of glucose [44], busulfan [101], methotrexate [101], cholesterol, urea [69]
and vitamin B12 calculated from the PLSR prediction plot of these analytes, compared to
the maximum Raman intensity of maximum peak per unit acquisition time, per unit
concentration
Analyte

Intensity LOD(mM)
(arb.
units)

Glucose

1000

0.0006±0.0005

Busulfan

19704

0.0008±0.0001

MTX

1600

0.00076±0.0005

Cholesterol 216718

0.0006±0.0001

Urea

540000

0.00033±0.00001

VB12

1266666

0.00014±0.00002

Figure 8.4. LOD of glucose (44), urea (69), busulfan (101), methotrexate (101), cholesterol,
and vitamin B12 calculated from the PLSR prediction plot of these analytes, compared to the
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‘maximum Raman intensity of maximum peak per unit acquisition time, per unit
concentration’. The methodology used for calculating LOD was previously published (101)

8.8 Clinical Translation
Vibrational spectroscopic techniques have attracted a lot of attention as analytical methods
of choice for analysing biological samples. The promise of the techniques is based on the
abilities to objectively fingerprint the biochemical profile underlying early onset of disease
in cells, tissues or bodilyfluids [3,6,9]. The techniques have no requirement of specific
reagent, and the minimal sample preparation means there should be fewer procedural errors
and no major time delay in providing the results to the patients. In the case of FTIR,
considerable progress towards using this technique as a routine diagnostic tool for disease
diagnosis has been made. Recently, ClinSpec Diagnostic, based at the University of
Strathclyde’s Technology & Innovation Centre, won a £1.2 million investment to further
develop a “revolutionary” blood test using FTIR which could potentially improve brain
cancer survival rates through early detection of the disease [104]. Researchers from Monash
University have similarly developed FTIR based techniques to analyse disease-causing
pathogens in human blood [105]. Advances in instrumentation have made FTIR an ideal tool
of choice for an increasing number of clinical application even though the sample drying step
is potentially a huge drawback [19,68,106].
Notably, it is demonstrated that the Raman analysis protocol can yield accuracies which are
comparable with those reported using infrared absorption based measurements of dried
serum, without the need for additional drying steps. However, there remain challenges to
fulfilling the requirements for clinical translation. Distortions in the spectra due to the water
contributions, low detectability of the low molecular weight fraction analytes, lack of
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standardisation steps and financial factors could be the hindrance for clinical translation in
the medical and clinical environment. Nevertheless, new strategies have been recently
developed to address these potential limitations, namely the inverted Raman geometry, low
cost (Lab-Tek plate) substrates, serum fractionation techniques, selective spectral region
analysis and sophisticated data preprocessing (EMSC) and analysis (PLSR) techniques.
These advances have maximised the diagnostic accuracy and are cost-effective solutions that
are likely to be adopted in a clinical setting.
Application of the adapted EMSC based algorithm helped to eliminate the contribution from
water and scattering associated with the HMWF, and linear predictive models were built
from the PLSR analysis. It is worth noting that PLSR seeks to correlate systematic variations
in the spectroscopic profiles with the external target variable, in this case protein
concentration. As such, the method is not inherently specific to any molecular variations, in
the case where multiple species vary simultaneously over the same range. The accuracy of
the proposed method is comparable to that of the most commonly used method for detecting
albumin from biological fluids, the Enzyme Linked Immunosorbent Assay (ELISA)
[107,108], and the most commonly used gold-standard method i.e., the Clauss assay for
fibrinogen [109]. The proposed approach can be expeditiously employed for early detection
of pathological disorders associated with high or low plasma/serum analytes.
Bodily fluids are usually collected from a large number of patients in a hospital, potentially
delaying the performance of the analysis and availability of results, which may in turn delay
the therapy, and prolong patient anxiety. The accuracy of the conventional test kits that
enable point-of-care testing can be poor, and they are can be avoided due to high cost
[110,111]. The enormous advantage of employing this inverted Raman spectral analysis for
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real-time serum/plasma analysis in a clinical setting is that, in the face of emerging diseases,
one could get an early diagnosis in a cost effective manner before the disease becomes
symptomatic (Figure 1). Integrated with smaller spectroscopic instrumentation,
implementation of such a screening/diagnostic tool in developing countries where
conventional diagnostics methods are scarce and avoided due to high cost, would bring about
a dramatic impact on population screening.

8.9 Conclusion
The potential advantages of employing Raman spectroscopy of bodily fluids for disease
diagnosis apart from its high sensitivity and specificity are: low cost, no reagents are required,
samples can be probed in the native state and rapid results can be obtained. Although there
is a wealth of information to support the application of Raman analysis for bodily fluids, this
approach is still considered young and upcoming in the eyes of medical community, thereby
hindering its clinical translation. The examples summarised in this article attest to the cost
effective, easy to use, reproducible method of Raman measurement protocol for detecting
imbalances in serum/plasma proteins and low molecular weight analytes, as well as
therapeutic drug monitoring. Significantly improved sensitivity of Raman spectroscopic
measurements of blood samples in liquid form is achievable by means of serum fractionation
and the implementation of chemometric approaches. In the case of clinical translation, there
remain challenges to overcome before it can be a reality. Nevertheless, it has been
demonstrated that options and alternatives are available to overcome these challenges in
using Raman spectroscopy for liquid sample analysis, leading to a better accuracy and
repeatability and thus a better sensitivity. Naturally, the next phase includes not only refining
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this method and improving the technical capabilities to match those of the current clinical
needs, but also technical advances to translate them from research laboratory to clinical
practice. In addition, to ensure further relevancy of this method, comparison studies between
the gold standard of current diagnostic methods and the current method in a large multicentred randomised clinical trials are required. Once these factors are taken into account, it
is possible to envisage a routine platform providing clinical biochemical analysis at minimal
cost.
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Chapter 9
Conclusion

Through a systematic assessment of the analytical conditions, comparing Raman
spectroscopy to FTIR, use of the 785 nm laser line to the 532 nm laser line as Raman source,
use of Lab-Tek plate to other substrates, upright to inverted geometry of Raman, and data
preprocessing techniques, the settings and techniques used for liquid serum analysis were
tailored to optimise the quality of the results generated in the study. It is observed in this
study that inverted immersion Raman spectroscopy employing a 532 nm laser and Lab-Tek
plate substrate generated spectra of better overall quality, with higher signal-to-noise ratios.
Hence, these methods and settings were used for further investigation into the diagnostic
capabilities of Raman spectroscopy.
The results from the study conducted to detect imbalances in high molecular weight plasma
proteins from simulated plasma show that extraction of the fibrinogen from the protein
mixture solution by ion exchange chromatography is more specific than ultra-filtration,
allowing the quantification of variations of fibrinogen levels [1]. It was observed that mild
sonication could be applied to increase the solubility of the fibrinogen. EMSC successfully
removed the background associated with the scattering as well as the water signal, and a
PLSR prediction model was built, correlating the systemic variations in the spectral profile
with that of the high molecular weight protein concentrations. In general, the scattering
problems caused by fibrinogen favour the use of blood serum for the biochemical analysis of
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analytes other than coagulants. However, to further ensure the relevancy and consistency of
these results, experiments need to be carried out in human plasma from healthy and patient
samples. An alternative study should be conducted using Raman optical activity to ensure
ultrasonication does not disintegrate the protein at lower frequencies.
The comparative study conducted between Raman and FTIR using glucose as a model
analyte demonstrated that the Raman analysis protocol can yield accuracies which are
comparable with those reported using infrared absorption based measurements of dried
serum, without the need for additional drying steps [2]. It is noteworthy that Raman
spectroscopy yields significantly lower values of RMSECV for all the Raman prediction
models, suggesting higher sensitivity and accuracy and the suitability of this technique to
discriminate patients with very similar concentrations of blood glucose. However, lower R2
values and higher standard deviations were observed for Raman spectroscopy, which could
be due to the intrinsic variability of individual samples, depending upon the physiological
state of the individual on that day. Hence, the study should ultimately be conducted on a
larger number of patient samples to further confirm the suitability of Raman as a biochemical
tool for screening LMWF analytes in liquid serum samples.
The potential of Raman spectroscopy as a bioanalytical tool to simultaneously detect
imbalances in the high and low molecular weight fraction of human serum has been
demonstrated [3]. In this study, EMSC was employed to remove water and spectral
interferents such as β-carotene that can interfere with the spectra of target proteins. It has also
been demonstrated that selecting spectral regions where the bands of the target protein are
stronger leads to higher specificity of the model and allows detection of multiple analytes
from the same dataset. The strategy illustrated in this study enables simultaneous detection
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of various analytes (total protein content, -globulin, albumin, urea and glucose) from human
serum using Raman spectroscopy with minimal sample preparation, no labelling and no
additional sample drying steps, with accuracy comparable to that of the conventional gold
standard methods. Depletion of the HMWF is a non-optional step in the investigation of
protein imbalances or disease related biomarkers in the LMWF of serum. Although this study
provided promising results for the detection of total protein content, albumin, urea and
glucose, the spectral co-efficient of prediction of -globulin is somewhat unsatisfactory with
no prominent features of -globulin. Raman optical activity (ROA) could be a viable option
to probe structural differences of globulins due to its stereochemical potential and could yield
structural information not otherwise available [4], [5]. ROA and Tip enhanced Raman
spectroscopy (TERS) have been proven to be effective techniques for quantification of
glycosylated status of target proteins [6]-[8].
Further improvements in the sensitivities and reduced variabilities of the techniques
ultimately rely on the reproducibility of the measurement, instrument calibration, using water
as an internal standard and improved signal to noise ratio. The proposed Raman methodology
could potentially be improved by integrating an automated focussing and sampling
methodology, and regular maintenance of the instrument. As longer accumulation times to
reduce the noise are not recommended, because of sample evaporation and also speed of
measurement throughput, optimisation of instrumentation for higher signal throughput could
be explored, for example by sacrificing spectral resolution.
This simple approach of Raman spectroscopy coupled with ultra-filtration, multivariate
analysis has been extended to therapeutic drug monitoring of Busulfan and Methotrexate
from humans serum and a method to calculate LOD, and LOQ with higher accuracy was
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demonstrated [9]. Further studies are needed to investigate the determination of these drugs
in patient serum to ensure successful implementation of this method as a diagnostic tool. The
proof of concept shown in this study gives rise to the hope of utilising Raman spectroscopy
as a biochemical tool for monitoring a variety of drugs and small molecules from bodily
fluids.
Ultimately, the studies presented in this thesis are transferable to any other low and high
molecular weight analytes or therapeutic drugs. The studies shown in this thesis attest to the
cost-effective, easy to use, reproducible method of Raman measurement protocol for
detection of imbalances in serum/plasma proteins, as well as therapeutic drug monitoring.
Since Raman spectroscopy has established itself as a reliable and non-destructive technique,
this proposed methodology can also find application as a rapid drug-screening tool for
athletes or in forensic science, where the sample size may be extremely small and needs to
be preserved. Several factors such as improving accuracy, consistency and standardised
sample collection and measurement procedure still must be addressed before clinical
translation as biofluids are biochemically heterogeneous. Once these factors are taken into
account, it is possible to envisage a point-of-care routine biochemical-fingerprinting
platform, a truly revolutionary step in biomedical science.
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